id,location,condition,intervention,phase,sponsor_type,immuno_subgroup,sponsor_type_clean,sponsor_type_grouped,phase_named,condition_group,intervention_group,sponsor
1,China,Cervical Cancers,DRUG: Chemo-immunotherapy|RADIATION: CCRT,23,OTHER,other,OTHER,Other,Phase II & III,gynecologic,radiotherapy,Women's Hospital School Of Medicine Zhejiang University
2,China,Malignant Tumors,BIOLOGICAL: EBV mRNA vaccine,1,OTHER,cancer vaccine,OTHER,Other,Phase I,other,cancer vaccine,West China Hospital
3,China,Malignant Tumor,BIOLOGICAL: EBV immunological agent,1,OTHER,other,OTHER,Other,Phase I,other,other,West China Hospital
4,China,Rectal Malignant Neoplasms,COMBINATION_PRODUCT: Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Shandong Cancer Hospital and Institute
5,China,Advanced Cancers,BIOLOGICAL: Blood-stage infection of P.vivax,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,multiple,other,"CAS Lamvac Biotech Co., Ltd."
6,United States,Advanced Malignant Neoplasm|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm,OTHER: Laboratory Biomarker Analysis|DRUG: Methylphenidate|OTHER: Physical Activity|OTHER: Placebo|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,OTHER,other,OTHER,Other,Phase III,multiple,biomarker / diagnostics,M.D. Anderson Cancer Center
7,United States,"Neoplasm|Cancer, Malignant Tumors",DRUG: COM503|DRUG: Zimberelimab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,other,other,Compugen Ltd
8,China,Advanced Malignant Solid Tumor,OTHER: Plasmodium immunotherapy,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,multiple,other,"CAS Lamvac Biotech Co., Ltd."
9,China,Cervical Cancers,DRUG: Neoadjuvant Chemotherapy|DRUG: Neoadjuvant Chemotherapy|DRUG: Immunotherapy|PROCEDURE: Radical surgery|PROCEDURE: Fertility-preserving surgery,2,OTHER,other,OTHER,Other,Phase II,gynecologic,chemotherapy,Obstetrics & Gynecology Hospital of Fudan University
10,"Canada, United Kingdom",Gynaecological Cancers,DRUG: Ceralasertib|DRUG: Olaparib|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,"Institute of Cancer Research, United Kingdom"
11,China,Advanced Solid Tumor,COMBINATION_PRODUCT: Radiotherapy combined with immunotherapy,12,OTHER,combination product,OTHER,Other,Phase I & II,multiple,combination product,China-Japan Friendship Hospital
12,China,Gastrointestinal Cancers,DRUG: Entecavir,3,OTHER,other,OTHER,Other,Phase III,other,other,Sun Yat-sen University
13,United States,Advanced Cancers|Melanoma,DRUG: MGN1703|DRUG: Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,skin,checkpoint inhibitor,M.D. Anderson Cancer Center
14,United States,Pleural Mesothelial Neoplasm,OTHER: Immunotherapy|OTHER: Quality-of-Life Assessment|RADIATION: Stereotactic Body Radiation Therapy,1,OTHER,other,OTHER,Other,Phase I,lung/thoracic,radiotherapy,Mayo Clinic
15,United Kingdom,Cancer|Neoplasms,BIOLOGICAL: ACIT-1,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,other,other,Cancer Vaccines Limited
16,"China, France, Israel, New Zealand, Republic of, Taiwan, United States",Advanced Liver Cancers,DRUG: Atezolizumab|DRUG: Bevacizumab 15 mg/kg|DRUG: Tiragolumab|DRUG: Tocilizumab|DRUG: TPST-1120|DRUG: Tobemstomig 2100 mg|DRUG: Bevacizumab 10 mg/kg|DRUG: Tobemstomig 600 mg|DRUG: Tobemstomig 1200 mg|DRUG: ADG126|DRUG: IO-108 1800 mg|DRUG: NKT2152|DRUG: IO-108 1200 mg,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,digestive,checkpoint inhibitor,Hoffmann-La Roche
17,China,"Breast Cancer, Metastatic Breast Cancer",RADIATION: Intensity-modulated radiotherapy|DRUG: Immunotherapy Therapy,12,OTHER,other,OTHER,Other,Phase I & II,breast,radiotherapy,Zhongnan Hospital
18,"Australia, Canada, Netherlands, Switzerland, United Kingdom",Metastatic Tumors,RADIATION: Palliative Radiation|DRUG: Chemotherapy|DRUG: Immunotherapy|DRUG: Hormones|OTHER: Observation|RADIATION: Stereotactic Ablative Radiotherapy,3,OTHER,other,OTHER,Other,Phase III,multiple,radiotherapy,David Palma
19,United States,"Solid Tumor, Adult",DRUG: DF9001|DRUG: pembrolizumab|DRUG: KEYTRUDA®,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,multiple,checkpoint inhibitor,Dragonfly Therapeutics
20,China,Cervical Cancers,DRUG: Serplulimab|DRUG: Chemotherapy|RADIATION: radiotherapy,2,OTHER,other,OTHER,Other,Phase II,gynecologic,radiotherapy,Tianjin Medical University Cancer Institute and Hospital
21,France,LOCALLY ADVANCED CERVICAL CANCERS,COMBINATION_PRODUCT: combination of relatlimab and nivolumab wich are two immunotherapy treatments|OTHER: Nivolumab alone,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,ARCAGY/ GINECO GROUP
22,China,Cervical Cancers,DRUG: Toripalimab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
23,China,Cervical Cancers,DRUG: Neoadjuvant immunochemotherapy,2,OTHER,other,OTHER,Other,Phase II,gynecologic,chemotherapy,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
24,"Australia, France, United States","Solid Tumor, Adult|Solid Tumor Cancer",DRUG: DF6215|DRUG: pembrolizumab|DRUG: KEYTRUDA®,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,Dragonfly Therapeutics
25,China,Glioblastoma (GBM)|Head and Neck Squamous Cell Carcinoma|Non-Small Cell Lung Cancer|Esophageal Cancer,DIAGNOSTIC_TEST: PET/CT （[18F]AlF-NOTA-PCP2）|DIAGNOSTIC_TEST: [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Man Hu
26,China,Gastric Cancers,DRUG: Pre-operative chemotherapy|PROCEDURE: Robotic radical gastrectomy after neoadjuvant therapy,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,The First Affiliated Hospital with Nanjing Medical University
27,"Canada, Republic of, Spain, United States",Locally Advanced or Metastatic Solid Tumours,DRUG: AZD0171|DRUG: Durvalumab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,multiple,checkpoint inhibitor,AstraZeneca
28,United Kingdom,"Neoplasms|Prostatic Neoplasms, Castration-Resistant|Stomach Neoplasms|Esophageal Neoplasms|Head and Neck Neoplasms|Colorectal Neoplasms|Pancreatic Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Mesothelioma, Malignant|Uterine Cervical Neoplasms|Kidney Neoplasms|Sarcoma|Pheochromocytomas",DRUG: HTL0039732 Capsules|DRUG: HTL0039732 Capsules and atezolizumab infusion,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,gynecologic,checkpoint inhibitor,Cancer Research UK
29,France,Esophagus Cancer|Unresectable Malignant Neoplasm,"DRUG: Durvalumab|COMBINATION_PRODUCT: IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,UNICANCER
30,United Kingdom,"Tumor, Solid",BIOLOGICAL: LEU011,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,other,other,Leucid Bio
31,United States,"Cervical Cancer|HPV Cancers|Anal Cancer|Oropharyngeal Cancer|Vulvar, Vaginal, Penile, Rectal Cancer",BIOLOGICAL: PDS0101|BIOLOGICAL: M7824|BIOLOGICAL: NHS-IL12,12,NIH,other,NIH,Government,Phase I & II,gynecologic,other,National Cancer Institute (NCI)
32,China,Solid Tumors,DRUG: Retroviral vector-transduced autologous T cells to express anti-ALPP CARs,12,OTHER,other,OTHER,Other,Phase I & II,multiple,other,Xinqiao Hospital of Chongqing
33,Canada,All Solid Tumors,BIOLOGICAL: MET-4,23,OTHER,other,OTHER,Other,Phase II & III,multiple,other,"University Health Network, Toronto"
34,China,Rectal Cancer,DRUG: Camrelizumab ＋Immunotherapy,3,OTHER,other,OTHER,Other,Phase III,digestive,other,Peking University Cancer Hospital & Institute
35,United States,Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Leptomeninges|Breast Cancer|HER2-positive Breast Cancer,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,breast,adoptive cell therapy,City of Hope Medical Center
36,"France, Germany, Italy, Netherlands, Spain, United Kingdom, United States",Pediatric Cancer|Solid Tumor Pediatric|Hematological Malignancies,DRUG: Durvalumab / Tremelimumab Combination Therapy,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,hematologic,checkpoint inhibitor,AstraZeneca
37,China,Recurrence Tumor|Metastatic Cancer|Solid Tumor,BIOLOGICAL: TIL|DRUG: Aldesleukin|DRUG: Cyclophosphamide|DRUG: Fludarabine,12,OTHER,other,OTHER,Other,Phase I & II,multiple,other,Tongji Hospital
38,"Belgium, Denmark, France, Netherlands, Republic of, United States","Solid Tumor, Adult",DRUG: DF1001|DRUG: Nivolumab|DRUG: Nab paclitaxel|DRUG: Sacituzumab Govitecan-hziy,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,multiple,checkpoint inhibitor,Dragonfly Therapeutics
39,China,Solid Tumors,DRUG: Methotrexate tablets|DRUG: Anti-PD-1 monoclonal antibody|RADIATION: Radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Yancheng First People's Hospital
40,China,Advanced Malignancies,DRUG: IBI363 + chemotherapy|DRUG: IBI363 + Investigator's Choice SOC,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,other,chemotherapy,Innovent Biologics (Suzhou) Co. Ltd.
41,Republic of,"Solid Tumor, Adult|Solid Tumor|Gastric Cancer|Hepatocellular Carcinoma|Metastatic Colorectal Cancer|Advanced Solid Tumor",DRUG: PB101,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,other,Panolos Bioscience
42,United States,"Breast Cancer|Breast Tumor|Cancer of Breast|Cancer of the Breast|Malignant Tumor of Breast|Tumors, Breast",BIOLOGICAL: BC1 cell line|BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab)|BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab) expansion cohort,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,breast,other,BriaCell Therapeutics Corporation
43,United States,Colorectal Neoplasms,DRUG: Botensilimab|DRUG: Balstilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Weill Medical College of Cornell University
44,Netherlands,Resectable MMR-deficient Solid Tumors|Resectable MMR-proficient Solid Tumors,DRUG: botensilimab|DRUG: balstilimab,23,OTHER,other,OTHER,Other,Phase II & III,multiple,other,The Netherlands Cancer Institute
45,France,Localized Resectable Tumor|MSI/dMMR,DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Centre Leon Berard
46,"Australia, New Zealand",Advanced Biliary Tract Cancer|Neuroendocrine Tumors|Female Reproductive System Neoplasm|MSI-H Solid Malignant Tumor,DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Olivia Newton-John Cancer Research Institute
47,United States,Colorectal Neoplasms,DRUG: GRT-C901|DRUG: GRT-R902|DRUG: Atezolizumab|DRUG: Ipilimumab|DRUG: Fluoropyrimidine plus leucovorin|DRUG: Bevacizumab,23,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II & III,digestive,checkpoint inhibitor,Seattle Project Corporation
48,United States,Advanced Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Solid Neoplasm,OTHER: Hafnium Oxide-containing Nanoparticles NBTXR3|RADIATION: Radiation Therapy|RADIATION: Radiation Therapy,12,OTHER,other,OTHER,Other,Phase I & II,digestive,radiotherapy,M.D. Anderson Cancer Center
49,United States,Biliary Tract Cancers,DRUG: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]|DRUG: Durvalumab|DRUG: Tremelimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,other,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
50,Taiwan,Refractory Tumor|Solid Tumor,BIOLOGICAL: Dendritic Cell Vaccine|DRUG: Lenvatinib|DRUG: Nivolumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,multiple,checkpoint inhibitor,"National Health Research Institutes, Taiwan"
51,"Puerto Rico, United States",Anal Intraepithelial Neoplasia|High Grade Squamous Intraepithelial Neoplasia|HIV Positivity|Human Papillomavirus-16 Positive|Human Papillomavirus-18 Positive,DEVICE: Electroporation|BIOLOGICAL: HPV DNA Plasmids Therapeutic Vaccine VGX-3100|OTHER: Laboratory Biomarker Analysis,2,NETWORK,cancer vaccine,NETWORK,Network,Phase II,digestive,cancer vaccine,AIDS Malignancy Consortium
52,China,Non-Small Cell Lung Cancer|Electroacupuncture|Immune Checkpoint Inhibitors,OTHER: Electroacupuncture combined with immunotherapy|DRUG: Zilongjin tablet combined with immunotherapy|DRUG: Immunotherapy,23,OTHER,other,OTHER,Other,Phase II & III,lung/thoracic,other,Kong Fanming
53,United States,Advanced Cancer,DRUG: personalized vaccine|DRUG: Pembrolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,multiple,checkpoint inhibitor,Ezra Cohen
54,"Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Republic of, Singapore, Spain, Taiwan, United Kingdom, United States",Locally Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: NVL-520,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,multiple,other,Nuvalent Inc.
55,United States,Relapsed/Refractory Solid Tumors,DRUG: Lamivudine|DRUG: PD-L1 Blocker,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,multiple,checkpoint inhibitor,Thomas Marron
56,United States,Nerve Sheath Tumors,DRUG: Nivolumab|DRUG: Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,other,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
57,"Australia, Belgium, Canada, France, Hungary, Italy, New Zealand, Republic of, Spain, United Kingdom, United States",Advanced Solid Tumors,DRUG: Monalizumab|DRUG: Durvalumab|DRUG: Cetuximab|DRUG: mFOLFOX6|DRUG: Bevacizumab,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,multiple,checkpoint inhibitor,MedImmune LLC
58,United States,Oropharyngeal Cancer|Neck Cancer|Human Papillomavirus|HPV|Anal Cancer|Cervical Cancer|Penile Cancer|Vulvar Cancer|Vaginal Cancer|Colon Cancer,DRUG: Bintrafusp Alfa|DRUG: PDS01ADC|DRUG: Entinostat,12,NIH,other,NIH,Government,Phase I & II,gynecologic,other,National Cancer Institute (NCI)
59,"Canada, United States",Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Copanlisib Hydrochloride|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|PROCEDURE: X-Ray Imaging,12,NIH,checkpoint inhibitor,NIH,Government,Phase I & II,multiple,checkpoint inhibitor,National Cancer Institute (NCI)
60,United States,Gastroesophageal Junction (GEJ) Cancers|Advanced HNSCC,DRUG: N-803|DRUG: Pembrolizumab|BIOLOGICAL: PD-L1 t-haNK,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,digestive,checkpoint inhibitor,National Cancer Institute (NCI)
61,China,Head/Neck Neoplasm,DRUG: PD1/PDL1/CTLA4 inhibitors,23,OTHER,other,OTHER,Other,Phase II & III,head/neck,other,Second Affiliated Hospital of Guangzhou Medical University
62,China,Advanced Breast Cancer|Advanced Liver Cancer,BIOLOGICAL: Blood-stage infection of P.vivax,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,digestive,other,"CAS Lamvac Biotech Co., Ltd."
63,China,Small-cell Lung Cancer,DRUG: hypofractionated radiotherapy with immunotherapy,12,OTHER_GOV,other,OTHER_GOV,Government,Phase I & II,lung/thoracic,radiotherapy,Anhui Provincial Hospital
64,France,Advanced Solid Tumors|Metastatic Solid Tumors,DRUG: NP137|DRUG: anti-PD-1/PD-L1,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Centre Leon Berard
65,Australia,Solid Tumor,BIOLOGICAL: Radvax,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,Vaxine Pty Ltd
66,United States,Recurrent Prostate Cancer,DRUG: ADXS-504,1,OTHER,other,OTHER,Other,Phase I,genitourinary,other,Mark Stein
67,China,Colon Neoplasm,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Anti-PD-L1 Monoclonal Antibody|DRUG: Clostridium butyricum|PROCEDURE: Colectomy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
68,United States,Ovarian Cancer|Ovarian Neoplasms,BIOLOGICAL: Vigil|OTHER: Placebo,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,gynecologic,other,"Gradalis, Inc."
69,"China, France, Japan, Puerto Rico, Republic of, Spain, United States",Advanced Solid Tumors,DRUG: ASP1570|DRUG: pembrolizumab|DRUG: Trifluridine + Tipiracil|DRUG: Bevacizumab|DRUG: Docetaxel,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,multiple,checkpoint inhibitor,"Astellas Pharma Global Development, Inc."
70,China,Advanced Solid Tumor,BIOLOGICAL: Adebrelimab|BIOLOGICAL: SHR-1802|DRUG: Carboplatin/Cisplatin|DRUG: Paclitaxel/Nab-Paclitaxel/Pemetrexed,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,multiple,chemotherapy,"Shanghai Hengrui Pharmaceutical Co., Ltd."
71,Spain,NSCLC|Pancoast Tumor,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Fundación GECP
72,"Spain, United States",Advanced Solid Tumor,BIOLOGICAL: Nemvaleukin alfa|BIOLOGICAL: Pembrolizumab,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,multiple,checkpoint inhibitor,"Mural Oncology, Inc"
73,China,Lung Cancers|Radiation Treatment for Tumors,RADIATION: Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy|RADIATION: Conventional fractionated radiotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Tianjin Medical University Cancer Institute and Hospital
74,"Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Republic of, Singapore, Spain, Switzerland, Taiwan, United Kingdom, United States",Locally Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: NVL-655,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,multiple,other,Nuvalent Inc.
75,China,Stomach Neoplasms|Digestive System Neoplasms|Neoplasms|Digestive System Diseases|Stomach Diseases|Neoplasms by Site,DRUG: Camrelizumab|DRUG: SOX|PROCEDURE: Surgery,2,OTHER,other,OTHER,Other,Phase II,digestive,other,The Second Affiliated Hospital of Fujian Medical University
76,,Breast Cancer,BIOLOGICAL: DC-CIK Immunotherapy|DRUG: Capecitabine Monotherapy,2,OTHER,other,OTHER,Other,Phase II,breast,other,The First People's Hospital of Changzhou
77,China,"Lung Cancer|Liver Cancer|Solid Tumor, Adult",DEVICE: IRSW-MIM,23,OTHER,other,OTHER,Other,Phase II & III,digestive,other,Second Affiliated Hospital of Guangzhou Medical University
78,United States,Metastatic Malignant Neoplasm in the Liver|Metastatic Uveal Melanoma,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous CD8+ SLC45A2-specific T Lymphocytes|DRUG: Cyclophosphamide|BIOLOGICAL: Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,M.D. Anderson Cancer Center
79,United States,"Medulloblastoma, Childhood|Atypical Teratoid/Rhabdoid Tumor of CNS|Embryonal Tumor With Multilayered Rosettes|Pineoblastoma|Embryonal Tumor of CNS",BIOLOGICAL: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA),1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Children's National Research Institute
80,"Australia, Canada, France, Japan, Republic of, Spain, United States",Advanced Solid Tumors Cancer,DRUG: ABBV-927|DRUG: ABBV-927|DRUG: ABBV-181,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,AbbVie
81,France,Hematological Malignancies|Regulatory T Cell Depletion|Relapse,PROCEDURE: T-reg depleted DLI|PROCEDURE: Standard DLI,3,OTHER,other,OTHER,Other,Phase III,hematologic,other,Assistance Publique - Hôpitaux de Paris
82,Brazil,Uterine Cervical Neoplasms,DRUG: Nivolumab 40 mg in 4 ml Injection|DRUG: Ipilimumab 200 MG in 40 ML Injection|RADIATION: Chemoradiation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,Hospital Israelita Albert Einstein
83,United States,Advanced Malignant Skin Neoplasm|Metastatic Malignant Skin Neoplasm,DRUG: Atezolizumab|DRUG: Avelumab|BIOLOGICAL: Cemiplimab|BIOLOGICAL: Durvalumab|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Short-Term Fasting,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,skin,checkpoint inhibitor,University of Southern California
84,Canada,Metastatic Tumor,RADIATION: Palliative Radiotherapy|DRUG: Chemotherapy|DRUG: Hormone therapy|DRUG: Immunotherapy|DRUG: Targeted Systemic Therapy|OTHER: Observation|RADIATION: Stereotactic Ablative Radiotherapy|PROCEDURE: Surgery|OTHER: Radiofrequency Therapy (RFA)|RADIATION: Fractionated Radiation,3,OTHER,other,OTHER,Other,Phase III,multiple,radiotherapy,David Palma
85,China,Nasopharyngeal Neoplasms|PD-1 Inhibitor|Induction Therapy|Complete Response|Chemotherapy,DRUG: Two-cycle induction chemotherapy + immunotherapy|DRUG: Three-cycle induction chemotherapy + immunotherapy,2,OTHER,other,OTHER,Other,Phase II,head/neck,chemotherapy,The First Affiliated Hospital of Xiamen University
86,"Puerto Rico, United States",Clear Cell Renal Cell Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Lymph Nodes|Metastatic Malignant Neoplasm in the Soft Tissue|Metastatic Malignant Neoplasm in the Viscera|Rhabdoid Tumor of the Kidney|Sarcomatoid Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
87,China,Relapsed/Refractory Solid Tumors,BIOLOGICAL: NKG2D-CAR-NK92 cells,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,multiple,other,Xinxiang medical university
88,"Estonia, Iceland, Netherlands, Norway, Sweden",Small-cell Lung Cancer,PROCEDURE: Thoracic radiotherapy|DRUG: Chemo-immunotherapy,3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,radiotherapy,Norwegian University of Science and Technology
89,"Germany, Italy",Non Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Urothelial Carcinoma,RADIATION: Carbon Ion Therapy|DRUG: Immunotherapy (Pembrolizumab),2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,CNAO National Center of Oncological Hadrontherapy
90,Republic of,Kidney Neoplasm,RADIATION: SBRT(Stereotatic Body Radiation Therapy),3,OTHER,other,OTHER,Other,Phase III,genitourinary,radiotherapy,Samsung Medical Center
91,United States,Solid Tumor,DRUG: ALG.APV-527,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,multiple,other,Aptevo Therapeutics
92,United States,"Tumor, Solid",DRUG: Durvalumab and Tremelimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"John L. Villano, MD, PhD"
93,United States,"Central Nervous System Tumor, Pediatric|Glioma|Ependymoma|Medulloblastoma|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma",BIOLOGICAL: HER2-specific chimeric antigen receptor (CAR) T cell,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Seattle Children's Hospital
94,China,Head and Neck Tumors,"DRUG: Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU",2,OTHER,other,OTHER,Other,Phase II,head/neck,chemotherapy,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
95,United States,Metastatic Castration-Resistant Prostate Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Lymph Nodes|Stage IVB Prostate Cancer AJCC v8,DRUG: Avelumab|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Peposertib|OTHER: Questionnaire Administration|RADIATION: Radium Ra 223 Dichloride,12,NIH,other,NIH,Government,Phase I & II,genitourinary,radiotherapy,National Cancer Institute (NCI)
96,United States,Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor,GENETIC: AGAR T cells,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Baylor College of Medicine
97,"Belgium, Republic of, Spain, United States","Solid Tumor, Adult|Metastatic Solid Tumor|Refractory Cancer",DRUG: ADU-1805|DRUG: Pembrolizumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,Sairopa B.V.
98,United States,Brain Tumor Adult,BIOLOGICAL: DRI cell therapy,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,brain/CNS,adoptive cell therapy,University of Alabama at Birmingham
99,"Republic of, Spain, Taiwan, United States",Neoplasms,DRUG: TSR-022|DRUG: Nivolumab|DRUG: TSR-042|DRUG: TSR-033|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,other,checkpoint inhibitor,"Tesaro, Inc."
100,"Argentina, Brazil, Canada, Czechia, Denmark, France, Italy, Mexico, Poland, Republic of, Spain, United Kingdom, United States",Neoplasms,BIOLOGICAL: Dostarlimab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,other,other,"Tesaro, Inc."
101,United States,"Head and Neck Squamous Cell Carcinoma|Cancer|Cancer of Head and Neck|Cancer, Advanced|Cancer, Metastatic|Tumor|Tumor Recurrence|Tumor Neck|Tumor Metastasis|Oral Cancer|Oropharyngeal Cancer|Oropharynx Cancer|Oropharynx Cancer, Stage III|Oropharynx Cancer, Recurrent|Oropharynx Cancer, Metastatic",DRUG: Pembrolizumab|RADIATION: Radiation therapy|DRUG: Cisplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"Loren Mell, MD"
102,China,Biliary Tract Cancer|Immune Checkpoint Inhibitor|Predictive Cancer Model,DRUG: Immune Checkpoint Inhibitors,12,OTHER,other,OTHER,Other,Phase I & II,other,other,Peking Union Medical College Hospital
103,China,"Cervical Cancer|Neoplasm Recurrence, Local|Oligometastatic",DRUG: Paclitaxel and Cisplatin/ Carboplatin|DRUG: Iparomlimab and Tuvonralimab|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,gynecologic,radiotherapy,Shandong Cancer Hospital and Institute
104,United States,Cervical Cancer|Cervical Cancer Recurrent|Cervical Cancer Metastatic,RADIATION: Stereotactic body radiation therapy (SBRT)|DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
105,United States,Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor,GENETIC: CARE T cells|DRUG: Cytoxan|DRUG: Fludara,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Baylor College of Medicine
106,United Kingdom,Head and Neck Cancer,OTHER: Intra-tumoral T4 immunotherapy,1,OTHER,other,OTHER,Other,Phase I,head/neck,other,King's College London
107,United States,Breast Cancer|Breast Neoplasms,DRUG: Pembrolizumab|DRUG: IRX 2,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Providence Health & Services
108,United States,Breast Cancer|Breast Neoplasm|Metastatic Breast Cancer|Breast Cancer Metastatic,BIOLOGICAL: SV-BR-1-GM|DRUG: Low dose cyclophosphamide|DRUG: Interferon Inoculation|DRUG: retifanlimab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,breast,cytokine / immunomodulator,BriaCell Therapeutics Corporation
109,United States,Liver Cell Carcinoma|Solid Tumor|Wilms Tumor|Malignant Rhabdoid Tumor|Yolk Sac Tumor|Rhabdomyosarcoma|Liposarcoma|Embryonal Sarcoma of the Liver,GENETIC: CATCH T cells,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Baylor College of Medicine
110,China,Colorectal Cancer|Colon Cancer|Rectum Cancer,BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Essen Biotech
111,China,Esophageal Squamous Cell Carcinoma|Unresectable Locally Advanced Esophageal Cancer,DRUG: PD-1inhibitor|DRUG: nab-paclitaxel + cisplatin|RADIATION: Radiotherapy,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Shanghai Chest Hospital
112,China,Non Small Cell Lung Cancer,RADIATION: radiotherapy|DRUG: Chemotherapy + immunotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Hunan Province Tumor Hospital
113,China,Non-Small Cell Lung Cancer,RADIATION: hypofractionated radiotherapy with immunotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Peking University Cancer Hospital & Institute
114,China,Esophageal Neoplasm Metastatic|Esophageal Cancer Stage IVb,DRUG: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|BIOLOGICAL: PD-1 inhibitor|RADIATION: Consolidation Radiation|RADIATION: Salvage Radiation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
115,"Australia, China, Spain, United States",Advanced Solid Tumors,DRUG: BGB-30813|DRUG: Tislelizumab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,BeiGene
116,United States,Head and Neck Neoplasm,RADIATION: 50 Gy Radiation Therapy|RADIATION: 55 Gy Radiation Therapy|RADIATION: 60 Gy Radiation Therapy|DRUG: Atezolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,head/neck,checkpoint inhibitor,Medical College of Wisconsin
117,Belgium,Advanced Solid Tumors,DRUG: EOS301984|DRUG: Anti-PD-1 monoclonal antibody,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,iTeos Therapeutics
118,Thailand,Cholangiocarcinoma|Neuroblastoma,DRUG: cytokine induced killer cells,12,OTHER,cytokine / immunomodulator,OTHER,Other,Phase I & II,other,cytokine / immunomodulator,Siriraj Hospital
119,Singapore,Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: Intramuscular ACM-CpG Monotherapy (Escalation)|DRUG: Intramuscular ACM-CpG Monotherapy (Expansion),1,OTHER,other,OTHER,Other,Phase I,multiple,other,"National Cancer Centre, Singapore"
120,China,Advanced Gastric Cancer|Advanced Colorectal Cancer|Advanced Ovarian Cancer|Peritoneal Metastasis,RADIATION: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|DRUG: Cadonilimab,12,OTHER,other,OTHER,Other,Phase I & II,gynecologic,radiotherapy,Zhang Tao
121,Canada,Esophageal Cancer,DRUG: Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|DRUG: Adjuvant chemoradiotherapy,1,OTHER,other,OTHER,Other,Phase I,digestive,radiotherapy,University of Manitoba
122,China,"Solid Tumor, Adult",BIOLOGICAL: Neoantigen mRNA Vaccine,1,OTHER,cancer vaccine,OTHER,Other,Phase I,multiple,cancer vaccine,Second Affiliated Hospital of Guangzhou Medical University
123,"France, Greece, Spain, United Kingdom, United States",Advanced Solid Tumor,BIOLOGICAL: RP3|BIOLOGICAL: Nivolumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,Replimune Inc.
124,China,"Solid Tumor, Adult",BIOLOGICAL: Neoantigen Polypeptide Vaccine,1,OTHER,cancer vaccine,OTHER,Other,Phase I,multiple,cancer vaccine,Second Affiliated Hospital of Guangzhou Medical University
125,China,Esophageal Neoplasms|Esophageal Diseases|Digestive System Neoplasms,DRUG: camrelizumab|DRUG: Paclitaxel drugs|DRUG: Platinum drug|RADIATION: Radiation,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,digestive,radiotherapy,Fujian Cancer Hospital
126,France,HCC - Hepatocellular Carcinoma|Metastatic Cancer|Metastatic Tumor,DRUG: Ipilimumab Injection|DRUG: Atezolizumab Injection|DRUG: Bevacizumab,23,OTHER,checkpoint inhibitor,OTHER,Other,Phase II & III,digestive,checkpoint inhibitor,Federation Francophone de Cancerologie Digestive
127,"Belgium, Spain","Neoplasms, Colon",BIOLOGICAL: Dostarlimab|DRUG: CAPEOX,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,other,GlaxoSmithKline
128,United Kingdom,Metastatic Esophageal Cancer|Metastatic Gastric Cancer,DRUG: Atezolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Royal Marsden NHS Foundation Trust
129,United States,Malignant Brain Neoplasm|Recurrent Malignant Brain Neoplasm|Refractory Malignant Brain Neoplasm,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,City of Hope Medical Center
130,France,Refractory or Recurrent Solid Tumor,DRUG: Spartalizumab in Pediatric cohort|DRUG: Low-dose Pazopanib in Pediatric Cohort|DRUG: Spartalizumab in Adult cohort|DRUG: Low-dose Pazopanib in Adult Cohort,12,OTHER,other,OTHER,Other,Phase I & II,multiple,other,"University Hospital, Bordeaux"
131,China,Cancer,DRUG: research drug in combination with Toripalimab|DRUG: Toripalimab,12,OTHER,combination product,OTHER,Other,Phase I & II,other,combination product,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
132,France,Ovarian Cancer,DRUG: ARM A Durvalumab/chemotherapy association|DRUG: ARM B Durvalumab/Tremelimumab/chemotherapy association,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,gynecologic,checkpoint inhibitor,ARCAGY/ GINECO GROUP
133,"Australia, United States",Advanced Solid Tumor,BIOLOGICAL: BNT317 DL1|BIOLOGICAL: BNT317 DL2|BIOLOGICAL: BNT317 DL3|BIOLOGICAL: BNT317 DL4|BIOLOGICAL: BNT317 DL5 (intermediate)|BIOLOGICAL: BNT317 DL6 (intermediate)|BIOLOGICAL: BNT317 DL7 (additional),1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,BioNTech SE
134,Netherlands,"Prostatic Neoplasms, Castration-Resistant",BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Radboud University Medical Center
135,Canada,Breast Cancer|Lung Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Gynecologic Cancer|Sarcoma|Unknown Primary Tumors|Head and Neck Cancer|Skin Cancer,DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,British Columbia Cancer Agency
136,United States,Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma|Melanoma,BIOLOGICAL: second generation 4-1BBζ B7H3-EGFRt-DHFR|BIOLOGICAL: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|DRUG: Pembrolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,skin,checkpoint inhibitor,Seattle Children's Hospital
137,Finland,Solid Tumor,BIOLOGICAL: TILT-123,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,TILT Biotherapeutics Ltd.
138,United States,"Breast Cancer Female|Breast Cancer, Male|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|Residual Disease|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma",BIOLOGICAL: DC1 Vaccine|BIOLOGICAL: WOKVAC Vaccine,2,OTHER,cancer vaccine,OTHER,Other,Phase II,breast,cancer vaccine,H. Lee Moffitt Cancer Center and Research Institute
139,China,Advanced Solid Tumor,DRUG: LTC004+Toripalimab,2,OTHER,other,OTHER,Other,Phase II,multiple,other,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
140,United Kingdom,Breast Neoplasm,DRUG: AZD6738|DRUG: Olaparib|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,"Institute of Cancer Research, United Kingdom"
141,China,"Pancreas Cancer|Lung Cancer|Liver Cancer|Mesothelioma|CAR-T Cell Therapy|Solid Tumor, Adult",BIOLOGICAL: Cell therapy for solid tumors,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,digestive,adoptive cell therapy,Second Affiliated Hospital of Guangzhou Medical University
142,China,Cholangiocarcinoma,BIOLOGICAL: autologous Tcm cellular immunotherapy,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,other,other,"Newish Technology (Beijing) Co., Ltd."
143,United States,Urothelial Carcinoma Bladder|Bladder Cancer,RADIATION: Concurrent Immunotherapy and Radiation Therapy,1,OTHER,other,OTHER,Other,Phase I,genitourinary,radiotherapy,Abramson Cancer Center at Penn Medicine
144,Italy,Glioblastoma,BIOLOGICAL: Dendritic Cells Vaccine,12,OTHER,cancer vaccine,OTHER,Other,Phase I & II,brain/CNS,cancer vaccine,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
145,United States,Papillomavirus Infections|Cervical Intraepithelial Neoplasia|Carcinoma In Situ|Vulvar Neoplasms|Vulvar Diseases,BIOLOGICAL: E7 TCR cells|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,12,NIH,adoptive cell therapy,NIH,Government,Phase I & II,gynecologic,adoptive cell therapy,National Cancer Institute (NCI)
146,United States,"Breast Neoplasm|Breast Neoplasm, Male|Triple Negative Breast Cancer",DRUG: Cyclophosphamide|DRUG: Indomethacin|DRUG: Omeprazole|DIETARY_SUPPLEMENT: Multivitamin,1,OTHER,other,OTHER,Other,Phase I,breast,other,Providence Health & Services
147,China,Elderly Patients|Metastatic Lung Cancer,DRUG: Single drug chemotherapy plus immunotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Hubei Cancer Hospital
148,China,Hepatocarcinoma|Lung Cancer|Melanoma|Renal Cancer|Head and Neck Cancer|Pancreas Cancer|Ovarian Cancer|Colo-rectal Cancer|Cervical Cancer|Breast Cancer,DRUG: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy,23,OTHER,checkpoint inhibitor,OTHER,Other,Phase II & III,gynecologic,checkpoint inhibitor,Second Affiliated Hospital of Guangzhou Medical University
149,United States,Small Cell Lung Cancer,DRUG: Combination immunotherapy with Ipilimumab and Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Yale University
150,Canada,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia,BIOLOGICAL: CLIC-1901,12,OTHER,other,OTHER,Other,Phase I & II,hematologic,other,Ottawa Hospital Research Institute
151,China,Rare Tumor,DRUG: Almonertinib 110 MG|DRUG: Dacomitinib 45 MG|DRUG: Alectinib 150 MG|DRUG: Crizotinib 250 MG|DRUG: Pyrotinib 160/80 MG|DRUG: Imatinib 400 MG|DRUG: Niraparib 200/300 MG|DRUG: Palbociclib 125mg|DRUG: Vemurafenib 240 MG|DRUG: Sintilimab 100MG|DRUG: Atezolizumab 1680 MG,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
152,United States,"Gastrointestinal Epithelial Cancer|Gastrointestinal Neoplasms|Cancer of Gastrointestinal Tract|Cancer, Gastrointestinal|Gastrointestinal Cancer|Colo-rectal Cancer|Pancreatic Cancer|Gall Bladder Cancer|Colon Cancer|Esophageal Cancer|Stomach Cancer",DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-Infiltrating Lymphocytes (TIL)|DRUG: Aldesleukin,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,genitourinary,other,"Intima Bioscience, Inc."
153,Italy,Bladder Cancer|Adult Solid Tumor,DRUG: Nivolumab|DRUG: Visugromab (CTL-002)|DRUG: Placebo,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,genitourinary,checkpoint inhibitor,CatalYm GmbH
154,"Belgium, United States",Selected Advanced Solid Tumors,DRUG: EOS006215|DRUG: Anticancer agent,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,iTeos Belgium SA
155,"Malaysia, Thailand",Hepatocellular Carcinoma,BIOLOGICAL: AlloStim® immunotherapy|DRUG: FOLFOX regimen|DRUG: Sorafenib|DRUG: Lenvatinib,23,INDUSTRY,other,INDUSTRY,Industry,Phase II & III,digestive,other,"Mirror Biologics, Inc."
156,Norway,Esophageal Cancer,DRUG: Nivolumab|RADIATION: Radiotherapy|DRUG: Chemotherapy|PROCEDURE: Surgery,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Oslo University Hospital
157,United States,Hematopoietic and Lymphoid Cell Neoplasm|Metastatic Malignant Solid Neoplasm,RADIATION: External Beam Radiation Therapy|OTHER: Laboratory Biomarker Analysis|RADIATION: Stereotactic Body Radiation Therapy,2,OTHER,other,OTHER,Other,Phase II,multiple,radiotherapy,M.D. Anderson Cancer Center
158,China,Gastric Cancer,COMBINATION_PRODUCT: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Changzhou No.2 People's Hospital
159,France,Advanced Solid Tumor,DRUG: MAQ-001|DRUG: Ipilimumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,MabQuest SA
160,United States,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|DRUG: Letrozole 2.5Mg Tab|DRUG: Palbociclib 125mg,2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,Weill Medical College of Cornell University
161,United States,Ovarian Cancer Recurrent,DRUG: Rintatolimod|DRUG: Pembrolizumab|DRUG: Cisplatin,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,gynecologic,checkpoint inhibitor,Robert Edwards
162,China,Non-small Cell Lung Cancer,DRUG: Toripalimab|OTHER: Cryoablation,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Shanghai Chest Hospital
163,United States,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms,DRUG: Olaparib|DRUG: Tremelimumab,12,OTHER,other,OTHER,Other,Phase I & II,gynecologic,other,New Mexico Cancer Research Alliance
164,United States,Advanced or Metastatic Solid Tumors|Non-Hodgkin Lymphoma,DRUG: WTX-330,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,"Werewolf Therapeutics, Inc."
165,France,Triple Negative Breast Neoplasms,DRUG: Pembrolizumab injection|DRUG: Capecitabine tablets|RADIATION: Local radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,UNICANCER
166,United States,Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer|Metastatic Ovarian Cancer|Metastatic Breast Carcinoma|Metastatic Endocrine Tumors/ Neuroendocrine Tumors,DRUG: Pembrolizumab (Keytruda)|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Aldesleukin|BIOLOGICAL: Young TIL,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,gynecologic,checkpoint inhibitor,National Cancer Institute (NCI)
167,United States,"HPV Positive Cancer|Vulvar, Vaginal, Penile, Rectal Cancer|Anal Cancer|Oropharyngeal Cancer|Cervical Cancer",BIOLOGICAL: PRGN-2009 (Phase I)|BIOLOGICAL: PRGN-2009 (Phase II)|BIOLOGICAL: M7824|DIAGNOSTIC_TEST: MRI|DIAGNOSTIC_TEST: Bone scan|DIAGNOSTIC_TEST: CT scan|DIAGNOSTIC_TEST: Brain CT|DIAGNOSTIC_TEST: Brain MRI|PROCEDURE: Biopsy (Phase I)|PROCEDURE: Biopsy (Phase II),12,NIH,other,NIH,Government,Phase I & II,gynecologic,biomarker / diagnostics,National Cancer Institute (NCI)
168,China,Patients With Advanced Solid Tumor|Advanced Solid Tumor With Oncogenic Driver Mutations,DRUG: PD-1|DRUG: MET inhibitor|DRUG: ALK inhibitor|DRUG: BRAF Inhibito|DRUG: EGFR Monoclonal antibody|DRUG: GH21|DRUG: MEK Inhibitor,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,"Suzhou Genhouse Bio Co., Ltd."
169,China,"Pancreas Cancer|CAR-T Cell Therapy|Mesothelin|Solid Tumor, Adult",BIOLOGICAL: CAR-T cells,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,multiple,adoptive cell therapy,Second Affiliated Hospital of Guangzhou Medical University
170,"Australia, Canada, Ireland, Portugal, Republic of, Spain, United States","Advanced Solid Tumor|Unresectable Solid Tumor|Clear Cell Renal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer Squamous|Non-Small Cell Lung Cancer Non-squamous|Colorectal Cancer (MSI-H)|Gastric Cancer|Cervical Cancer|Basal Cell Carcinoma|Bladder Cancer|Merkel Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck|Cutaneous Squamous Cell Carcinoma|Pleural Mesothelioma|Esophageal Cancer|Endometrial Carcinoma|Solid Tumor|Solid Tumor, Adult|MSI-H Solid Malignant Tumor|Cancer With A High Tumor Mutational Burden|Epithelial Ovarian Carcinoma|Primary Peritoneal Cancer|Gastroesophageal Junction (GEJ) Cancer|Acral Melanoma|Mucosal Melanoma|Cutaneous Melanoma|DMMR Solid Malignant Tumor|Fallopian Tube Cancer|Ovarian Cancer|MSI-H Cancer|DMMR Cancer|Pancreas Adenocarcinoma (MSI-H)|Skin Cancer|Viral Cancer|Cervical Cancers|Endometrial Cancer",DRUG: MDNA11|DRUG: Pembrolizumab (KEYTRUDA®),12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,gynecologic,checkpoint inhibitor,"Medicenna Therapeutics, Inc."
171,United States,Advanced Fallopian Tube Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Synovial Sarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Fallopian Tube Carcinoma|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Synovial Sarcoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Unresectable Melanoma|Unresectable Ovarian Carcinoma|Unresectable Synovial Sarcoma,DRUG: Cyclophosphamide|DRUG: Decitabine|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|BIOLOGICAL: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes,12,OTHER,other,OTHER,Other,Phase I & II,gynecologic,biomarker / diagnostics,Roswell Park Cancer Institute
172,United States,Cutaneous Malignant Melanoma|Renal Cell Cancer|Urothelial Cancer of Renal Pelvis,RADIATION: Low Dose Rate Brachytherapy (LDR)|DRUG: Standard-of-Care Immunotherapy,1,OTHER,other,OTHER,Other,Phase I,genitourinary,radiotherapy,Case Comprehensive Cancer Center
173,China,Metastatic Castration-resistant Prostate Cancer (CRPC),DRUG: Immunotherapy|DRUG: Targeted therapy|DEVICE: Hyperthermia,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Pengyuan Liu
174,"France, Italy, Spain, United States",Hepatocellular Carcinoma,DEVICE: TheraSphere Y-90 glass microsphere therapy|DRUG: Durvalumab (Imfinzi) immunotherapy|DRUG: Tremelimumab immunotherapy,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,Boston Scientific Corporation
175,China,Locally Advanced Esophageal Squamous Cell Carcinoma,DRUG: Chemotherapy|DRUG: Immunotherapy (Pembrolizumab)|RADIATION: radiotherapy,23,OTHER,checkpoint inhibitor,OTHER,Other,Phase II & III,digestive,checkpoint inhibitor,Peking Union Medical College Hospital
176,"Canada, United States","Lung Cancer, Nonsmall Cell|Lung Cancer Stage IV|Lung Cancer Metastatic",DRUG: SLC-391|BIOLOGICAL: pembrolizumab,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,lung/thoracic,checkpoint inhibitor,SignalChem Lifesciences Corporation
177,China,"Endometrial Neoplasms|Neoplasm Recurrence, Local|Neoplasm Metastasis",DRUG: Paclitaxel and Cisplatin|DRUG: Cadonilimab|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,gynecologic,radiotherapy,Shandong Cancer Hospital and Institute
178,China,Pancreatic Cancer,DRUG: PD-1|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|RADIATION: PULSAR,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Fudan University
179,China,"Nonsmall Cell Lung Cancer|Solid Tumor, Adult",BIOLOGICAL: TCR-T cells,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,lung/thoracic,adoptive cell therapy,Second Affiliated Hospital of Guangzhou Medical University
180,China,Anti-cancer Cell Immunotherapy|T Cell and NK Cell,BIOLOGICAL: ITNK cell therapy,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,other,adoptive cell therapy,Second Affiliated Hospital of Guangzhou Medical University
181,United States,Metastatic Cancer|Melanoma Cancer|Lung Cancer|Bladder Cancer|Renal Cancer|Head/Neck Cancers,"RADIATION: Stereotactic Body Radiotherapy|BIOLOGICAL: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
182,United States,Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy|MSI-H Tumors,DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Relatlimab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
183,United States,"Solid Tumor, Adult",BIOLOGICAL: CF33-CD19 IT Monotherapy|BIOLOGICAL: CF33-CD19 IV Monotherapy|BIOLOGICAL: CF33-CD19 IT Combination|BIOLOGICAL: CF33-CD19 IV Combination|DRUG: Blinatumomab|DRUG: Hydroxyurea,1,INDUSTRY,combination product,INDUSTRY,Industry,Phase I,multiple,combination product,Imugene Limited
184,China,Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)|Breast Cancer Recurrent|Gastric Cancer With Metastasis,BIOLOGICAL: EpCAM CAR-T cells,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,digestive,adoptive cell therapy,Sichuan University
185,China,Breast Cancer|Breast Carcinoma|Breast Cancer Metastatic|Breast Cancer Triple Negative,BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamid|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,breast,checkpoint inhibitor,Essen Biotech
186,France,Oligometastatic Non-small Cell Lung Cancer (NSCLC),RADIATION: Radical local treatment|DRUG: SoC-based immunotherapy (+/- chemotherapy),3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,radiotherapy,"Gustave Roussy, Cancer Campus, Grand Paris"
187,"France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom",Advanced Solid Tumor,DRUG: Atezolizumab|DRUG: Futibatinib|DRUG: Amivantamab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Vall d'Hebron Institute of Oncology
188,United States,Prostate Cancer,DRUG: Ipilimumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
189,China,Advanced Solid Tumor,DRUG: HS-10386,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,"Jiangsu Hansoh Pharmaceutical Co., Ltd."
190,United States,Ependymoma|Medulloblastoma|Glioblastoma|Primary Brain Tumor,DRUG: Ibrutinib|DRUG: Indoximod|DRUG: Cyclophosphamide|DRUG: Etoposide,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Theodore S. Johnson
191,China,Biliary Tract Neoplasms|Immunotherapy,DRUG: Durvalumab|DRUG: Lenvatinib Oral Product|DRUG: Chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Peking Union Medical College Hospital
192,Australia,Pancreatic Cancer,DRUG: Durvalumab|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Calcium folinate (leucovorin)|DRUG: Fluorouracil|DRUG: Pegylated G-CSF,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,digestive,checkpoint inhibitor,Australasian Gastro-Intestinal Trials Group
193,United States,Prostate Cancer|Prostate Disease,DRUG: Nivolumab|RADIATION: Brachytherapy|RADIATION: External Beam Radiation Therapy|DRUG: Androgen Deprivation Therapy,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
194,"France, Monaco","Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4",RADIATION: Radiotherapy|DRUG: Pembrolizumab|DRUG: Chemotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,UNICANCER
195,United States,Cancer|Melanoma Stage III|Melanoma Stage IV|Cutaneous Melanoma,BIOLOGICAL: KB707|DRUG: Opdualag|DRUG: KEYTRUDA ®( Pembrolizumab),12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,skin,checkpoint inhibitor,"Krystal Biotech, Inc."
196,United States,Pancreatic Cancer|Cancer of the Pancreas,BIOLOGICAL: huCART-meso cells,1,OTHER,other,OTHER,Other,Phase I,digestive,other,University of Pennsylvania
197,United States,Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma,BIOLOGICAL: second generation 4-1BBζ EGFR806-EGFRt|BIOLOGICAL: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG,1,OTHER,other,OTHER,Other,Phase I,sarcoma,other,Seattle Children's Hospital
198,Republic of,Biliary Tract Neoplasms|Gallbladder Cancer|Cholangiocarcinoma,DRUG: Durvalumab + Gem/Cis|DRUG: Gem/Cis,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Asan Medical Center
199,China,"Stomach Cancer|Stomach Cancer Recurrent|Stomach Cancer, Adenocarcinoma|Esophageal Cancer|Esophageal Cancer Metastatic to Bone|Esophageal Cancer Metastatic to Lung|Esophageal Cancer Metastatic to Liver",BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamid|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Essen Biotech
200,China,Immunotherapy,BIOLOGICAL: CAR-T cell immunotherapy,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,other,adoptive cell therapy,The Affiliated Hospital of Xuzhou Medical University
201,China,Small-cell Lung Cancer,RADIATION: split-course adaptive hypofractionated radiotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Fujian Medical University Union Hospital
202,China,"Lung Cancer|Lung Cancer Metastatic|Lung Cancer, Non-small Cell|Lung Cancer Recurrent",BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,Essen Biotech
203,"Netherlands, Spain, United Kingdom",Locally Advanced Solid Tumor,RADIATION: 89Zr-Df-crefmirlimab PET scan|DRUG: Nivolumab|DRUG: Cetrelimab|OTHER: zirconium Zr 89 crefmirlimab berdoxam,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,University Medical Center Groningen
204,"Belgium, France",Triple Negative Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: MEDI4736|DRUG: MEDI9447,12,OTHER,other,OTHER,Other,Phase I & II,breast,chemotherapy,Jules Bordet Institute
205,China,Esophageal Carcinoma|Radiotherapy|Immunotherapy,DRUG: Immunotherapy|DRUG: chemotherapy: Paclitaxel/Cisplatin|RADIATION: TDLN-sparing RT,3,OTHER,other,OTHER,Other,Phase III,digestive,radiotherapy,Fudan University
206,United States,Adult Acute Myeloid Leukemia in Remission|Acute Biphenotypic Leukemia|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Acute Myeloid Leukemia|Adult Acute Lymphoblastic Leukemia|Interleukin-3 Receptor Subunit Alpha Positive|Minimal Residual Disease|Refractory Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: cyclophosphamide|BIOLOGICAL: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|OTHER: laboratory biomarker analysis|BIOLOGICAL: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|DRUG: Fludarabine Phosphate,1,OTHER,other,OTHER,Other,Phase I,hematologic,biomarker / diagnostics,City of Hope Medical Center
207,China,"Brain Tumor|Brain Metastases|Brain Cancer|Glioma|Gliomas, Malignant|Glioblastoma|Meningioma",BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,brain/CNS,checkpoint inhibitor,Essen Biotech
208,Netherlands,Cutaneous Squamous Cell Carcinoma (CSCC)|Cutaneous Squamous Cell Cancer|Cutaneous Squamous Cell Carcinoma of the Head and Neck|Cutaneous Squamous Cell Carcinoma,DRUG: Nivolumab|DRUG: Ipilumimab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,The Netherlands Cancer Institute
209,"Canada, China, France, Germany, Hong Kong, Italy, Japan, Republic of, Singapore, Spain, Taiwan, United States","Carcinoma, Non-Small-Cell Lung|Cutaneous Melanoma|Carcinoma, Renal Cell|Carcinoma, Ovarian Epithelial|Nasopharyngeal Carcinoma|Carcinoma, Thymic|Anal Cancer|Mesothelioma|Esophagogastric Cancer|High Microsatellite Instability Colorectal Carcinoma|Squamous Cell Carcinoma of Head and Neck|Triple Negative Breast Neoplasms",DRUG: KFA115|DRUG: pembrolizumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,gynecologic,checkpoint inhibitor,Novartis Pharmaceuticals
210,"Australia, United States",Solid Tumor,DRUG: ACTM-838,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,"Actym Therapeutics, Inc."
211,"Taiwan, United States","Solid Tumor, Unspecified, Adult|Lymphoma",DRUG: Single Arm,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,Cytosite Biopharma Inc.
212,China,Head and Neck Cancer,DRUG: Tislelizumab|DRUG: Afatinib|RADIATION: Low dose radiotherapy,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,West China Hospital
213,Italy,Breast Cancer|Chest Wall Tumor,DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,European Institute of Oncology
214,United States,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndromes|Acute Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Chronic Myeloid Leukemia,BIOLOGICAL: Orca-T,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,"Orca Biosystems, Inc."
215,"Canada, France, Spain, United States","Advanced Solid Tumors|Genital Neoplasm, Female|Urogenital Neoplasms|Lung Neoplasm|Neoplasms by Site|Papillomavirus Infection|Epstein-Barr Virus Infections|Carcinoma|Neoplasms|Vulvar Neoplasms|Vulvar Diseases|Abdominal Neoplasm",DRUG: STAR0602,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,gynecologic,other,"Marengo Therapeutics, Inc."
216,Denmark,"Pancreas Cancer, Metastatic",DRUG: Pembrolizumab|DEVICE: Irreversible electroporation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,"Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery"
217,United States,"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|High Grade B-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma",BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|DRUG: Bendamustine Hydrochloride|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Fludarabine Phosphate,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,City of Hope Medical Center
218,"Australia, United States",B-cell Lymphoma|Non-Hodgkin Lymphoma|B-cell Malignancy|Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Large B-cell Lymphoma,BIOLOGICAL: CTX112,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,CRISPR Therapeutics AG
219,China,Non-small Cell Lung Cancer,COMBINATION_PRODUCT: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy,2,OTHER,combination product,OTHER,Other,Phase II,lung/thoracic,combination product,Changzhou No.2 People's Hospital
220,United States,Diffuse Intrinsic Pontine Glioma|High Grade Glioma|Embryonal Tumor|Ependymal Tumor,GENETIC: C7R-GD2.CART cells (IV and ICV infusion)|GENETIC: C7R-GD2.CAR T cells (IV infusion),1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Baylor College of Medicine
221,United States,Pancreatic Ductal Adenocarcinoma|Colorectal Cancer|KRAS G12D|KRAS G12R|KRAS G12V|KRAS G12A|KRAS G12C|KRAS G12S|KRAS G13D|NRAS G12D|NRAS G12R|NRAS G12V|NRAS G12C|NRAS G12S,DRUG: ELI-002 7P,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,digestive,other,Elicio Therapeutics
222,"Australia, Canada, United States",Advanced Solid Tumors,DRUG: BMS-986484|BIOLOGICAL: Nivolumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,Bristol-Myers Squibb
223,United States,Bladder Cancer,DRUG: N-803 and BCG|DRUG: N-803,23,INDUSTRY,other,INDUSTRY,Industry,Phase II & III,genitourinary,other,"ImmunityBio, Inc."
224,France,Non Small Cell Lung Cancer,DRUG: ICI treatment discontinuation|DRUG: ICI treatment continuation,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Institut Bergonié
225,France,Malignant Solid Neoplasms,DRUG: Nilotinib (400 mg BID)|DRUG: Everolimus (10 mg QD)|DRUG: Sorafenib (400 mg BID)|DRUG: Lapatinib (1500 mg QD)|DRUG: Pazopanib (800 mg QD)|DRUG: Olaparib (300 mg BID)|COMBINATION_PRODUCT: Durvalumab + Tremelimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Centre Leon Berard
226,France,Endometrial Carcinoma|Cervix Carcinoma,DRUG: NP137|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,gynecologic,checkpoint inhibitor,NETRIS Pharma
227,Germany,Lung Cancer Non-Small Cell Cancer (NSCLC),"PROCEDURE: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|RADIATION: Chemoradiotherapy|DRUG: Immunotherapy",2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Eleni Gkika
228,Sweden,Colorectal Cancer,DRUG: pTTL,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,digestive,other,Neogap Therapeutics AB
229,United States,Advanced Unresectable Solid Tumor|Metastatic Solid Tumor,DRUG: TAB004|DRUG: Toripalimab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,TopAlliance Biosciences
230,Brazil,Squamous Cell Carcinoma of Larynx,"DRUG: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|RADIATION: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|DRUG: Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Latin American Cooperative Oncology Group
231,"Australia, United States",T Cell Lymphoma|B Cell Lymphoma|Acute Myeloid Leukemia,BIOLOGICAL: CTX131,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,CRISPR Therapeutics
232,United States,Non-Small Cell Lung Cancer|NSCLC|Advanced Non-Small Cell Lung Cancer|Metastatic Non Small Cell Lung Cancer,DRUG: Reduced Dose of Chemotherapy and Immunotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Virginia Commonwealth University
233,United Kingdom,Metastatic Colorectal Cancer,DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Royal Marsden NHS Foundation Trust
234,United States,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Mixed Phenotype Acute Leukemia|Undifferentiated Leukemia|Myelodysplastic Syndrome|Acute Leukemia|Therapy-Related Myelodysplastic Syndrome,BIOLOGICAL: Orca-T|BIOLOGICAL: Standard-of-Care,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,hematologic,other,"Orca Biosystems, Inc."
235,Netherlands,"Uveal Melanoma, Metastatic",DRUG: Ipilimumab and nivolumab|DRUG: Melphalan chemosaturation via percutaneous hepatic perfusion,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,skin,checkpoint inhibitor,Leiden University Medical Center
236,United States,Recurrent Pulmonary Osteosarcoma|Recurrent High-grade Glioma,BIOLOGICAL: pp65 RNA LP (DP1)|BIOLOGICAL: pp65/tumor mRNA RNA-LP (DP2)|PROCEDURE: Surgical Biopsy/Resection,12,OTHER,cancer vaccine,OTHER,Other,Phase I & II,brain/CNS,cancer vaccine,University of Florida
237,China,Esophageal Cancer|Immunotherapy|Induction Therapy|Chemoradiotherapy|Surgery,DRUG: Cardonilizumab|RADIATION: Chemoradiotherapy ±immunotherapy|PROCEDURE: Radical surgery,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
238,"Argentina, Belgium, Brazil, Canada, Chile, Czechia, Hungary, India, Italy, Mexico, Republic of, Spain, Taiwan, United States","Carcinoma, Ovarian Epithelial|Ovarian Neoplasms|Ovarian Cancer|Ovarian Serous Adenocarcinoma|Fallopian Tube Neoplasms|Fallopian Tube Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Peritoneal Cancer|Peritoneal Carcinoma|Peritoneal Neoplasms",BIOLOGICAL: Oregovomab|DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Placebo|DRUG: Carboplatin,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,gynecologic,chemotherapy,CanariaBio Inc.
239,United States,Lung Cancer,BIOLOGICAL: CAN-2409 + valacyclovir,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,lung/thoracic,other,"Candel Therapeutics, Inc."
240,China,Bladder Cancer Stage IV,DRUG: Chidamide,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Sun Yat-sen University
241,France,Hepatocellular Carcinoma,DRUG: EXL01,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Center Eugene Marquis
242,China,"Lung Cancer, Small Cell",DRUG: Chemotherapy （Etoposide and Carboplatin）|DRUG: Immunotherapy （Envafolimab）|DRUG: Trilaciclib,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Shanghai Chest Hospital
243,China,Non-Small Cell Lung Cancer,COMBINATION_PRODUCT: Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy|DRUG: Immunotherapy (with or without chemotherapy) maintenance therapy,2,OTHER,combination product,OTHER,Other,Phase II,lung/thoracic,combination product,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
244,Spain,Colorectal Cancer|Endometrial Cancer,DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,Vall d'Hebron Institute of Oncology
245,Portugal,Triple Negative Breast Cancer (TNBC),OTHER: Morning pembrolizumab infusions,12,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase I & II,breast,checkpoint inhibitor,"Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E."
246,United States,Gastrointestinal Cancer|Pancreatic Cancer|Gastric Cancer|Colon Cancer|Rectal Cancer,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: anti-KRAS G12D mTCR PBL,12,NIH,adoptive cell therapy,NIH,Government,Phase I & II,digestive,adoptive cell therapy,National Cancer Institute (NCI)
247,China,Cervical Cancer|Induction Chemotherapy|Immunotherapy,DRUG: Toripalimab,12,OTHER,other,OTHER,Other,Phase I & II,gynecologic,other,Tianjin Medical University Cancer Institute and Hospital
248,Republic of,Ovarian Cancer by FIGO Stage|Ovarian Cancer Stage III|Ovarian Cancer Stage IV,BIOLOGICAL: Oregovomab|DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,gynecologic,chemotherapy,CanariaBio Inc.
249,United States,Urothelial Cancer|Metastatic Urothelial Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Bladder Cancer,DRUG: Sacituzumab Govitecan (SG)|DRUG: Enfortumab vedotin-ejfv (EV)|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,Dana-Farber Cancer Institute
250,United States,Pancreatic Cancer|Metastatic Pancreatic Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Radiation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Massachusetts General Hospital
251,United States,Cervical Cancer|Throat Cancer|Oropharynx Cancer|Anal Cancer|Vulva Cancer|Vaginal Cancer|Penile Cancer|Metastatic Cancer|HPV-Related Malignancy|HPV-Related Carcinoma|HPV-Related Cervical Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Adenocarcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Associated Vaginal Adenocarcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Related Endocervical Adenocarcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV Positive Rectal Squamous Cell Carcinoma,BIOLOGICAL: E7 TCR-T cells|DRUG: Aldesleukin,2,OTHER,adoptive cell therapy,OTHER,Other,Phase II,gynecologic,adoptive cell therapy,Christian Hinrichs
252,United States,Metastatic Colorectal Cancer,BIOLOGICAL: AlloStim,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,other,"Mirror Biologics, Inc."
253,United States,Pancreatic Cancer|Gastric Cancer|Gastrointestinal Cancer|Colon Cancer|Rectal Cancer,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Anti-KRAS G12V mTCR PBL|DRUG: Aldesleukin,12,NIH,adoptive cell therapy,NIH,Government,Phase I & II,digestive,adoptive cell therapy,National Cancer Institute (NCI)
254,China,Neoadjuvant Therapy|Concurrent Chemoradiotherapy|Immunotherapy|Locally Advanced Non-Small Cell Lung Cancer,DRUG: Neoadjuvant therapy|RADIATION: Concurrent chemoradiotherapy|DRUG: Consolidative immunotherapy,3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,radiotherapy,Sun Yat-sen University
255,China,Lung Cancer|Surgery|Non-small Cell Lung Cancer,"DRUG: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Second Affiliated Hospital of Guangzhou Medical University
256,United States,HER2-positive Breast Cancer|Breast Cancer,DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,University of Texas Southwestern Medical Center
257,"Canada, Chile, Republic of, United States","HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",DRUG: ZW25 (Zanidatamab)|DRUG: Capecitabine|DRUG: Cisplatin|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: Bevacizumab|DRUG: Gemcitabine,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,chemotherapy,Jazz Pharmaceuticals
258,"Australia, United States","Solid Tumor, Adult|Mesothelioma|NSCLC",DRUG: VT3989|DRUG: Nivolumab & Ipilimumab|DRUG: Osimertinib,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,lung/thoracic,checkpoint inhibitor,"Vivace Therapeutics, Inc"
259,"Argentina, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Norway, Poland, Portugal, Republic of, Romania, Spain, Taiwan, Turkey, United States","Neoplasms, Head and Neck",DRUG: Dostarlimab|DRUG: Belrestotug|DRUG: Nelistotug|DRUG: GSK4381562,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,head/neck,other,GlaxoSmithKline
260,China,Metastatic Malignant Solid Neoplasm|Radiotherapy|Immune Checkpoint Blockade|Resistance to Immunotherapy,RADIATION: Intestinal Low Dose Radiotherapy-1Gy|RADIATION: Intestinal Low Dose Radiotherapy-2-3Gy|DRUG: PD-1/PD-L1 Inhibitors,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Chuangzhen Chen
261,China,Advanced Solid Tumor|Tumor Associated Lymph Node T Cell|Immunotherapy,DRUG: Tumor Associated Lymph node T cell|DRUG: cyclophosphamide|DRUG: IL-2|DRUG: Serplulimab Injection,1,INDUSTRY,cytokine / immunomodulator,INDUSTRY,Industry,Phase I,multiple,cytokine / immunomodulator,"Guangzhou FineImmune Biotechnology Co., LTD."
262,China,Liver Cancer,BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Zhiyong Huang
263,United States,Uveal Melanoma,RADIATION: stereotactic body radiotherapy|DRUG: Immunotherapy,2,OTHER,other,OTHER,Other,Phase II,skin,radiotherapy,California Pacific Medical Center Research Institute
264,United States,Metastatic Malignant Neoplasm in the Liver|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,PROCEDURE: Hepatectomy|BIOLOGICAL: Pembrolizumab|DRUG: Vactosertib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Chloe Atreya, MD, PhD"
265,Singapore,Locally Recurrent Cancer|Metastatic Nasopharyngeal Cancer,DRUG: pembrolizumab|DRUG: bevacizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,head/neck,checkpoint inhibitor,"National University Hospital, Singapore"
266,"Australia, Belgium, Netherlands, Switzerland, United Kingdom, United States","Melanoma|Merkel Cell Carcinoma, Unspecified|Renal Cell Carcinoma|Non Small Cell Lung Cancer",BIOLOGICAL: zirconium Zr 89 crefmirlimab berdoxam,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,genitourinary,other,"ImaginAb, Inc."
267,China,Stomach Neoplasms|Gastric Cancer|Linitis Plastica of Stomach,DRUG: Tislelizumab|DRUG: Oxaliplatin|DRUG: S-1|DRUG: Capecitabine,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sun Yat-sen University
268,"Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Estonia, France, Georgia, Germany, Greece, Guatemala, India, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands, Poland, Portugal, Republic of, Romania, Serbia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom",Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma,DRUG: Zanidatamab|DRUG: Tislelizumab|DRUG: Trastuzumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Cisplatin|DRUG: 5-Fluorouracil,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,digestive,chemotherapy,Jazz Pharmaceuticals
269,China,Esophageal Squamous Cell Carcinoma,DRUG: paclitaxel|DRUG: carboplatin|DRUG: tislelizumab|RADIATION: radiotherapy,12,OTHER,other,OTHER,Other,Phase I & II,digestive,radiotherapy,Qiu Guoqin
270,United States,Neuroblastoma,"BIOLOGICAL: Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|DRUG: Cytoxan",12,OTHER,cancer vaccine,OTHER,Other,Phase I & II,other,cancer vaccine,Baylor College of Medicine
271,"Argentina, Australia, Chile, Singapore, Spain, United States",Metastasis,DRUG: THOR-707|DRUG: Checkpoint inhibitor|DRUG: anti-EGFR antibody,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,other,other,"Synthorx, Inc, a Sanofi company"
272,United States,Metastatic Cancer,DRUG: Keytruda Injectable Product|DRUG: Yervoy Injectable Product|DRUG: GM-CSF|PROCEDURE: Non-ablative Cryosurgical freezing,2,OTHER,other,OTHER,Other,Phase II,multiple,other,"ImmunSYS, LLC"
273,Italy,Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer,DRUG: Erlotinib|DRUG: Trastuzumab|DRUG: Trastuzumab emtansine|DRUG: Pertuzumab|DRUG: Lapatinib|DRUG: Everolimus|DRUG: Vemurafenib|DRUG: Cobimetinib|DRUG: Alectinib|DRUG: Brigatinib|DRUG: Palbociclib|DRUG: Ponatinib|DRUG: Vismogedib|DRUG: Itacitinib|DRUG: Ipatasertib|DRUG: Entrectinib|DRUG: Atezolizumab|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Pemigatinib|DRUG: Oncology Drugs|DRUG: Pralsetinib|DRUG: Selpercatinib|DRUG: Talazoparib|DRUG: Tepotinib|DRUG: Alpelisib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Fondazione per la Medicina Personalizzata
274,"Puerto Rico, United States",Prostate Cancer,BIOLOGICAL: Aglatimagene besadenovec + valacyclovir|BIOLOGICAL: Placebo + valacyclovir,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,genitourinary,other,"Candel Therapeutics, Inc."
275,"Australia, Brazil, China, Denmark, France, Germany, Greece, Italy, Mexico, Poland, Republic of, Spain, Turkey, United Kingdom, United States",Urothelial Cancer,DRUG: Atezolizumab|DRUG: Tobemstomig|DRUG: Tiragolumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,other,checkpoint inhibitor,Hoffmann-La Roche
276,United States,Pancreatic Cancer,PROCEDURE: Biopsy|DRUG: FOLFIRINOX|DRUG: Ciprofloxacin|DRUG: Metronidazole|DRUG: Pembrolizumab|PROCEDURE: Surgical Resection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Icahn School of Medicine at Mount Sinai
277,United Kingdom,Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage I,RADIATION: Stereotactic body radiotherapy|DRUG: Nivolumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,Royal Marsden NHS Foundation Trust
278,United States,Metastatic Cancer|Cervical Cancer,DRUG: Lorigerlimab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,M.D. Anderson Cancer Center
279,United States,Gynecologic Cancer|Colorectal Cancer|Pancreatic Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Ovarian Cancer|Endometrial Cancer|Ovarian Carcinoma|Ovary Neoplasm|Squamous Cell Lung Cancer|Adenocarcinoma of Lung|Adenosquamous Cell Lung Cancer,BIOLOGICAL: Neoantigen specific TCR-T cell drug product|BIOLOGICAL: Aldesleukin (IL-2),12,INDUSTRY,adoptive cell therapy,INDUSTRY,Industry,Phase I & II,gynecologic,adoptive cell therapy,Alaunos Therapeutics
280,China,"Lung Cancer, Non-small Cell",RADIATION: hypofractionated radiation therapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Jiangsu Cancer Institute & Hospital
281,Brazil,Renal Cancer Metastatic,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Hospital das Clínicas de Ribeirão Preto
282,China,Esophageal Squamous Cell Carcinoma|Esophageal Cancer|Metastatic Esophageal Squamous Cell Carcinoma,RADIATION: LDRT+CFRT|DRUG: Immunotherapy|DRUG: Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Shanghai Chest Hospital
283,China,Melanoma,"BIOLOGICAL: Antigen-specific CAR T, CTL and DCvac to treat melanoma.",12,OTHER,other,OTHER,Other,Phase I & II,skin,other,Shenzhen Geno-Immune Medical Institute
284,China,Non-Small Cell Lung Cancer,DRUG: Chemotherapy|DRUG: Immunotherapy|PROCEDURE: Radical resection of lung cancer|RADIATION: SBRT,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,First People's Hospital of Hangzhou
285,United States,Pancreatic Cancer|Locally Advanced Pancreatic Cancer,DRUG: Pembrolizumab|DEVICE: Irreversible Electroporation,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
286,United States,"Central Nervous System Tumor|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma|Ependymoma|Medulloblastoma, Childhood|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma, Childhood|Glioma",BIOLOGICAL: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Seattle Children's Hospital
287,United States,Endometrial Cancer,DRUG: Atezolizumab - 28 Day Cycle|DRUG: Bevacizumab|DRUG: Ipatasertib|DRUG: Talazoparib|DRUG: Trastuzumab emtansine|DRUG: Tiragolumab|DRUG: Atezolizumab - 21 Day Cycle|DRUG: Inavolisib|DRUG: Letrozole|DRUG: Giredestrant|DRUG: Abemaciclib,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,gynecologic,checkpoint inhibitor,"Alliance Foundation Trials, LLC."
288,Switzerland,Bladder Cancer,DRUG: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|DRUG: Atezolizumab|DRUG: Cisplatin|DRUG: Gemcitabine,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Swiss Group for Clinical Cancer Research
289,United States,Metastatic Prostate Cancer|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Pancreatic Cancer,DRUG: Evofosfamide|DRUG: Zalifrelimab|DRUG: Balstilimab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,genitourinary,other,ImmunoGenesis
290,"Mexico, United States",Prostate Cancer,BIOLOGICAL: aglatimagene besadenovec|BIOLOGICAL: placebo|DRUG: valacyclovir,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,genitourinary,other,"Candel Therapeutics, Inc."
291,France,Non-Small Cell Lung Cancer,DRUG: EXL01,12,OTHER,other,OTHER,Other,Phase I & II,lung/thoracic,other,"University Hospital, Lille"
292,United States,Cancer|Solid Tumor|Colorectal Cancer|Pancreas Cancer|Non Small Cell Lung Cancer|Head and Neck Cancer|Gynecologic Cancer|Skin Cancer|Kidney Cancer,BIOLOGICAL: DK210 (EGFR)|RADIATION: Radiation therapy|BIOLOGICAL: Immune checkpoint blockers|DRUG: Chemotherapy,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,radiotherapy,DEKA Biosciences
293,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Metastatic Basal Cell Carcinoma|Metastatic Carcinoma in the Skin|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Unresectable Basal Cell Carcinoma|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma|Unresectable Skin Squamous Cell Carcinoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|PROCEDURE: Kidney Biopsy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|DRUG: Prednisone|DRUG: Sirolimus,12,NIH,checkpoint inhibitor,NIH,Government,Phase I & II,skin,checkpoint inhibitor,National Cancer Institute (NCI)
294,Mexico,Metastatic Cancer|Metastatic Breast Cancer|Metastatic Lung Cancer|Solid Tumor|Cancer,DRUG: SV-101,1,OTHER,other,OTHER,Other,Phase I,lung/thoracic,other,Williams Cancer Foundation
295,France,Non-small Cell Lung Cancer Stage IV,DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Intergroupe Francophone de Cancerologie Thoracique
296,China,Hepatic Cancer|Surgery,"DRUG: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Second Affiliated Hospital of Guangzhou Medical University
297,Netherlands,Esophageal Cancer,DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Erasmus Medical Center
298,United States,"Solid Tumor, Adult|HCC - Hepatocellular Carcinoma|CRC (Colorectal Cancer)|Pancreatic Adenocarcinoma|NSCLC Non-small Cell Lung Cancer|Squamous Cell Cancer of the Head and Neck|UC (Urothelial Cancer)|MSI-H Cancer",DRUG: Decoy20|DRUG: Tislelizumab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,digestive,other,"Indaptus Therapeutics, Inc"
299,United States,Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: Anti-hCD70 CAR transduced PBL,12,NIH,other,NIH,Government,Phase I & II,gynecologic,other,National Cancer Institute (NCI)
300,United States,Melanoma,OTHER: Immunotherapy|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,2,OTHER,other,OTHER,Other,Phase II,skin,radiotherapy,M.D. Anderson Cancer Center
301,China,Tumor Associated Lymph Node T Cell|Advanced Solid Tumor|Immunotherapy|Serplulimab Injection,BIOLOGICAL: Tumor Associated Lymph node T cell|DRUG: Serplulimab Injection,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,"Guangzhou FineImmune Biotechnology Co., LTD."
302,China,Gastric Cancer|Colon Cancer|MSI-H|DMMR Cancer,"DRUG: PD1/PDL1 antibody monotherapy, up to 24 weeks|COMBINATION_PRODUCT: Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|PROCEDURE: Radical surgery",2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Peking University
303,United States,Advanced Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head-and-neck Squamous-cell Carcinoma|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck|Locally Advanced Head and Neck Squamous Cell Carcinoma|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck,DRUG: Pembrolizumab (immunotherapy)|RADIATION: Quad-shot palliative radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Wake Forest University Health Sciences
304,United Kingdom,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Lymphoma, Follicular|Lymphoma, B-Cell|Large B-cell Lymphoma",DRUG: ALETA-001,12,OTHER,other,OTHER,Other,Phase I & II,hematologic,other,Cancer Research UK
305,United States,Advanced Cancer,BIOLOGICAL: pING-hHER3FL,1,OTHER,other,OTHER,Other,Phase I,multiple,other,Herbert Lyerly
306,United States,"Anatomic Stage IV Breast Cancer AJCC V8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC V8|Unresectable Breast Carcinoma|Metastatic Melanoma|Unresectable Melanoma|Cutaneous Squamous Cell Carcinoma|Merkel Cell Carcinoma|Soft Tissue Sarcoma|Bone Sarcoma|Sarcoma,Soft Tissue|Sarcoma of Bone|Basal Cell Carcinoma",BIOLOGICAL: Anti-CD40 Agonist Monoclonal Antibody CDX-1140|DRUG: Poly ICLC|RADIATION: Radiation Therapy|BIOLOGICAL: Recombinant Flt3 Ligand|DRUG: Pembrolizumab|DRUG: Tocilizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,breast,checkpoint inhibitor,University of Southern California
307,China,Stage III Non-small Cell Lung Cancer,DRUG: Neoadjuvant chemo-immunotherapy|DRUG: Bevacizumab|RADIATION: Radiotherapy|DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Sun Yat-sen University
308,United States,Non Small Cell Lung Cancer|Pancreatic Ductal Adenocarcinoma,DRUG: Mavrostobart (PT199)|DRUG: Tislelizumab|DRUG: Gemcitabine + nab-Paclitaxel|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Carboplatin + Pemetrexed|DRUG: Pembrolizumab + Carboplatin + Pemetrexed,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,digestive,checkpoint inhibitor,Phanes Therapeutics
309,United States,Muscle-Invasive Bladder Carcinoma|Metastatic Urothelial Carcinoma,DRUG: SEphB4-HSA|DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Enfortumab vedotin,23,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II & III,genitourinary,checkpoint inhibitor,"Vasgene Therapeutics, Inc"
310,"France, Greece, Republic of, Spain, Taiwan, United Kingdom, United States",Urothelial Carcinoma|Bladder Cancer,DRUG: Atezolizumab|DRUG: Enfortumab Vedotin|DRUG: Niraparib|DRUG: Magrolimab (Hu5F9-G4)|DRUG: Tiragolumab|DRUG: Sacituzumab Govitecan|DRUG: Tocilizumab|DRUG: Cisplatin|DRUG: Gemcitabine,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,genitourinary,checkpoint inhibitor,Hoffmann-La Roche
311,United States,Liver Cancer,GENETIC: GAP T cells|DRUG: Cytoxan|DRUG: Fludara,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Baylor College of Medicine
312,United States,Gastrointestinal Carcinoma|Pancreatic Cancer|Hepatocellular Cancer|Cholangiocarcinoma|Duodenal Cancer|Colorectal Cancer|Small Bowel Cancer|Metastatic Cancers,BIOLOGICAL: KRAS TCR-Transduced PBL|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,2,NIH,adoptive cell therapy,NIH,Government,Phase II,digestive,adoptive cell therapy,National Cancer Institute (NCI)
313,United States,Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
314,United States,Metastatic Colorectal Cancer,"DRUG: Retifanlimab|BIOLOGICAL: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform|DRUG: N-803|DRUG: SX-682",12,NIH,cancer vaccine,NIH,Government,Phase I & II,digestive,cancer vaccine,National Cancer Institute (NCI)
315,"France, Germany, Spain, United States",Non-Small Cell Lung Cancer,DRUG: Cemiplimab|DRUG: Platinum-based chemotherapy|DRUG: REGN7075,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,checkpoint inhibitor,Regeneron Pharmaceuticals
316,China,Esophagus Cancer|Neoadjuvant Therapy,DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,other,other,"Wuhan Union Hospital, China"
317,Spain,Non Small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Fundación GECP
318,United States,Biliary Cancer|Bile Duct Cancer|Cancer of the Bile Duct,DRUG: oxaliplatin|DRUG: capecitabine|BIOLOGICAL: Keytruda|BIOLOGICAL: CDX-1140,12,NIH,other,NIH,Government,Phase I & II,other,other,National Cancer Institute (NCI)
319,China,Esophageal Cancer,COMBINATION_PRODUCT: Experimental: Arm 1 Organ preservation|COMBINATION_PRODUCT: Active Comparator: Arm 2 Surgery,3,OTHER,combination product,OTHER,Other,Phase III,digestive,combination product,Ruijin Hospital
320,United States,Acute Lymphoblastic Leukemia|Large B-cell Lymphoma,"DRUG: KYMRIAH|DRUG: YESCARTA|DRUG: Fludarabine 30mg/m2 4 doses|DRUG: Cyclophosphamide 500 mg/m2; 2 doses|DRUG: Fludarabine 30mg/m2 3 doses|DRUG: Cyclophosphamide 500 mg/m2; 3 doses|DRUG: Fludarabine 25mg/m2 3 days|DRUG: Cyclophosphamide 250 mg/m2; 3 days|DRUG: Tecartus|DRUG: Abecma, Intravenous Suspension|DRUG: Cyclophosphamide 900 mg/m2; 1 day|DRUG: Breyanzi Injectable Product",2,OTHER,other,OTHER,Other,Phase II,hematologic,other,"Masonic Cancer Center, University of Minnesota"
321,United States,Glioblastoma,BIOLOGICAL: Autologous genetically modified gamma-delta T cells|BIOLOGICAL: Allogeneic genetically modified gamma-delta T cells,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,brain/CNS,other,In8bio Inc.
322,United States,Lung Cancer Stage II|Lung Cancer Stage III|Non Small Cell Lung Cancer,RADIATION: SBRT|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: cis Platinum|DRUG: Etoposide|RADIATION: IMRT|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Wake Forest University Health Sciences
323,United States,Breast Cancer,DRUG: Pembrolizumab|RADIATION: RT Boost,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,breast,checkpoint inhibitor,Stephen Shiao
324,China,Non-small Cell Lung Cancer,DRUG: anlotinib combined with penpulimab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,The First Affiliated Hospital of Zhengzhou University
325,United States,Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer|Colon Cancer,DRUG: Copanlisib|DRUG: Nivolumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
326,"Finland, United Kingdom, United States",Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Relapsed/Refractory AML,DRUG: Bexmarilimab|DRUG: Azacitidine|DRUG: Venetoclax,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,Faron Pharmaceuticals Ltd
327,United States,Metastatic Breast Cancer,DRUG: HER2 BATs with Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,breast,checkpoint inhibitor,University of Virginia
328,United States,TNBC - Triple-Negative Breast Cancer|Breast Cancer,DRUG: Pembrolizumab|RADIATION: Radiation Therapy|DRUG: Axatilimab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Stephen Shiao
329,France,Unresectable Gastrointestinal Stromal Tumor (GIST)|Locally Advanced Gastrointestinal Stromal Tumor (GIST)|Metastatic Gastrointestinal Stromal Tumor,DRUG: Atezolizumab 1200 mg|DRUG: Imatinib 400 MG,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Centre Leon Berard
330,"Argentina, Australia, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Republic of, Romania, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United States",Urothelial Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,other,checkpoint inhibitor,Bristol-Myers Squibb
331,United States,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,BIOLOGICAL: Durvalumab|DRUG: Selumetinib|BIOLOGICAL: Tremelimumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,M.D. Anderson Cancer Center
332,France,Oropharynx Cancer|Larynx Cancer|Hypopharynx Cancer|Primary Head and Neck Tumor,DRUG: Vesanoid|RADIATION: Standard radiotherapy|RADIATION: Tailored radiotherapy|DRUG: Cisplatin|DRUG: Cetuximab,3,OTHER,other,OTHER,Other,Phase III,head/neck,radiotherapy,Centre Leon Berard
333,China,Esophageal Cancer,DRUG: neoadjuvant anti-PD-1|DRUG: neoadjuvant anti-PD-1 with LDRT,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Shanghai Chest Hospital
334,United States,Advanced Solid Tumor|Refractory Hodgkin Lymphoma,DRUG: HCB301,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,FBD Biologics Limited
335,United States,Colorectal Cancer|Breast Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Non Small Cell Lung Cancer|Pancreatic Cancer|Liver Cancer,BIOLOGICAL: YE-NEO-001,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,other,"NantBioScience, Inc."
336,United States,Prostate Cancer|Adenocarcinoma of the Prostate,DRUG: Nivolumab|DRUG: Degarelix|DRUG: BMS-986253,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,Mark Stein
337,United States,Rectal Cancer,DRUG: Epacadostat|RADIATION: Short-course radiation therapy|DRUG: CAPOX chemotherapy|DRUG: FOLFOX chemotherapy,12,OTHER,other,OTHER,Other,Phase I & II,digestive,radiotherapy,Washington University School of Medicine
338,Netherlands,Melanoma Stage III|Melanoma Stage IV,OTHER: Fecal microbiota transplantation,12,OTHER,other,OTHER,Other,Phase I & II,skin,other,The Netherlands Cancer Institute
339,China,Cervical Cancer|Adaptive Radiotherapy,COMBINATION_PRODUCT: Moderated hypofractionated online adaptive radiotherapy|COMBINATION_PRODUCT: Conventional radiotherapy,3,OTHER,combination product,OTHER,Other,Phase III,gynecologic,combination product,Peking Union Medical College Hospital
340,China,Immunotherapy,BIOLOGICAL: CAR-T cell immunotherapy,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,other,adoptive cell therapy,The Affiliated Hospital of Xuzhou Medical University
341,United States,Previously Treated Non-Small Cell Lung Cancer,DRUG: Screening Platform,23,NETWORK,other,NETWORK,Network,Phase II & III,lung/thoracic,other,SWOG Cancer Research Network
342,Netherlands,Urologic Neoplasms|Urogenital Neoplasms|Male Urogenital Diseases|Penile Cancer|Penile Squamous Cell Carcinoma|Locally Advanced Penile Carcinoma,DRUG: Carboplatin/Paclitaxel|DRUG: Pembrolizumab|PROCEDURE: Partial or total penectomy with inguinal and/or pelvic lymph node dissection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,The Netherlands Cancer Institute
343,Taiwan,Premenopausal Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer,DRUG: Goserelin|DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,National Taiwan University Hospital
344,United States,Colorectal Cancer Metastatic,DRUG: isunakinra,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,other,Buzzard Pharmaceuticals
345,Netherlands,Colorectal Cancer,BIOLOGICAL: DC vaccination,12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,Radboud University Medical Center
346,"China, Taiwan, United States",Advanced Solid Tumor|Refractory Non-Hodgkin Lymphoma,DRUG: HCB101,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,FBD Biologics Limited
347,China,Non-small Cell Lung Cancer|Small Cell Lung Cancer|Pancreas Cancer|Hepatocellular Carcinoma|Gastric Cancer|Renal Cell Carcinoma,BIOLOGICAL: Infusion of iNKT cells and CD8+T cells,12,OTHER_GOV,adoptive cell therapy,OTHER_GOV,Government,Phase I & II,genitourinary,other,Shanghai Public Health Clinical Center
348,Denmark,Cancer of Rectum,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Odense University Hospital
349,"Australia, Canada, Hong Kong, Republic of, Singapore, Taiwan, United States",Non Small Cell Lung Cancer|Nonsquamous Non Small Cell Lung Cancer|Squamous Non Small Cell Lung Cancer|Lung Cancer,DRUG: Domvanalimab|DRUG: Etrumadenant|DRUG: Zimberelimab,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,other,"Arcus Biosciences, Inc."
350,United States,Advanced or Metastatic Solid Tumors|Microsatellite Instability Low|Microsatellite Instability High|Microsatellite Stable|Ovarian Cancer|Gastric Cancer|Colo-rectal Cancer|Esophageal Cancer|Endometrial Cancer|Head Neck Cancer|Cervical Cancer|Lung Cancer,DRUG: NC410|DRUG: pembrolizumab,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,gynecologic,checkpoint inhibitor,"NextCure, Inc."
351,China,Lung Cancer (NSCLC),DRUG: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,"Shanghai Pulmonary Hospital, Shanghai, China"
352,United States,Colorectal Cancer Metastatic|Liver Metastases|Colorectal Cancer,DRUG: Botensilimab|DRUG: Balstilimab|DRUG: AGEN1423|RADIATION: Radiation,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Weill Medical College of Cornell University
353,China,Immunotherapy|Gastric Cancer|Rectal Cancer|Chemotherapy Effect|Radiotherapy,DRUG: Terelizumab (aka Tislelizumab)|DRUG: CapeOx|DRUG: Trastuzumab|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
354,"Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Puerto Rico, Republic of, Singapore, Spain, Sweden, Switzerland, United Kingdom, United States",Endometrial Cancer,BIOLOGICAL: Sacituzumab tirumotecan|DRUG: Doxorubicin|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,gynecologic,chemotherapy,Merck Sharp & Dohme LLC
355,Netherlands,Urinary Bladder Cancer|Invasive Bladder Cancer,"COMBINATION_PRODUCT: nivolumab 480mg|COMBINATION_PRODUCT: nivolumab 3mg/kg, ipilimumab 1mg/kg|COMBINATION_PRODUCT: nivolumab 1mg/kg, ipilimumab 3mg/kg",12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
356,China,Non Small Cell Lung Cancer,"DRUG: Albumin-bound paclitaxel, Carboplatin, Toripalimab",2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Hao Long
357,United States,HPV-Associated Cervical Carcinoma|HPV-Related Carcinoma|HPV-Related Malignancy|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Adenocarcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV-Related Endocervical Adenocarcinoma|Cervical Cancer|Oropharynx Cancer|Anal Cancer|Vulvar Cancer|Penile Cancer|Vaginal Cancer,BIOLOGICAL: E7 TCR-T cells|DRUG: Aldesleukin,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,gynecologic,adoptive cell therapy,Christian Hinrichs
358,United States,Adult Primary Liver Cancer|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer,DRUG: TSR-022 and TSR-042,2,OTHER,other,OTHER,Other,Phase II,digestive,other,University of Hawaii
359,Belgium,Glioblastoma Multiforme of Brain,BIOLOGICAL: Dendritic cell vaccine plus temozolomide chemotherapy,12,OTHER,cancer vaccine,OTHER,Other,Phase I & II,brain/CNS,cancer vaccine,"University Hospital, Antwerp"
360,China,HNSCC|Lysogenic HSV Virus|Neoadjuvant Therapy|Immunotherapy|Targeted Therapy,DRUG: Tislelizumab|DRUG: Afatinib|BIOLOGICAL: Lysogenic HSV virus.,12,OTHER,oncolytic virus,OTHER,Other,Phase I & II,other,other,West China Hospital
361,United States,Endocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancers|Neuroendocrine Tumors|Multiple Myeloma,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: Individual Patient TCR-Transduced PBL|DRUG: Pembrolizumab (KEYTRUDA(R)),2,NIH,checkpoint inhibitor,NIH,Government,Phase II,gynecologic,checkpoint inhibitor,National Cancer Institute (NCI)
362,United States,Cancer,OTHER: Treatment recommendations made by Molecular Tumor Board.,2,OTHER,other,OTHER,Other,Phase II,other,other,Dartmouth-Hitchcock Medical Center
363,United States,Lung Cancer,DRUG: Pembrolizumab|DRUG: Guadecitabine|DRUG: Mocetinostat,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,lung/thoracic,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
364,United States,Breast Neoplasm Female|Breast Cancer|Breast Carcinoma|Breast Tumor,DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Bicalutamide,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Providence Health & Services
365,Italy,"Brain Tumor, Pediatric|Medulloblastoma, Childhood|Embryonal Tumor|High Grade Glioma|Diffuse Midline Glioma|Diffuse Intrinsic Pontine Glioma|Brain Tumor Adult",BIOLOGICAL: GD2-CART01 (iC9-GD2-CAR T-cells),1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Bambino Gesù Hospital and Research Institute
366,China,Lung Cancer|Cancer|Immunotherapy|CAR-T Cell,"BIOLOGICAL: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR",1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,lung/thoracic,adoptive cell therapy,Second Affiliated Hospital of Guangzhou Medical University
367,United States,Colon Cancer|Resected Stage,DRUG: Cetuximab|DRUG: Expanded CB-NK cells|DRUG: Fludarabine phosphate|DRUG: Cyclophosphamide,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,digestive,adoptive cell therapy,M.D. Anderson Cancer Center
368,United States,Neuroblastoma|Ganglioneuroblastoma,BIOLOGICAL: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|BIOLOGICAL: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|BIOLOGICAL: Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells),1,OTHER,other,OTHER,Other,Phase I,other,other,Seattle Children's Hospital
369,United States,Endometrial Cancer,DRUG: Pembrolizumab|DRUG: IMGN853,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,Dana-Farber Cancer Institute
370,United States,Advanced Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DIETARY_SUPPLEMENT: Cobalamin|DRUG: Dexamethasone|DRUG: Docetaxel|DIETARY_SUPPLEMENT: Folic Acid|DRUG: Gemcitabine|DRUG: Nogapendekin Alfa|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|BIOLOGICAL: Ramucirumab,23,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II & III,lung/thoracic,checkpoint inhibitor,SWOG Cancer Research Network
371,United States,Extensive Stage Lung Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Carboplatin|BIOLOGICAL: Durvalumab|DRUG: Etoposide|DRUG: Olaparib|RADIATION: Radiation Therapy,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,M.D. Anderson Cancer Center
372,France,Breast Cancer,DRUG: Atezolizumab Injection|DRUG: Bevacizumab|DRUG: Pertuzumab|DRUG: Trastuzumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,"Gustave Roussy, Cancer Campus, Grand Paris"
373,China,"Pheochromocytoma/Paraganglioma|Rhabdomyosarcoma|Paget Disease, Extramammary|Renal Angiomyolipoma|Perivascular Epithelioid Cell Tumor, Malignant|Sarcoma|Urachal Cancer|Neuroendocrine Cancer|Basal Cell Carcinomas|Sarcomatoid Carcinoma|Penile Cancer|Adrenal Cortical Cancer|Germ Cell Cancer Metastatic|Non-Clear Cell Renal Cell Carcinoma|Prostate Cancers|Clear Cell Renal Cancer|Urothelial Carcinoma|Kidney Cancer|Rare Tumors",DRUG: Ivocizumab,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Fudan University
374,China,Esophageal Cancer,DRUG: Trilaciclib Injection [Cosela]|DRUG: Placebo,2,OTHER,other,OTHER,Other,Phase II,digestive,other,The First Affiliated Hospital with Nanjing Medical University
375,China,Local Advanced Non-small Cell Lung Cancer,DRUG: Toripalimab|RADIATION: Concurrent chemoradiation therapy and consolidation immunotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
376,China,Multiple Cancer|Colorectal Cancer,DRUG: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|DRUG: All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Sixth Affiliated Hospital, Sun Yat-sen University"
377,China,Non-small Cell Lung Cancer,DRUG: Anlotinib plus the same Immune Checkpoint Inhibitors.|DRUG: Anlotinib plus the new Immune Checkpoint Inhibitors.|DRUG: Anlotinib,23,OTHER,other,OTHER,Other,Phase II & III,lung/thoracic,other,Hunan Province Tumor Hospital
378,Spain,Non-Small Cell Lung Cancer|Adjuvant Chemotherapy,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nivolumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Fundación GECP
379,China,Esophagus Cancer,COMBINATION_PRODUCT: Tislelizumab (BGB-A317) with chemoradiotherapy,2,OTHER,combination product,OTHER,Other,Phase II,other,combination product,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
380,United States,Head and Neck Carcinoma of Unknown Primary|Locally Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Pharyngeal Squamous Cell Carcinoma|Resectable Head and Neck Squamous Cell Carcinoma,RADIATION: External Beam Radiation Therapy|RADIATION: Intraoperative Radiation Therapy|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|PROCEDURE: Salvage Surgery,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,head/neck,checkpoint inhibitor,Ohio State University Comprehensive Cancer Center
381,China,Larynx Cancer|Hypopharyngeal Cancer,PROCEDURE: Surgery|RADIATION: Radiation|DRUG: Toripalimab,2,OTHER,other,OTHER,Other,Phase II,other,radiotherapy,Fudan University
382,"Belgium, Canada, Germany, Netherlands, Spain, Sweden, United Kingdom, United States",Melanoma|Non-Small Cell Lung Cancer|Bladder Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Renal Cancer|Head and Neck Cancer|Other Solid Cancers,DRUG: Autogene cevumeran|DRUG: Atezolizumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,genitourinary,checkpoint inhibitor,"Genentech, Inc."
383,United States,Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer,GENETIC: iCasp9M28z T cell infusions|DRUG: cyclophosphamide|DRUG: pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
384,United States,Gliosarcoma|MGMT-Unmethylated Glioblastoma,PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|DEVICE: NovoTTF-100A Device|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy|DRUG: Temozolomide,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,brain/CNS,checkpoint inhibitor,National Cancer Institute (NCI)
385,China,Head and Neck Cancer,COMBINATION_PRODUCT: anti-PD-1 or PD-L1 antibody|RADIATION: postoperative radiaotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
386,China,Colorectal Cancer|Immunotherapy|Radiotherapy|Targeted Therapy|Liver Metastasis,DRUG: Immunotherapy (Sintilimab)|DRUG: Targeted Therapy Agent (Fruquintinib)|RADIATION: Radiotherapy (SBRT and LDRT),2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Shandong Cancer Hospital and Institute
387,China,Non-small Cell Lung Cancer,DRUG: Immune checkpoint inhibitor,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Peking Union Medical College Hospital
388,United States,Glioblastoma Multiforme,DRUG: Pembrolizumab|RADIATION: Stereotactic Radiation Therapy|PROCEDURE: Surgical Resection,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,brain/CNS,checkpoint inhibitor,Chirag G. Patil
389,United States,Glioblastoma,DRUG: Daratumumab,12,OTHER,other,OTHER,Other,Phase I & II,brain/CNS,other,West Virginia University
390,China,Cervical Cancer,DRUG: Neoadjuvant Therapy|RADIATION: CCRT|RADIATION: Brachytherapy,3,OTHER,other,OTHER,Other,Phase III,gynecologic,radiotherapy,Sichuan Cancer Hospital and Research Institute
391,China,Liver Metastases,DRUG: Tislelizumab in Combination with Oxaliplatin and Tegafur,23,OTHER,combination product,OTHER,Other,Phase II & III,digestive,combination product,Zhejiang University
392,China,"SCLC,Extensive Stage|Brain Metastases",RADIATION: HA-WBRT plus SBRT,12,OTHER,other,OTHER,Other,Phase I & II,brain/CNS,radiotherapy,Fudan University
393,"Puerto Rico, United States",Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Invasive Bladder Giant Cell Urothelial Carcinoma|Invasive Bladder Lymphoepithelioma-Like Carcinoma|Invasive Bladder Nested Urothelial Carcinoma|Invasive Bladder Plasmacytoid Urothelial Carcinoma|Invasive Bladder Sarcomatoid Urothelial Carcinoma|Invasive Bladder Urothelial Carcinoma|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Malignant Testicular Leydig Cell Tumor|Malignant Testicular Sertoli Cell Tumor|Metastatic Bladder Carcinoma|Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma|Metastatic Bladder Giant Cell Urothelial Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Lipid-Rich Urothelial Carcinoma|Metastatic Bladder Micropapillary Urothelial Carcinoma|Metastatic Bladder Plasmacytoid Urothelial Carcinoma|Metastatic Bladder Sarcomatoid Urothelial Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Chromophobe Renal Cell Carcinoma|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Papillary Renal Cell Carcinoma|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Urachal Adenocarcinoma|Urethral Clear Cell Adenocarcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
394,United Kingdom,Cancer of Unknown Primary Site,DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Imperial College London
395,"Belgium, Georgia, Republic of, Spain, United States",Breast Carcinoma,BIOLOGICAL: eftilagimod alpha|DRUG: Paclitaxel|OTHER: placebo,23,INDUSTRY,other,INDUSTRY,Industry,Phase II & III,breast,chemotherapy,Immutep S.A.S.
396,Poland,Breast Cancer,DRUG: Keytruda|RADIATION: Preoperative radiation therapy|DRUG: Placebo,2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,Maria Sklodowska-Curie National Research Institute of Oncology
397,United States,Breast Cancer|Triple Negative Breast Cancer,DRUG: Niraparib|DRUG: Dostarlimab|RADIATION: Radiation therapy,2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,Massachusetts General Hospital
398,United States,"Neoplasms, Brain|Glioblastoma Multiforme|Glioblastoma of Cerebellum|Neoplasms|Astrocytoma|Astrocytoma, Cerebellar|Neuroectodermal Tumors|Neuroectodermal Tumors, Primitive|Cerebellar PNET, Childhood|Cerebellar Neoplasms|Cerebellar Neoplasms, Primary|Cerebellar Neoplasm, Malignant|Cerebellar Neoplasm Malignant Primary|Neoplasm Metastases|Neoplasm Malignant|Neoplasms, Neuroepithelial|Neoplasms, Germ Cell and Embryonal|Neoplasms by Histologic Type|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Central Nervous System Neoplasms, Primary|Central Nervous System Neoplasms, Malignant|Nervous System Neoplasms|Neoplasms by Site|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Medulloblastoma Recurrent|HSV|Virus|Pediatric Brain Tumor|Nervous System Cancer|Primitive Neuroectodermal Tumor (PNET) of Cerebellum",BIOLOGICAL: G207,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,M.D. Anderson Cancer Center
399,China,Extensive-stage Small Cell Lung Cancer,RADIATION: Radiotherapy to all residual lesions|DRUG: Chemoimmunotherapy,12,OTHER_GOV,other,OTHER_GOV,Government,Phase I & II,lung/thoracic,radiotherapy,Anhui Provincial Hospital
400,"France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States",Cervical Carcinoma,BIOLOGICAL: LN-145|BIOLOGICAL: LN-145 + pembrolizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,gynecologic,checkpoint inhibitor,"Iovance Biotherapeutics, Inc."
401,United States,"Carcinoma, Non-Small-Cell Lung",DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Hackensack Meridian Health
402,"China, Hong Kong, Italy, Japan, Republic of, Spain, Taiwan, United Kingdom, United States",Hepatocellular Carcinoma|Biliary Tract Cancer,DRUG: Volrustomig|DRUG: Bevacizumab|DRUG: Lenvatinib|DRUG: Rilvegostomig|DRUG: Gemcitabine|DRUG: Cisplatin,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,chemotherapy,AstraZeneca
403,China,Toxicity Due to Radiotherapy|Non-small Cell Lung Cancer,RADIATION: High-dose fractionated radiotherapy|RADIATION: Low-dose fractionated radiotherapy,12,OTHER_GOV,other,OTHER_GOV,Government,Phase I & II,lung/thoracic,radiotherapy,Anhui Provincial Hospital
404,China,Head and Neck Cancer,RADIATION: radical radiotherapy (60Gy)|RADIATION: radical radiotherapy (66Gy)|RADIATION: radical radiotherapy (70Gy)|COMBINATION_PRODUCT: anti-PD-1 or PD-L1 antibody,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
405,United States,Glioblastoma,DRUG: Poly-ICLC|DEVICE: Tumor Treating Fields|BIOLOGICAL: Peptides,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Albert Einstein College of Medicine
406,"Canada, United States",Ovarian Cancer,DRUG: Durvalumab|DRUG: BA3011|DRUG: BA3021|DRUG: ENB003|DRUG: Toripalimab,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,gynecologic,checkpoint inhibitor,Canadian Cancer Trials Group
407,United States,Clear Cell Renal Cell Carcinoma|Cervical Carcinoma|Esophageal Carcinoma|Pancreatic Adenocarcinoma|Malignant Pleural Mesothelioma,BIOLOGICAL: CTX131,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,gynecologic,other,CRISPR Therapeutics AG
408,China,Advanced Lung Cancer,BIOLOGICAL: Targeted CEA CAR-T|BIOLOGICAL: Targeted CEA CAR-T,1,INDUSTRY,adoptive cell therapy,INDUSTRY,Industry,Phase I,lung/thoracic,adoptive cell therapy,"Chongqing Precision Biotech Co., Ltd"
409,United States,Colorectal Adenocarcinoma|Colon Cancer|Colon Adenocarcinoma|Rectum Cancer|Rectal Cancer|Rectal Adenocarcinoma|Colorectal Cancer,DRUG: Cabozantinib|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"University of Colorado, Denver"
410,China,Cervical Cancer,DRUG: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|DRUG: Chemoradiotherapy (small pelvic) + Zimberelimab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,radiotherapy,Suzhou Municipal Hospital
411,France,Inflammatory Breast Cancer,DRUG: Pembrolizumab Injection|DRUG: neoadjuvant EC-paclitaxel chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Institut Paoli-Calmettes
412,China,Non-small Cell Lung Cancer,RADIATION: definitive radiotherapy|DRUG: induction chemo-immunotherapy|DRUG: concurrent chemotherapy|DRUG: Immunotheapy consolidation|DRUG: Thymosin Alpha1,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Sun Yat-sen University
413,"Canada, Republic of, Spain, United States",Metastatic or Locally Advanced Unresectable Solid Tumors,DRUG: Tuvusertib|DRUG: Lartesertib|DRUG: Avelumab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,"EMD Serono Research & Development Institute, Inc."
414,"Canada, United States",Locally Advanced Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Tazemetostat,12,NIH,checkpoint inhibitor,NIH,Government,Phase I & II,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
415,United States,"Recurrent Medulloblastoma|Recurrent Brain Tumor, Childhood|Malignant Glioma",DRUG: PEP-CMV,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Daniel Landi
416,United States,Breast Cancer|HER2+ Breast Cancer,BIOLOGICAL: VRP-HER2|BIOLOGICAL: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Herbert Lyerly
417,United States,"Non Small Cell Lung Cancer|Lung Cancer, Nonsmall Cell|Non Small Cell Lung Cancer Metastatic",DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Nintedanib,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
418,China,Liver Cancer,DRUG: PD1/PDL1 inhibitor,3,OTHER,other,OTHER,Other,Phase III,digestive,other,Second Affiliated Hospital of Guangzhou Medical University
419,Spain,MSI-H Colorectal Cancer|Melanoma|Anal Carcinoma|Mesothelioma|Triple Negative Breast Cancer|Lung Adenocarcinoma|Cholangiocarcinoma|Cervical Carcinoma|Kidney Clear Cell Carcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma|Uterine Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Sarcoma|Lung Squamous Cell Carcinoma|Urothelial Carcinoma|Thyroid Carcinoma|Hepatocellular Carcinoma|Uveal Melanoma|HER2-positive Breast Cancer|Pancreatic Adenocarcinoma|Squamous Esophageal Carcinoma|Epithelial Ovarian Cancer|Uterine Carcinosarcoma|Small Cell Lung Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Colorectal Adenocarcinoma|Prostate Adenocarcinoma|Carcinoma of Unknown Primary|Other Histology,DRUG: Spartalizumab|DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,SOLTI Breast Cancer Research Group
420,China,Esophagus Cancer|Esophagogastric Junction Cancer|Chemoradiation|Targeted Therapy|Immunotherapy|Chemotherapy Effect,RADIATION: Radiotherapy|DRUG: Platinum based chemotherapy|DRUG: Paclitaxel based chemotherapy|DRUG: Immunotherapy|DRUG: 5-FU Analog based chemotherapy|DRUG: Nimotuzumab,3,OTHER,other,OTHER,Other,Phase III,digestive,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
421,France,Bladder Cancer,DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,UNICANCER
422,China,Unresectable Locally Advanced Non-small Cell Lung Cancer,DRUG: Adebrelimab + Apatinib,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Wei Zhou
423,Netherlands,Rectal Cancer,DRUG: Atezolizumab|DRUG: Bevacizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,The Netherlands Cancer Institute
424,"Germany, Switzerland",Stage III Non-small Cell Lung Cancer|Locally Advanced|Unresectable,RADIATION: standard Radiotherapy|DRUG: Chemotherapy|DRUG: Immunotherapy|RADIATION: Experimental Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,TheraOp
425,Netherlands,Metastatic Pancreatic Cancer,BIOLOGICAL: Durvalumab|DRUG: Rintatolimod,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,"Joachim Aerts, MD PhD"
426,United States,Pancreatic Cancer,BIOLOGICAL: N-803|DRUG: Aldoxorubicin HCl|BIOLOGICAL: PD-L1 t-haNK|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Cyclophosphamide|DRUG: 5-Fluorouracil|DRUG: Leucovorin|PROCEDURE: SBRT|DRUG: Irinotecan liposome,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,"ImmunityBio, Inc."
427,United States,Non Hodgkin Lymphoma,DRUG: AB-101|DRUG: Rituximab|DRUG: Interleukin-2|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Bendamustine,12,INDUSTRY,cytokine / immunomodulator,INDUSTRY,Industry,Phase I & II,hematologic,cytokine / immunomodulator,"Artiva Biotherapeutics, Inc."
428,China,Nasopharyngeal Cancer,DRUG: Irinotecan Liposomal combined With Nituzumab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,XIANG YANQUN
429,"Germany, Hong Kong, Japan, Spain, Taiwan, United States","Carcinoma, Non-Small-Cell Lung|Melanoma|Nasopharyngeal Carcinoma|Microsatellite Stable Colorectal Cancer|Triple Negative Breast Cancer",DRUG: DKY709|DRUG: PDR001,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,other,Novartis Pharmaceuticals
430,United States,Endometrial Cancer,DRUG: Pembrolizumab|RADIATION: Vaginal cuff brachytherapy (VCB)|DRUG: Paclitaxel|DRUG: Carboplatin,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,gynecologic,checkpoint inhibitor,University of Oklahoma
431,China,Locally Advanced and Metastatic Pancreatic Cancer,DRUG: PD-L1/CTLA4 BsAb|COMBINATION_PRODUCT: GP|COMBINATION_PRODUCT: FOLFIRINOX,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Changhai Hospital
432,United States,"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB3 Cervical Cancer FIGO 2018|Stage II Cervical Cancer FIGO 2018|Stage IIA Cervical Cancer FIGO 2018|Stage IIA1 Cervical Cancer FIGO 2018|Stage IIA2 Cervical Cancer FIGO 2018|Stage IIB Cervical Cancer FIGO 2018|Stage III Cervical Cancer FIGO 2018|Stage IIIA Cervical Cancer FIGO 2018|Stage IIIB Cervical Cancer FIGO 2018|Stage IIIC Cervical Cancer FIGO 2018|Stage IIIC1 Cervical Cancer FIGO 2018|Stage IIIC2 Cervical Cancer FIGO 2018|Stage IVA Cervical Cancer FIGO 2018",DRUG: Cisplatin|BIOLOGICAL: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|RADIATION: Radiation Therapy,2,OTHER,cancer vaccine,OTHER,Other,Phase II,gynecologic,cancer vaccine,M.D. Anderson Cancer Center
433,Hong Kong,Neuroblastoma Recurrent,BIOLOGICAL: Natural killer cell|DRUG: Dinutuximab beta|DRUG: Interleukin-2|DRUG: Granulocyte-Macrophage Colony-Stimulating Factor|DRUG: Spironolactone|DRUG: Naxitamab,2,OTHER,cytokine / immunomodulator,OTHER,Other,Phase II,other,cytokine / immunomodulator,Hong Kong Children's Hospital
434,"Italy, Netherlands, Spain, Switzerland",Non-small Cell Lung Cancer|Stage IV|Oligometastasis,DRUG: Durvalumab|DRUG: Carboplatin|DRUG: Paclitaxel|RADIATION: Stereotactic body radiation therapy (SBRT)|PROCEDURE: Surgical resection - definitive local treatment.|RADIATION: Radical radiotherapy - definitive local treatment.|DRUG: Tremelimumab,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,lung/thoracic,checkpoint inhibitor,ETOP IBCSG Partners Foundation
435,"Denmark, Sweden",Breast Cancer|Triple Negative Breast Neoplasms,"DRUG: epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|DRUG: epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,breast,checkpoint inhibitor,Lund University Hospital
436,Mexico,Metastatic Castration-resistant Prostate Cancer,DRUG: SV-102,1,OTHER,other,OTHER,Other,Phase I,genitourinary,other,Williams Cancer Foundation
437,United States,Urothelial Carcinoma|Bladder Cancer,DRUG: Durvalumab (Cohort 1-3)|RADIATION: External Beam Radiotherapy (EBRT)|BIOLOGICAL: Bacillus Calmette-Guérin (BCG)|DRUG: Gemcitabine|DRUG: Docetaxel|BIOLOGICAL: Tremelimumab|DRUG: Durvalumab (Cohort 4/5)|OTHER: To be determined,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,"Noah Hahn, M.D."
438,Netherlands,Epithelial Ovarian Cancer|Ovarian Carcinoma,BIOLOGICAL: XP-DC vaccinations,12,OTHER,other,OTHER,Other,Phase I & II,gynecologic,other,Radboud University Medical Center
439,"Australia, Georgia, Germany, Netherlands, Poland, Romania, Spain",Advanced Cancer|Metastatic Cancer,DRUG: FS222,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,multiple,other,invoX Pharma Limited
440,United States,"Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Myelodysplasia|Myeloproliferative Disorder|Myelofibrosis|Lymphoma|Lymphoma, Non-Hodgkin|Plasma Cell Disorder",DRUG: Cyclophosphamide|DRUG: Fludarabine|RADIATION: Total Body Irradiation|DRUG: Tacrolimus|DRUG: cellcept|DRUG: g-csf|PROCEDURE: Peripheral Blood Transplant,3,OTHER,other,OTHER,Other,Phase III,hematologic,radiotherapy,Dartmouth-Hitchcock Medical Center
441,United States,Metastatic Solid Cancers|Colorectal Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Gastrointestinal Cancer|Ovarian Cancer|Genitourinary Cancer,DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: KRAS TCR-Transduced PBL|BIOLOGICAL: GRT-C903/GRT-R904,1,NIH,adoptive cell therapy,NIH,Government,Phase I,gynecologic,adoptive cell therapy,National Cancer Institute (NCI)
442,United States,Neuroblastoma,DRUG: Dinutuximab|BIOLOGICAL: NK Cells|DRUG: Lenalidomide,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,other,adoptive cell therapy,New Approaches to Neuroblastoma Therapy Consortium
443,China,"Nutrition Disorders|Immunotherapy|Cancer|Survival, Prosthesis",DRUG: Megestrol Acetate and olanzapine|DRUG: Starch powder 50 mg,3,OTHER,other,OTHER,Other,Phase III,other,other,Qingdao Central Hospital
444,United Kingdom,Bladder Cancer,DRUG: Durvalumab|BIOLOGICAL: S-488210/S-488211,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,"University College, London"
445,China,Esophageal Cancer,DRUG: Carboplatin|DRUG: Nab paclitaxel|DRUG: Sintilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,Sichuan University
446,United States,Metastatic Non-small Cell Lung Cancer,DRUG: Dupilumab|DRUG: PD-1/PD-L1 blockade|DRUG: Anakinra,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,Thomas Marron
447,China,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT)|DRUG: Toripalimab|DRUG: Neoadjuvant Chemotherapy|PROCEDURE: Surgery|DRUG: Adjuvant Chemotherapy|RADIATION: Adjuvant Radiotherapy|DRUG: Endocrine therapy,2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,Xijing Hospital
448,Netherlands,Colorectal Cancer|Liver Metastases|Liver Metastasis Colon Cancer,DRUG: IP-001,12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,M.R. Meijerink
449,United States,Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma,DRUG: Nivolumab|PROCEDURE: Surgical Resection|RADIATION: Radiation (5 days)|RADIATION: Radiation (3 days),12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,head/neck,checkpoint inhibitor,Providence Health & Services
450,United States,Billiary Track Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
451,China,Recurrent Nasopharyngeal Carcinoma,PROCEDURE: endoscopic surgery,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Eye & ENT Hospital of Fudan University
452,Canada,Non Small Cell Lung Cancer|Complete Surgical Resection|Circulating Tumor DNA,DRUG: Nivolumab|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin|PROCEDURE: ctDNA blood test,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,"University Health Network, Toronto"
453,Netherlands,Metastatic Breast Cancer,DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,The Netherlands Cancer Institute
454,United States,Head and Neck Cancer|Lung Cancer,DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: 5Fluorouracil|DRUG: Carboplatin|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,"Rutgers, The State University of New Jersey"
455,"Argentina, Australia, Austria, Belgium, Brazil, France, Hong Kong, Hungary, Italy, Republic of, Romania, Spain, Taiwan, United Kingdom, United States",Non-small Cell Lung Cancer (NSCLC),DRUG: S095018|DRUG: S095024|DRUG: S095029|DRUG: S095018 Recommended Dose Expansion (RDE)|DRUG: S095024 RDE|DRUG: S095029 RDE|DRUG: Cemiplimab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,lung/thoracic,checkpoint inhibitor,Servier Bio-Innovation LLC
456,"Argentina, Australia, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Switzerland, United Kingdom, United States",Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Relatlimab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Nab-Paclitaxel|DRUG: Pemetrexed,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,lung/thoracic,checkpoint inhibitor,Bristol-Myers Squibb
457,United States,Metastatic Hormone Refractory Prostate Cancer,DRUG: Cabozantinib|DRUG: Nivolumab|DRUG: Abiraterone acetate|DRUG: Prednisone|PROCEDURE: Peripheral blood collection,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,genitourinary,checkpoint inhibitor,Washington University School of Medicine
458,United States,Advanced Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
459,China,Breast Cancer,"DRUG: Anlotinib ,|DRUG: Benmelstobart|DRUG: Capecitabine",2,OTHER,other,OTHER,Other,Phase II,breast,other,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
460,China,Metastatic Nasopharyngeal Cancer,RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
461,Canada,Pancreatic Cancer|Hepatocellular Cancer|Biliary Tract Cancer|Cholangiocarcinoma,BIOLOGICAL: Durvalumab|DRUG: Gemcitabine|DRUG: Nab paclitaxel|BIOLOGICAL: Tremelimumab|DRUG: Propranolol|DRUG: Cisplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,AHS Cancer Control Alberta
462,United States,Breast Cancer,BIOLOGICAL: PVX-410|BIOLOGICAL: Durvalumab|DRUG: Hiltonol,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,breast,checkpoint inhibitor,Massachusetts General Hospital
463,United States,Gastric Cancer|GastroEsophageal Cancer|Adenocarcinoma,DRUG: Pembrolizumab Monotherapy|DRUG: Ramucirumab|DRUG: Paclitaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Harry H Yoon
464,United States,Minimal Residual Disease|KRAS G12D|KRAS G12R|NRAS G12D|NRAS G12R|Pancreatic Ductal Adenocarcinoma|Colorectal Cancer|Non-small Cell Lung Cancer|Ovarian Cancer|Cholangiocarcinoma|Bile Duct Cancer|Gallbladder Carcinoma,DRUG: ELI-002 2P,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,gynecologic,other,Elicio Therapeutics
465,United States,Endometrial Cancer|Cancer of Endometrium|Carcinoma of Endometrium|Endometrial Carcinoma,BIOLOGICAL: AdHER2DC vaccine|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: N-803|DRUG: Lenvatinib|DEVICE: PATHWAY HER2 (4B5) assay,12,NIH,checkpoint inhibitor,NIH,Government,Phase I & II,gynecologic,checkpoint inhibitor,National Cancer Institute (NCI)
466,United States,Non-Small Cell Lung Cancer,DRUG: Nivolumab,2,FED,checkpoint inhibitor,FED,Government,Phase II,lung/thoracic,checkpoint inhibitor,VA Office of Research and Development
467,China,Esophageal Cancer|Chemotherapy Effect|Chemoradiation|Surgery|Targeted Therapy|Immunotherapy|Esophagogastric Juction Cancer,DRUG: Platinum based chemotherapy|DRUG: Paclitaxel based chemotherapy|RADIATION: Radiotherpay|PROCEDURE: Surgery|DRUG: Immunotherapy|DRUG: 5-FU Analog based chemotherpay|DRUG: Nimotuzumab,3,OTHER,other,OTHER,Other,Phase III,digestive,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
468,China,HER2 Negative Breast Cancer,DRUG: Retinoic Acid|DRUG: anti-PD-1 antibody and chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Fudan University
469,Canada,B-Cell Leukemia|Non-Hodgkin's Lymphoma|B-cell Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma|B-cell Lymphoma,BIOLOGICAL: CLIC-2201,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,British Columbia Cancer Agency
470,China,Neoadjuvant Therapy|Esophageal Squamous Cell Carcinoma,DRUG: anlotinib|RADIATION: Thoracic radiotherapy,23,OTHER_GOV,other,OTHER_GOV,Government,Phase II & III,digestive,radiotherapy,Army Medical Center of PLA
471,"United Kingdom, United States",Advanced Cancer|Angiosarcoma|Colorectal Cancer Without Liver Metastases|Endometrial Cancer|Fibrolamellar Carcinoma|Non-small-cell Lung Cancer|Ovarian Cancer|Prostate Cancer,DRUG: Botensilimab|DRUG: Balstilimab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,gynecologic,other,Agenus Inc.
472,China,Ovarian Cancer,BIOLOGICAL: KM1|DRUG: Chemotherapy,1,OTHER,other,OTHER,Other,Phase I,gynecologic,chemotherapy,Tongji Hospital
473,United States,Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8,BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|PROCEDURE: Computed Tomography|PROCEDURE: Biospecimen Collection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,M.D. Anderson Cancer Center
474,"Puerto Rico, United States",Endometrial Endometrioid Adenocarcinoma|Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,PROCEDURE: Biospecimen Collection|RADIATION: Brachytherapy|PROCEDURE: Computed Tomography|RADIATION: External Beam Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|PROCEDURE: X-Ray Imaging,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,gynecologic,checkpoint inhibitor,National Cancer Institute (NCI)
475,"Denmark, France",Metastatic Melanoma,BIOLOGICAL: TILT-123,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,skin,other,TILT Biotherapeutics Ltd.
476,"Australia, Belgium, Brazil, Canada, China, Denmark, Finland, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Republic of, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States",Endometrial Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Rilvegostomig|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Docetaxel,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,gynecologic,checkpoint inhibitor,AstraZeneca
477,China,"Carcinoma, Non-Small-Cell Lung",PROCEDURE: bronchial artery interventional therapy|DRUG: Chemotherapy drug|RADIATION: IMRT|DRUG: Immunotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Dong Wang
478,United States,Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage III Lung Cancer,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|DRUG: Nab-paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography|RADIATION: Radiation Therapy|OTHER: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|BIOLOGICAL: Cemiplimab|BIOLOGICAL: Atezolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,Vanderbilt-Ingram Cancer Center
479,"Puerto Rico, United States",Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Early Stage Triple-Negative Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|PROCEDURE: Surgical Procedure,3,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase III,breast,checkpoint inhibitor,SWOG Cancer Research Network
480,"Australia, United States",Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma,DRUG: Ficerafusp alfa|DRUG: Pembrolizumab (KEYTRUDA®)|DRUG: Placebo,23,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II & III,head/neck,checkpoint inhibitor,Bicara Therapeutics
481,China,Bile Duct Carcinoma|Gall Bladder Cancer|Biliary Tract Cancer|Cholangiocarcinoma,"DRUG: PD-1/CTLA-4 Dual Functional Antibody|DRUG: Gemcitabine, Cisplatin|DRUG: Anlotinib|DRUG: Oxaliplatin + 5-Fluorouracil/Leucovorin",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,First Affiliated Hospital of Zhejiang University
482,China,Esophageal Squamous Cell Carcinoma,DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
483,United States,Ependymoma,BIOLOGICAL: HLA-A2 restricted synthetic tumor antigen|DRUG: Imiquimod|OTHER: enzyme-linked immunosorbent assay|OTHER: flow cytometry|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,other,biomarker / diagnostics,James Felker
484,United States,Gynecologic Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cavity Cancer,DRUG: FT536|DRUG: Fludarabine|DRUG: CY,1,OTHER,other,OTHER,Other,Phase I,gynecologic,other,"Masonic Cancer Center, University of Minnesota"
485,China,Small Cell Lung Cancer Extensive Stage,RADIATION: thoracic radiotherapy,1,OTHER,other,OTHER,Other,Phase I,lung/thoracic,radiotherapy,Fudan University
486,United States,Triple Negative Breast Cancer,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Capecitabine,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,breast,checkpoint inhibitor,Providence Health & Services
487,China,Ovarian Cancer,DRUG: Fasudil Hydrochloride,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,Zhejiang Provincial People's Hospital
488,United States,Stage IV Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Stereotactic body radiation therapy,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,lung/thoracic,checkpoint inhibitor,University of Chicago
489,"Australia, New Zealand","Merkel Cell Carcinoma|Merkel Cell Carcinoma, Stage I|Merkel Cell Carcinoma, Stage II|Merkel Cell Carcinoma, Stage III|Neuroendocrine Tumors|Carcinoma Neuroendocrine Skin",DRUG: Avelumab|DRUG: Placebo,2,OTHER,other,OTHER,Other,Phase II,skin,other,Melanoma and Skin Cancer Trials Limited
490,"Denmark, Lithuania, Netherlands, Norway, Sweden, Switzerland",Small-cell Lung Cancer,DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Norwegian University of Science and Technology
491,Germany,Nasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharyngeal Neoplasms|Nasopharynx Cancer,DRUG: Nivolumab|DRUG: Cisplatin|DRUG: 5-Fluorouracil|DRUG: Gemcitabine|RADIATION: Radiotherapy|DRUG: Interferon beta-1a|PROCEDURE: MRI|PROCEDURE: PET|BEHAVIORAL: Patient-Reported Outcomes,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,German Society for Pediatric Oncology and Hematology GPOH gGmbH
492,Canada,Hepatocellular Carcinoma (HCC)|Macrovascular Invasion|Liver Transplant Surgery|Downstaging,BIOLOGICAL: Atezolizumab & Bevacizumab|DRUG: Yttrium-90 (Y-90)|RADIATION: Stereotactic body radiotherapy (SBRT),12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,"University Health Network, Toronto"
493,United Kingdom,Non Small Cell Lung Cancer,DRUG: Guadecitabine|DRUG: Pembrolizumab|DRUG: ASTX727,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,lung/thoracic,checkpoint inhibitor,Royal Marsden NHS Foundation Trust
494,Netherlands,Stomach Cancer|Gastro Esophageal Junction Cancer,DRUG: Atezolizumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Docetaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,The Netherlands Cancer Institute
495,Canada,Melanoma,DRUG: Fecal Microbial Transplantation,1,OTHER,other,OTHER,Other,Phase I,skin,other,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
496,"Australia, Belgium, Canada, China, France, Germany, Italy, Japan, Poland, Republic of, Russian Federation, Spain, United Kingdom, United States",Non-muscle Invasive Bladder Cancer,DRUG: PF-06801591|DRUG: Bacillus Calmette-Guerin,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,genitourinary,other,Pfizer
497,China,Esophageal Squamous Cell Carcinoma,RADIATION: Neoadjuvant Radiotherapy|DRUG: Neoadjuvant Chemotherapy|DRUG: Immunotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Zhejiang Cancer Hospital
498,Belgium,High Grade Glioma|Diffuse Intrinsic Pontine Glioma,BIOLOGICAL: Dendritic cell vaccination + temozolomide-based chemoradiation|BIOLOGICAL: Dendritic cell vaccination +- conventional next-line treatment,12,OTHER,other,OTHER,Other,Phase I & II,brain/CNS,radiotherapy,"University Hospital, Antwerp"
499,China,Non-small Cell Lung Cancer|EGFR Activating Mutation,BIOLOGICAL: Sintilimab|DRUG: Carboplatin|DRUG: Nab paclitaxel,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Guangdong Provincial People's Hospital
500,China,Locally Recurrent Rectal Cancer,RADIATION: Conventional Radiotherapy|DRUG: Capecitabine|DRUG: 5-fluorouracil|DRUG: folinic acid|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Cetuximab|DRUG: Bevacizumab|RADIATION: Hypofractionated radiotherapy|DRUG: PD-1 antibody,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Fudan University
501,United States,"Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma|Recurrent CNS Tumor, Adult|Recurrent, CNS Tumor, Childhood|Refractory Primary Malignant Central Nervous System Neoplasm",BIOLOGICAL: SC-CAR4BRAIN,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Seattle Children's Hospital
502,"Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Poland, Republic of, Singapore, Spain, Taiwan, United Kingdom, United States",Endometrial Cancer,DRUG: Sacituzumab govitecan-hziy|DRUG: Doxorubicin|DRUG: Paclitaxel,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,gynecologic,chemotherapy,Gilead Sciences
503,China,Esophageal Cancer,DRUG: Arm A|DRUG: Arm A|RADIATION: Arm A|DRUG: Arm B|RADIATION: Arm B,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Tianjin Medical University Cancer Institute and Hospital
504,China,Laryngeal Cancer|Hypopharyngeal Cancer,DRUG: Toripalimab,2,OTHER,other,OTHER,Other,Phase II,other,other,Fudan University
505,United States,Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Urothelial Carcinoma|Head and Neck Squamous Cell Carcinoma|Merkel Cell Carcinoma|Melanoma|Renal Cell Carcinoma|Gastric Cancer|Cervical Cancer|Hepatocellular Carcinoma|Microsatellite Instability|Mismatch Repair Deficiency|Colorectal Cancer,DRUG: N-803 + Pembrolizumab|DRUG: N-803 + Nivolumab|DRUG: N-803 + Atezolizumab|DRUG: N-803 + Avelumab|DRUG: N-803 + Durvalumab|DRUG: N-803 + Pembrolizumab + PD-L1 t-haNK|DRUG: N-803 + Nivolumab + PD-L1 t-haNK|DRUG: N-803 + Atezolizumab + PD-L1 t-haNK|DRUG: N-803 + Avelumab + PD-L1 t-haNK|DRUG: N-803 + Durvalumab + PD-L1 t-haNK|DRUG: N-803 + Docetaxel + Pembrolizumab|DRUG: N-803 + Docetaxel + Nivolumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,gynecologic,checkpoint inhibitor,"ImmunityBio, Inc."
506,China,Colorectal Liver Metastases,RADIATION: Radiation: High- and Low-dose radiotherapy|DRUG: PD-1 Inhibitors,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,Jiangsu Cancer Institute & Hospital
507,China,Non-small Cell Lung Cancer,RADIATION: DCE-MRI based split-course hypo-RT|RADIATION: CT based split-course hypo-RT|DRUG: Concurrent chemotherapy|DRUG: Consolidative immunotherapy,3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,radiotherapy,Sun Yat-sen University
508,Canada,Head and Neck Squamous Cell Carcinoma|Metastatic Squamous Cell Carcinoma,RADIATION: SBRT|DRUG: Durvalumab|DRUG: Tremelimumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,head/neck,checkpoint inhibitor,Centre hospitalier de l'Université de Montréal (CHUM)
509,France,Non Small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Intergroupe Francophone de Cancerologie Thoracique
510,China,Cervical Cancer,DRUG: Cadonilimab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
511,China,Head and Neck Neoplasms|Recurrent Disease|Metastatic Cancer,DRUG: Penpulimab combined with cetuximab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Eye & ENT Hospital of Fudan University
512,United States,HPV-Related Cervical Carcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma,DRUG: Two IM injections Lenti-HPV-07|DRUG: One IM injection Lenti-HPV-07,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,gynecologic,other,Theravectys S.A.
513,United States,Kidney Cancer,BIOLOGICAL: cell infusion,1,NIH,other,NIH,Government,Phase I,genitourinary,other,"National Heart, Lung, and Blood Institute (NHLBI)"
514,United States,Triple Negative Breast Cancer|Metastatic Breast Cancer,DRUG: Pembrolizumab|BIOLOGICAL: PVX-410,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,breast,checkpoint inhibitor,Massachusetts General Hospital
515,United States,Anaplastic Thyroid Cancer|Thyroid Cancer|BRAF Mutation-Related Tumors,BIOLOGICAL: Cemiplimab|DRUG: XL092,1,OTHER,other,OTHER,Other,Phase I,other,checkpoint inhibitor,UNC Lineberger Comprehensive Cancer Center
516,China,Recurrent Nasopharyngeal Carcinoma,"DRUG: Immunotherapy,Toripalimab Injection|DRUG: Chemotherapy,Gemcitabine based regimen",3,OTHER,other,OTHER,Other,Phase III,head/neck,chemotherapy,Eye & ENT Hospital of Fudan University
517,China,Nasopharyngeal Carcinoma|Nasopharyngeal Cancer,DRUG: Cadonilimab|DRUG: Gemcitabine|DRUG: Cisplatin|RADIATION: Intensity-modulated radiotherapy,3,OTHER,other,OTHER,Other,Phase III,head/neck,radiotherapy,Sun Yat-sen University
518,"Republic of, United States",Advanced Solid Tumor|Metastatic Solid Tumor|Soft Tissue Sarcoma (STS)|Platinum-resistant Ovarian Cancer (PROC)|Hepatocellular Carcinoma (HCC)|Colorectal Cancer (CRC)|HER2 Negative Breast Cancer|Cutaneous Melanoma|Renal Cell Carcinoma (RCC),DRUG: GI-102 subcutaneous (SC)|DRUG: GI-102|DRUG: doxorubicin|DRUG: paclitaxel|DRUG: bevacizumab|DRUG: eribulin|DRUG: trastuzumab deruxtecan (T-DXd)|DRUG: pembrolizumab|DRUG: GI-102,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,gynecologic,checkpoint inhibitor,"GI Innovation, Inc."
519,"Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Israel, Italy, Japan, Netherlands, Philippines, Poland, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States, Vietnam",Muscle Invasive Bladder Cancer,DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,genitourinary,checkpoint inhibitor,AstraZeneca
520,France,Metastatic NSCLC,DRUG: Pembrolizumab before randomization|DRUG: Chemotherapy|DRUG: Pemetrexed|DRUG: Pembrolizumab after randomization,23,OTHER,checkpoint inhibitor,OTHER,Other,Phase II & III,multiple,checkpoint inhibitor,Intergroupe Francophone de Cancerologie Thoracique
521,United States,Non-Small Cell Lung Cancer Metastatic,DRUG: Durvalumab|DRUG: Pemetrexed|DRUG: Carboplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,University of Utah
522,China,Locally Advanced Rectal Cancer (LARC),DRUG: Sintilimab|RADIATION: Short-course radiotherapy|RADIATION: Long-course concurrent chemoradiotherapy|COMBINATION_PRODUCT: CAPOX,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
523,"France, Spain, United Kingdom, United States",Squamous Cell Carcinoma of Head and Neck,DRUG: TG4050,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,head/neck,other,Transgene
524,United States,Castration-resistant Prostate Cancer|Metastatic Cancer|Prostate Cancer,BIOLOGICAL: pTVG-HP|BIOLOGICAL: pTVG-AR|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,"University of Wisconsin, Madison"
525,China,Rectal Cancer,DRUG: AK112 with SCRT and CapeOX|DRUG: AK112 with SCRT,2,OTHER,other,OTHER,Other,Phase II,digestive,other,fan li
526,Norway,Glioblastoma,BIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide,23,OTHER,other,OTHER,Other,Phase II & III,brain/CNS,other,Oslo University Hospital
527,United States,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cemiplimab|PROCEDURE: Computed Tomography|DRUG: Dexamethasone|DRUG: Docetaxel|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Ramucirumab,23,NETWORK,other,NETWORK,Network,Phase II & III,lung/thoracic,checkpoint inhibitor,SWOG Cancer Research Network
528,United States,Epithelial Ovarian Cancer,DRUG: Pembrolizumab|DRUG: E7777,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,gynecologic,checkpoint inhibitor,"Alexander B Olawaiye, MD"
529,China,Recurrent Rectal Cancer,DRUG: PD-1 antibody|DRUG: Capecitabine|DRUG: 5FU|DRUG: folinic acid|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Raltitrexed|DRUG: Cetuximab|DRUG: Bevacizumab|RADIATION: Radiation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Fudan University
530,China,Esophageal Squamous Cell Carcinoma,RADIATION: Neoadjuvant chemoradiotherapy followed by immunotherapy|DRUG: Neoadjuvant chemoimmunotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Zhejiang Cancer Hospital
531,"Australia, Israel, Republic of, Spain, Taiwan, United Kingdom, United States",Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma,DRUG: 5-Fluorouracil (5-FU)|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: Atezolizumab|DRUG: Cobimetinib|BIOLOGICAL: Ramucirumab|DRUG: Paclitaxel|BIOLOGICAL: PEGylated recombinant human hyaluronidase (PEGPH20)|DRUG: BL-8040|DRUG: Linagliptin|DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: Cisplatin|DRUG: Tiragolumab|DRUG: 5-Fluorouracil (5-FU),12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,digestive,checkpoint inhibitor,Hoffmann-La Roche
532,"Australia, France, Israel, Republic of, Spain, Taiwan, United Kingdom, United States","Carcinoma, Non-Small-Cell Lung",DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: RO6958688|DRUG: Docetaxel|DRUG: CPI-444|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Gemcitabine|DRUG: Linagliptin|DRUG: Tocilizumab|DRUG: Ipatasertib|DRUG: Bevacizumab|DRUG: Sacituzumab Govitecan|OTHER: Radiation|DRUG: Evolocumab|DRUG: Tiragolumab|DRUG: XL092|DRUG: Camonsertib,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,lung/thoracic,checkpoint inhibitor,Hoffmann-La Roche
533,United States,Locally Advanced Rectal Adenocarcinoma,"DRUG: APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|DRUG: mFOLFOX and Radiation Therapy 5Gy x 5 days",2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,University of Texas Southwestern Medical Center
534,United States,Pancreatic Cancer,DRUG: Tadalafil|DRUG: Pembrolizumab|DRUG: Ipilimumab|DRUG: CRS-207,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
535,France,Non Small Cell Lung Cancer Metastatic,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Atezolizumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Intergroupe Francophone de Cancerologie Thoracique
536,China,Endometrial Adenocarcinoma|Endometrial Cancer,DRUG: QL1706 combined with chemotherapy ± Bevacizumab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,chemotherapy,Tianjin Medical University Cancer Institute and Hospital
537,United States,Non Small Cell Lung Cancer|Lung Cancer,DRUG: Pembrolizumab|DRUG: Difluoromethylornithine,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
538,United States,Breast Cancer,DRUG: SRG-514,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,breast,other,SURGE Therapeutics
539,United States,Breast Cancer,BIOLOGICAL: ESR1 peptide vaccine,1,OTHER,cancer vaccine,OTHER,Other,Phase I,breast,cancer vaccine,Herbert Lyerly
540,Italy,Small Cell Lung Cancer,RADIATION: Thoracic radiotherapy|DRUG: Atezolizumab 1200 mg e.v. q21,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Regina Elena Cancer Institute
541,United States,Epithelial Ovarian Cancer|Non-small Cell Lung Cancer|Renal Cell Carcinoma,BIOLOGICAL: ITIL-306,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,gynecologic,other,Instil Bio
542,United States,"Solid Tumor, Adult|Cancer|Neoplasms|Sarcoma|Sarcoma,Soft Tissue|Chondrosarcoma","BIOLOGICAL: AdAPT-001|DRUG: Checkpoint Inhibitor, Immune",2,INDUSTRY,other,INDUSTRY,Industry,Phase II,sarcoma,other,"EpicentRx, Inc."
543,United States,Pancreatic Cancer,DRUG: AGEN2373|DRUG: Balstilimab|DRUG: Cyclophosphamide|DRUG: GVAX|DRUG: AGEN2373 (RP2D)|DRUG: Balstilimab|DRUG: mKRASvax,12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
544,Australia,Stage II Melanoma,DRUG: Relatlimab and nivolumab fixed dose combination (FDC),2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Melanoma Institute Australia
545,"Belgium, France, Germany",Platinum-sensitive Ovarian Cancer|Relapsed Ovarian Cancer,DRUG: OSE2101|DRUG: Pembrolizumab 25 MG/ML [Keytruda],2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,ARCAGY/ GINECO GROUP
546,United States,Unresectable Melanoma,DRUG: Nivolumab|DRUG: Duvelisib,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,skin,checkpoint inhibitor,John Kirkwood
547,United States,Cervical Cancer|Advanced Cervical Carcinoma|Metastatic Cervical Cancer|Metastatic Cervical Carcinoma|Recurrent Cervical Carcinoma,DRUG: Dostarlimab|DRUG: Cobolimab,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,Meghan Shea
548,United States,Non-muscle-invasive Bladder Cancer,DRUG: STM-416,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,genitourinary,other,SURGE Therapeutics
549,France,Urothelial Carcinoma|Cancer,DRUG: Patients receiving neoadjuvant therapy before radical nephrectomy,2,OTHER,other,OTHER,Other,Phase II,other,other,Centre Hospitalier Universitaire de Nīmes
550,China,Thyroid Cancer,DRUG: Tislelizumab|DRUG: Anlotinib|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,other,radiotherapy,West China Hospital
551,United States,Breast Cancer,DRUG: Pembrolizumab|DRUG: Olaparib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Yuan Yuan
552,United States,"Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia|Lymphoma, B-Cell",BIOLOGICAL: Anti-CD19 and anti-CD20 bicistronic CAR T- cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,1,NIH,other,NIH,Government,Phase I,hematologic,other,National Cancer Institute (NCI)
553,France,Colorectal Cancer Metastatic|High Immune Infiltrate|Microsatellite Stable,DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Bevacizumab|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Federation Francophone de Cancerologie Digestive
554,Australia,Cutaneous Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma of the Head and Neck|Neoplasms|Non-melanoma Skin Cancer,DRUG: Cemiplimab,2,OTHER,other,OTHER,Other,Phase II,skin,checkpoint inhibitor,"Peter MacCallum Cancer Centre, Australia"
555,United States,Relapsed Neuroblastoma|Refractory Neuroblastoma|Relapsed Osteosarcoma|Relapsed Ewing Sarcoma|Relapsed Rhabdomyosarcoma|Uveal Melanoma|Phyllodes Breast Tumor,GENETIC: C7R-GD2.CART cells,1,OTHER,other,OTHER,Other,Phase I,breast,other,Baylor College of Medicine
556,"Germany, United States","Refractory Cancer|Recurrent Cancer|Solid Tumor, Adult|Cancer",BIOLOGICAL: IMA203 Product|BIOLOGICAL: IMA203 product- flat dose|BIOLOGICAL: IMA203CD8 Product|DRUG: nivolumab (Opdivo®)|DEVICE: IMADetect®,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,"Immatics US, Inc."
557,"Canada, United States",Neuroblastoma,DRUG: Ceritinib|DRUG: dasatinib|DRUG: sorafenib|DRUG: vorinostat|DRUG: DFMO,2,OTHER,other,OTHER,Other,Phase II,other,other,Giselle Sholler
558,China,Liver Transplantation|Hepatocellular Carcinoma,PROCEDURE: Downstaging procedures containing immunotherapy|PROCEDURE: Liver transplantation,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
559,"Argentina, Belgium, Brazil, Finland, France, Germany, Greece, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Republic of, South Africa, Spain, Thailand, Turkey, United Arab Emirates, United Kingdom, United States","Lung Cancer, Non-Small Cell",DRUG: Pembrolizumab|DRUG: Dostarlimab|DRUG: Belrestotug|DRUG: Nelistotug,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,lung/thoracic,checkpoint inhibitor,GlaxoSmithKline
560,China,Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage ⅢA|Non-small Cell Lung Cancer Stage IIIB,DRUG: nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Xiangya Hospital of Central South University
561,China,Pancreatic Cancer,DRUG: Camrelizumab+chemotherapy|RADIATION: hypofractionated radiotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Hebei Medical University Fourth Hospital
562,United States,"Carcinoma, Non-Small-Cell Lung",DRUG: MK-3475|DRUG: Gemcitabine,12,OTHER,other,OTHER,Other,Phase I & II,lung/thoracic,other,Providence Health & Services
563,China,Laryngeal Cancer|Hypopharynx Cancer,COMBINATION_PRODUCT: SBRT+Toripalimab Plus Docetaxel and Cisplatin,2,OTHER,combination product,OTHER,Other,Phase II,other,combination product,Sun Yat-sen University
564,United States,Metastatic Castration-Resistant Prostate Cancer (mCRPC),BIOLOGICAL: Sipuleucel-T,1,OTHER,other,OTHER,Other,Phase I,genitourinary,other,University of Oklahoma
565,United States,Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|Non-small Cell Carcinoma|NSCLC|NSCLC Stage IV,RADIATION: L-SABR|BIOLOGICAL: Anti-PD-(L)1 based immunotherapy|DRUG: Platinum based chemotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Memorial Sloan Kettering Cancer Center
566,"Argentina, Austria, Brazil, Canada, Chile, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Republic of, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam",Muscle Invasive Bladder Cancer,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Enfortumab Vedotin|PROCEDURE: Radical Cystectomy,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,genitourinary,checkpoint inhibitor,AstraZeneca
567,"France, Germany, Italy, Poland, Spain, United States",Breast Cancer,BIOLOGICAL: Placebo|BIOLOGICAL: GLSI-100,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,breast,other,"Greenwich LifeSciences, Inc."
568,France,"Solid Tumor, Adult|Pancreatic Cancer|Virus-associated Tumors|Non Small Cell Lung Cancer|Melanoma|Bladder Cancer|Triple Negative Breast Cancer",DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Institut Bergonié
569,United States,Glioblastoma,COMBINATION_PRODUCT: IGV-001 Cell Immunotherapy|COMBINATION_PRODUCT: Placebo|PROCEDURE: Standard of Care (SOC): Radiation Therapy|DRUG: SOC: Temozolomide,2,INDUSTRY,combination product,INDUSTRY,Industry,Phase II,brain/CNS,combination product,Imvax
570,"Republic of, United States",Advanced Solid Tumor|Metastatic Solid Tumor|Non-small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Renal Cell Carcinoma|Urinary Bladder Cancer|Melanoma|Sarcoma|Microsatellite Stable Colorectal Carcinoma|Merkel Cell Carcinoma|Esophageal Squamous Cell Carcinoma|Cervical Cancer|Vaginal Cancer|Vulvar Cancer,DRUG: GI-101|DRUG: Pembrolizumab (KEYTRUDA®)|DRUG: Lenvatinib|RADIATION: Local Radiotherapy|DRUG: GI-101A,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,gynecologic,checkpoint inhibitor,"GI Innovation, Inc."
571,China,Colorectal Cancer Stage IV|Mismatch Repair-deficient (dMMR)|Microsatellite Instability-high (MSI-H),DRUG: Cadonilimab,12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,Sun Yat-sen University
572,United States,Melanoma,DRUG: Pembrolizumab|DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,University of Chicago
573,United States,Head and Neck Cancer|Head Cancer|Head Cancer Neck|Neck Cancer|Head and Neck Squamous Cell Carcinoma|HNSCC,DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Cetuximab|DRUG: Cemiplimab|PROCEDURE: Surgical Resection of Primary +/- Neck Dissection|RADIATION: Post-operative radiation therapy|DRUG: Paclitaxel,1,OTHER,other,OTHER,Other,Phase I,head/neck,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
574,United States,Advanced Melanoma,DRUG: Propranolol|DRUG: Naltrexone,1,OTHER,other,OTHER,Other,Phase I,skin,other,Ryan Stephenson
575,United States,Pancreatic Cancer,DRUG: Cyclophosphamide|DRUG: Cyclophosphamide Pill|BIOLOGICAL: GVAX Pancreas Vaccine,2,OTHER,cancer vaccine,OTHER,Other,Phase II,digestive,cancer vaccine,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
576,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Recurrent Melanoma|Unresectable Melanoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Dabrafenib Mesylate|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|DRUG: Trametinib Dimethyl Sulfoxide,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,skin,checkpoint inhibitor,National Cancer Institute (NCI)
577,United States,Gastric Cancer|Breast Cancer|Cervical Cancer|Lung Cancer,BIOLOGICAL: KK-LC-1 TCR-T cells|DRUG: Aldesleukin,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,gynecologic,adoptive cell therapy,Christian Hinrichs
578,United States,Pancreatic Cancer,DRUG: Cyclophosphamide|BIOLOGICAL: GVAX pancreatic cancer|DRUG: Nivolumab|DRUG: Urelumab|DRUG: BMS-986253,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
579,United States,Glioblastoma,BIOLOGICAL: INO-5401|BIOLOGICAL: INO-9012|BIOLOGICAL: Cemiplimab|RADIATION: Radiation Therapy|DRUG: Temozolomide,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,brain/CNS,checkpoint inhibitor,Inovio Pharmaceuticals
580,United States,Bladder Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|PROCEDURE: Radical cystectomy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
581,United States,Advanced Extrapulmonary Neuroendocrine Carcinoma|Metastatic Extrapulmonary Neuroendocrine Carcinoma|Recurrent Extrapulmonary Neuroendocrine Carcinoma|Unresectable Extrapulmonary Neuroendocrine Carcinoma,BIOLOGICAL: Atezolizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Etoposide|PROCEDURE: Magnetic Resonance Imaging|OTHER: Patient Observation,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,multiple,checkpoint inhibitor,National Cancer Institute (NCI)
582,China,Breast Cancer,DRUG: Cadonilimab (AK104),2,OTHER,other,OTHER,Other,Phase II,breast,other,Hubei Cancer Hospital
583,France,Immunotherapy,"DRUG: olaparib, durvalumab, tremelimumab",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Centre Georges Francois Leclerc
584,United States,Advanced Solid Tumor|Head and Neck Squamous Cell Carcinoma,DRUG: CHS-114|DRUG: toripalimab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,head/neck,other,"Coherus Biosciences, Inc."
585,China,Rectal Cancer,RADIATION: node-sparing modified short-course radiotherapy|DRUG: PD-1 antibody|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: standard short-course radiotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,Sir Run Run Shaw Hospital
586,United States,Pancreatic Cancer,DRUG: IRE + intratumoral mitazalimab (CD40 antibody) injection|DEVICE: NanoKnife,1,OTHER,other,OTHER,Other,Phase I,digestive,other,"University of California, San Diego"
587,China,Nasopharyngeal Cancinoma (NPC),OTHER: Low-dose radiotherapy combine with chemoimmunotherapy,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Hunan Cancer Hospital
588,China,Early Low Rectal Cancer,DRUG: PD-1 antibody|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: Short-course radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Fudan University
589,United States,Endometrial Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Dostarlimab|DRUG: Cisplatin,1,OTHER,other,OTHER,Other,Phase I,gynecologic,chemotherapy,M.D. Anderson Cancer Center
590,Netherlands,Melanoma,DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Nivolumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,skin,checkpoint inhibitor,The Netherlands Cancer Institute
591,"Australia, United States",Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|Squamous Non-small-cell Lung Cancer|Large Cell Carcinoma Lung|Adenocarcinoma Lung,BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 1|BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 2|BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 3|DRUG: Atezolizumab|DRUG: Standard of care chemotherapy,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,lung/thoracic,checkpoint inhibitor,Imugene Limited
592,United States,Gastric Neoplasms|Esophageal Cancer|Liver Cancer|Liver Metastasis|MSS-CRC|MSS|Gastric Adenocarcinoma|Peritoneal Cancer|Peritoneal Carcinoma|Peritoneal Metastases|MSI-H|Gastric Cancer,BIOLOGICAL: vvDD-hIL-2-RG-1,1,OTHER,cytokine / immunomodulator,OTHER,Other,Phase I,digestive,cytokine / immunomodulator,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
593,"Belgium, France","Carcinoma, Renal Cell|Carcinoma, Non-Small-Cell Lung",OTHER: Live Bacterial Product - Akkermansia muciniphila,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,genitourinary,other,EverImmune
594,China,Metastatic or Recurrent Gastric Adenocarcinoma,DRUG: Envafolimab|DRUG: Oxaliplatin|DRUG: S1,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Liangjun Zhu M.M.
595,United States,"Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Head and Neck Carcinoma|Head and Neck Cancer Stage III|Head and Neck Cancer Stage IV|Head and Neck Cancer Metastatic|Cancer|Cancer of Esophagus|Cancer, Metastatic|Cancer of Head and Neck|Cancer of Mouth|Cancer of Neck",DRUG: Pembrolizumab|DRUG: Tadalafil,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"University of California, San Diego"
596,China,Colorectal Cancer|Liver Metastases,RADIATION: Stereotactic body radiation therapy|DRUG: PD-1 Monoclonal Antibody|DRUG: Chemotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,Jun Huang
597,"Australia, United States",Advanced Solid Tumor|Metastatic Cancer|Cutaneous Melanoma|Non-Small Cell Lung Cancer,DRUG: AU-007|DRUG: Aldesleukin|DRUG: Avelumab|DRUG: Nivolumab,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,lung/thoracic,checkpoint inhibitor,"Aulos Bioscience, Inc."
598,"Canada, United States",Basaloid Squamous Cell Carcinoma|Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Oropharyngeal Squamous Cell Carcinoma|Papillary Squamous Cell Carcinoma|Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Squamous Cell Carcinoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|DRUG: Cisplatin|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|RADIATION: Image Guided Radiation Therapy|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,head/neck,checkpoint inhibitor,National Cancer Institute (NCI)
599,China,Hepatocellular Carcinoma (HCC),"DRUG: Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin",12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,Zhejiang Cancer Hospital
600,United States,Locally Advanced Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma,DRUG: EGFR BATs after standard of care chemo,12,OTHER,other,OTHER,Other,Phase I & II,digestive,chemotherapy,University of Virginia
601,"Australia, Brazil, Canada, France, Italy, Netherlands, Spain",Urinary Bladder Neoplasms|Immune Checkpoint Inhibitors|Methotrexate|Vinblastine|Doxorubicin|Cisplatin|Gemcitabine,DRUG: Durvalumab|DRUG: Methotrexate|DRUG: Vinblastine|DRUG: Doxorubicin|DRUG: Cisplatin|DRUG: Durvalumab|DRUG: Gemcitabine|DRUG: Cisplatin,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,genitourinary,checkpoint inhibitor,AstraZeneca
602,China,Gastric Cancer|Diffuse Type Carcinoma,DRUG: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
603,Switzerland,Rectum Cancer|Rectal Cancer,DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"University Hospital, Geneva"
604,China,IIIA Stage Non-small Cell Lung Cancer,DRUG: Sintilimab Injection,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,The First Hospital of Jilin University
605,China,Breast Cancer|Triple Negative Breast Cancer (TNBC)|Early Stage Breast Cancer|Immunotherapy|Probiotic,OTHER: Biolosion (oral probiotic compound preparation),2,OTHER,other,OTHER,Other,Phase II,breast,other,Sun Yat-sen University
606,United States,Carcinomas|Renal Medullary Carcinoma,DRUG: Nivolumab|DRUG: Relatlimab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,M.D. Anderson Cancer Center
607,Japan,Bladder Cancer,DRUG: MK-3475|DRUG: ASG-22CE|PROCEDURE: maximal TURBT|RADIATION: Radiation therapy,2,OTHER,other,OTHER,Other,Phase II,genitourinary,radiotherapy,Kyoto University Hospital
608,United States,Melanoma,DRUG: Tavo|DRUG: Nivolumab|DEVICE: OncoSec Medical Electroporation Therapy System,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
609,Australia,"Lung Cancer, Nonsmall Cell|Renal Cell Carcinoma|Melanoma|Gastric Cancer|Hepatocellular Carcinoma|Endometrial Cancer|Mesothelioma",DIAGNOSTIC_TEST: Blood screening|DIAGNOSTIC_TEST: Tissue screening,12,OTHER,other,OTHER,Other,Phase I & II,gynecologic,biomarker / diagnostics,Western Sydney Local Health District
610,Spain,"Non Small Cell Lung Cancer|Brain Metastases, Adult|Lung Cancer",DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Fundación GECP
611,China,Nasopharyngeal Carcinoma|De-escaltion Therapy,PROCEDURE: Reduced-target resection|PROCEDURE: Full-target resection|DRUG: Adjuvant immunotherapy,3,OTHER,other,OTHER,Other,Phase III,head/neck,other,Sun Yat-sen University
612,United States,High Risk Cancer|Pancreatic Cancer,DRUG: Cohort A: Patients at high risk of developing pancreatic cancer.|DRUG: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
613,United States,"HER2-positive|Adenocarcinoma|Bile Duct Cancer|Biliary Tract Cancer|Bladder Cancer|Breast Cancer|Breast Neoplasm|Carcinoma, Ductal|Carcinoma, Hepatocellular|Cancer|Lung Cancer, Non-Small-Cell|Carcinoma, Ovarian Epithelial|Carcinoma, Small Cell|Carcinoma, Squamous|Carcinoma, Transitional Cell|Colorectal Cancer|Esophagogastric Junction Neoplasms|Inflammatory Breast Cancer|Stomach Neoplasms|Malignant Neoplasms|Ovarian Neoplasms|Pancreatic Cancer|HER2-positive Solid Tumors|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification|Prostate Cancer|Head and Neck Cancer|Endometrial Cancer|Lung Cancer, Small Cell",BIOLOGICAL: CT-0508|BIOLOGICAL: Pembrolizumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,gynecologic,checkpoint inhibitor,Carisma Therapeutics Inc
614,United States,Stage I Colon Cancer|Stage II Colon Cancer|Stage III Colon Cancer,DRUG: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|DRUG: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|DRUG: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Baylor College of Medicine
615,United States,"Brain Metastasis|Radiation Therapy|Immunotherapy, Active",RADIATION: F-Fluciclovine radiotracer,3,OTHER,other,OTHER,Other,Phase III,brain/CNS,radiotherapy,"University of Wisconsin, Madison"
616,China,Esophageal Carcinoma,DRUG: Immune Checkpoint Inhibitors,12,OTHER_GOV,other,OTHER_GOV,Government,Phase I & II,digestive,other,Anhui Provincial Hospital
617,United States,Genitourinary Cancer|Adrenocortical Carcinoma|Non-urothelial Bladder|Non-urothelial Upper Tract|Penile Cancer|Non-adenocarcinoma Prostate Cancer|Refractory Germ-cell|High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma,DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Dana-Farber Cancer Institute
618,United States,Prostate Cancer|Metastatic Castration-resistant Prostate Cancer,DRUG: Abemaciclib|DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Dana-Farber Cancer Institute
619,China,Radiotherapy|Immunotherapy|Liver Metastases|Colorectal Cancer,RADIATION: SBRT|DRUG: Chemotherapy|DRUG: PD-1 antibody,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Fudan University
620,United States,Common Warts (Verruca Vulgaris),"DRUG: Candin, Intradermal Solution|DRUG: Placebo",3,INDUSTRY,other,INDUSTRY,Industry,Phase III,other,other,"Nielsen BioSciences, Inc."
621,United States,Metastatic Melanoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,BIOLOGICAL: Aldesleukin|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: NGFR-transduced Autologous T Lymphocytes|BIOLOGICAL: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes,1,OTHER,other,OTHER,Other,Phase I,skin,biomarker / diagnostics,M.D. Anderson Cancer Center
622,United States,Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|OTHER: Immunotherapy|RADIATION: Palliative Radiation Therapy|RADIATION: Spatially-fractionated Radiation Therapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Mayo Clinic
623,"Canada, United States",Ovarian Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Bladder Cancer|Microsatellite Instability-High,OTHER: DPX-Survivac|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,gynecologic,checkpoint inhibitor,"ImmunoVaccine Technologies, Inc. (IMV Inc.)"
624,China,PD-1|Neoadjuvant Chemoradiotherapy|Gastroesophageal Junction Cancer,DRUG: PD-1inhibitor,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Wuhan Union Hospital, China"
625,China,Locally Advanced Rectal Cancer,RADIATION: radiation|DRUG: PD-1 Monoclonal Antibody|PROCEDURE: TME surgery,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Peking University People's Hospital
626,United States,Metastatic Pancreatic Adenocarcinoma,DRUG: Avelumab and Pepinemab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,digestive,other,Vaccinex Inc.
627,"Finland, United States",Melanoma|Head and Neck Squamous Cell Carcinoma,BIOLOGICAL: TILT-123|DRUG: Avelumab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,skin,other,TILT Biotherapeutics Ltd.
628,United States,Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|MSI High Colorectal Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Radiation Therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Massachusetts General Hospital
629,United States,Advanced Lung Cancer,BIOLOGICAL: BNT324|BIOLOGICAL: BNT327,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,lung/thoracic,other,BioNTech SE
630,"Australia, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Spain, Turkey, United Kingdom, United States",Non-Small Cell Lung Cancer,BIOLOGICAL: Sacituzumab Govitecan-hziy (SG)|DRUG: Docetaxel,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,lung/thoracic,other,Gilead Sciences
631,China,Biliary Tract Cancer,DRUG: Durvalumab combined with S-1,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
632,United States,Sinonasal Melanoma|Anorectal Melanoma,PROCEDURE: Surgical resection,2,OTHER,other,OTHER,Other,Phase II,digestive,other,M.D. Anderson Cancer Center
633,China,Limited Stage Small Cell Lung Cancer,DRUG: Sugemalimab|DRUG: Placebo,23,OTHER,other,OTHER,Other,Phase II & III,lung/thoracic,other,Sun Yat-sen University
634,Belgium,Muscle-Invasive Bladder Carcinoma,RADIATION: Metastasis directed therapy (MDT)|DRUG: Immunotherapy|PROCEDURE: Standard of care,2,OTHER,other,OTHER,Other,Phase II,genitourinary,radiotherapy,"University Hospital, Ghent"
635,United States,Renal Cell Carcinoma,"DRUG: Neoadjuvant Lenvatinib|DRUG: Neoadjuvant Pembrolizumab|PROCEDURE: Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|DRUG: Adjuvant Pembrolizumab",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,University of Texas Southwestern Medical Center
636,United States,Endometrial Cancer,BIOLOGICAL: Lifileucel,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,gynecologic,other,"Iovance Biotherapeutics, Inc."
637,Spain,"Lung Diseases|Carcinoma, Non-Small-Cell Lung|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Respiratory Tract Neoplasms|Carcinoma Bronchiogenic Stage III|Thoracic Neoplasms",DRUG: Carboplatin|DRUG: Placlitaxel|DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Fundación GECP
638,Brazil,"Lung Cancer, Nonsmall Cell|Non-Small Cell Lung Cancer NSCLC",DRUG: Low-dose nivolumab combined with platinum-based doublet chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,"Aline Fusco Fares, MD"
639,Italy,Melanoma,DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,European Institute of Oncology
640,United States,Cholangiocarcinoma|Gallbladder Cancer|Gallbladder Carcinoma|Intrahepatic Cholangiocarcinoma|Extrahepatic Cholangiocarcinoma|Bile Duct Cancer|Gall Bladder Cancer|Gall Bladder Carcinoma,DRUG: certepetide|DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: FOLFOX regimen|DRUG: Placebo,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,genitourinary,checkpoint inhibitor,"Lisata Therapeutics, Inc."
641,,Refractory Metastatic Colorectal Cancer|pMMR|MSS,BIOLOGICAL: RP2|BIOLOGICAL: RP3|BIOLOGICAL: atezolizumab|BIOLOGICAL: bevacizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,Replimune Inc.
642,United States,Squamous Cell Carcinoma of the Head and Neck,DRUG: Nivolumab+Relatlimab|DRUG: Nivolumab+Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Dan Zandberg
643,United States,Metastatic Melanoma,DRUG: ipilimumab|DRUG: nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
644,China,Non Small Cell Lung Cancer|EGFR Gene Mutation,DRUG: almonertinib|DRUG: Carboplatin|DRUG: Nab paclitaxel,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Guangdong Provincial People's Hospital
645,China,Hepatocellular Carcinoma|Chemotherapy Effect|Chemotherapeutic Toxicity,"DRUG: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|DRUG: Concurrent Lenvatinib|DRUG: Concurrent PD-1 antibody|DRUG: Sequential Lenvatinib|DRUG: Sequential PD-1 antibody",3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,Sun Yat-sen University
646,United States,Neuroblastoma,BIOLOGICAL: Hu3F8|DRUG: GM-CSF|DRUG: Isotretinoin,2,OTHER,other,OTHER,Other,Phase II,other,other,Memorial Sloan Kettering Cancer Center
647,"Australia, France, Georgia, Italy, Poland, Republic of, Spain, Taiwan, United Kingdom, United States",Advanced Non-Small Cell Lung Cancer,DRUG: Domvanalimab|DRUG: Quemliclustat|DRUG: Zimberelimab|DRUG: Docetaxel|DRUG: Platinum-Based Doublet,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,chemotherapy,Gilead Sciences
648,"Australia, France, Italy, Republic of, Spain, Taiwan, United States",Pancreatic Cancer,"COMBINATION_PRODUCT: TTX-030, nab-paclitaxel and gemcitabine|COMBINATION_PRODUCT: TTX-030, budigalimab, nab-paclitaxel and gemcitabine|COMBINATION_PRODUCT: Nab-Paclitaxel and gemcitabine",2,INDUSTRY,combination product,INDUSTRY,Industry,Phase II,digestive,combination product,"Trishula Therapeutics, Inc."
649,"Austria, France, Germany, New Zealand, Republic of, Spain, Taiwan, United Kingdom, United States","Carcinoma, Hepatocellular",DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Tiragolumab|DRUG: Tobemstomig,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,digestive,checkpoint inhibitor,Hoffmann-La Roche
650,France,Node; Prostate|Bone Metastases|Prostate Cancer Patients,COMBINATION_PRODUCT: SBRT + Durvalumab|RADIATION: SBRT,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Institut Cancerologie de l'Ouest
651,United States,Pancreatic Cancer,DRUG: FOLFIRINOX|DRUG: Losartan|DRUG: Nivolumab|RADIATION: SBRT|PROCEDURE: Surgery,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Massachusetts General Hospital
652,Switzerland,Leptomeningeal Metastasis|Non-small Cell Lung Cancer Stage IV|Melanoma Stage IV,DRUG: intrathecal nivolumab and intrathecal ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,lung/thoracic,checkpoint inhibitor,University of Zurich
653,China,Rectal Cancer,BIOLOGICAL: Envafolimab,3,OTHER,other,OTHER,Other,Phase III,digestive,other,Sir Run Run Shaw Hospital
654,China,Gastric Cancer,DRUG: Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,"Wuhan Union Hospital, China"
655,United States,Clinical Stage 0 Gastric Cancer AJCC v8|Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Gastric Cancer AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Gastric Adenocarcinoma|Localized Gastric Carcinoma|Localized Gastroesophageal Junction Adenocarcinoma|Pathologic Stage 0 Gastric Cancer AJCC v8|Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage I Gastric Cancer AJCC v8|Pathologic Stage IA Gastric Cancer AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Gastric Cancer AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastric Cancer AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastric Cancer AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,DRUG: Fluorouracil|RADIATION: Intensity-Modulated Radiation Therapy|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|DRUG: Oxaliplatin|PROCEDURE: Therapeutic Conventional Surgery,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,M.D. Anderson Cancer Center
656,United States,Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck,DRUG: Immune checkpoint inhibitor|RADIATION: Radiation Therapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,"John L. Villano, MD, PhD"
657,"Germany, United States",Prostate Cancer,DRUG: Xaluritamig,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,other,Amgen
658,France,Metastatic Breast Cancer,DRUG: AZD2014|DRUG: AZD4547|DRUG: AZD5363|DRUG: AZD8931|DRUG: Selumetinib|DRUG: Vandetanib|DRUG: Bicalutamide|DRUG: Olaparib|DRUG: Anthracyclines|DRUG: Taxanes|DRUG: cyclophosphamide|DRUG: DNA intercalators|DRUG: Methotrexate|DRUG: vinca alkaloids|DRUG: Platinum based chemotherapies|DRUG: Bevacizumab|DRUG: Mitomycin C|DRUG: Eribulin|DRUG: MEDI4736,2,OTHER,other,OTHER,Other,Phase II,breast,chemotherapy,UNICANCER
659,Norway,Melanoma Stage IV|Head and Neck Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|MSI-High|Clear Cell Renal Cell Carcinoma|Non-small Cell Lung Cancer,BIOLOGICAL: Fecal Microbiota Transplant (FMT),2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Oslo University Hospital
660,United States,Glioblastoma|Medulloblastoma|Ependymoma|Diffuse Intrinsic Pontine Glioma,DRUG: Indoximod|RADIATION: Partial Radiation|RADIATION: Full-dose Radiation|DRUG: Temozolomide|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Lomustine,2,OTHER,other,OTHER,Other,Phase II,brain/CNS,radiotherapy,Theodore S. Johnson
661,Canada,Prostate Cancer,DRUG: Adavosertib|DRUG: Savolitinib|DRUG: Darolutamide|DRUG: CFI-400945|DRUG: Ipatasertib|DRUG: Durvalumab and Tremelimumab|DRUG: Carboplatin,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,genitourinary,checkpoint inhibitor,Canadian Cancer Trials Group
662,China,Cervical Cancer,DRUG: Cadonilimab|DRUG: Anlotinib|DRUG: Granulocyte-Macrophage Colony-Stimulating Factor,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,Zhongnan Hospital
663,United States,Triple Negative Breast Cancer|Breast Cancer,DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,University of Kansas Medical Center
664,"Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom, United States",Melanoma,BIOLOGICAL: Nivolumab|OTHER: Placebo,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,skin,checkpoint inhibitor,Bristol-Myers Squibb
665,Kazakhstan,"Monitoring, Immunologic",DIETARY_SUPPLEMENT: Adenorine|BIOLOGICAL: Placebo|DRUG: FOLFOX regimen,12,OTHER,other,OTHER,Other,Phase I & II,other,other,MIPO Clinic
666,United States,Epstein-Barr Virus Infections|Cytomegalovirus Infections|Adenovirus|BK Virus Infection,DRUG: Rapidly generated virus specific T (R-MVST) cells,1,OTHER,oncolytic virus,OTHER,Other,Phase I,other,other,Columbia University
667,United States,Triple Negative Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Olaparib|DRUG: Capecitabine,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
668,United States,Cancer|Carcinoma|Squamous Cell Carcinoma|Head and Neck Cancer,BIOLOGICAL: Atezolizumab|BIOLOGICAL: Tocilizumab|BIOLOGICAL: Tiragolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Alain Algazi
669,Italy,Follicular Lymphoma,DRUG: Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|DRUG: Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|DRUG: Immunochemotherapy regimen: R-CHOP (Arm A)|DRUG: Immunochemotherapy regimen: R-CHOP (Arm B)|DRUG: Immunochemotherapy regimen: G-bendamustine (Arm A)|DRUG: Immunochemotherapy regimen: G-bendamustine (Arm B)|DRUG: Immunochemotherapy regimen: G-CHOP (Arm A)|DRUG: Immunochemotherapy regimen: G-CHOP (Arm B)|DRUG: Immunochemotherapy regimen: G-CVP (Arm A)|DRUG: Immunochemotherapy regimen: G-CVP (Arm B),3,OTHER,other,OTHER,Other,Phase III,hematologic,chemotherapy,Fondazione Italiana Linfomi - ETS
670,China,HNSCC|Lysogenic HSV Virus|Neoadjuvant Therapy|Immunotherapy|Targeted Therapy,BIOLOGICAL: Lysogenic HSV virus.|DRUG: Tislelizumab|DRUG: Afatinib,1,OTHER,oncolytic virus,OTHER,Other,Phase I,other,other,West China Hospital
671,United States,Castration-resistant Prostate Cancer|Metastatic Cancer,DRUG: Cabozantinib|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,"Rana McKay, MD"
672,China,Head and Neck Squamous Cell Carcinoma|Low-dose Radiotherapy|Immunotherapy|Targeted Therapy,DRUG: Tislelizumab|DRUG: Afatinib|RADIATION: Low dose radiotherapy,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,West China Hospital
673,Egypt,Eye Infections,"BIOLOGICAL: Intralesional injection of Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.)",2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,other,other,Zagazig University
674,United States,Prostate Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Olaparib|DRUG: Androgen Deprivation Therapy|RADIATION: Radiation Therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Zin W Myint
675,United States,Melanoma,DRUG: Nivolumab|DRUG: Hydroxychloroquine|DRUG: Ipilimumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,skin,checkpoint inhibitor,"Ravi Amaravadi, MD"
676,United States,Kidney Cancer|Renal Cell Carcinoma,DRUG: Cabozantinib|DRUG: Nivolumab|PROCEDURE: Cytoreductive nephrectomy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Mark Stein
677,China,Esophageal Squamous Cell Carcinoma,RADIATION: Split-course hypo-CCRT|DRUG: Induction chemo-immunotherapy|DRUG: Concurrent chemotherapy,1,OTHER,other,OTHER,Other,Phase I,digestive,radiotherapy,Sun Yat-sen University
678,China,Non-small Cell Lung Cancer|PDL1 Gene Mutation,DRUG: Serplulimab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Zhejiang Cancer Hospital
679,"Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom",Unresectable Stage III Melanoma|Stage IV Melanoma,DRUG: Nivolumab + Ipilimumab|DRUG: Encorafenib + Binimetinib,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,skin,checkpoint inhibitor,European Organisation for Research and Treatment of Cancer - EORTC
680,"Japan, United States",Limited Stage Lung Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,RADIATION: 3-Dimensional Conformal Radiation Therapy|DRUG: Atezolizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|RADIATION: Intensity-Modulated Radiation Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
681,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Melanoma,OTHER: Dietary Intervention|OTHER: Dietary Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,2,OTHER,other,OTHER,Other,Phase II,skin,supportive therapy,M.D. Anderson Cancer Center
682,China,Colorectal Cancer,DRUG: Camrelizumab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,yue junhan
683,Israel,Follicular Lymphoma,DRUG: Bendamustin|DRUG: Obinutuzumab,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Meir Medical Center
684,"Canada, Spain, United States",HER2+/HR+ Breast Cancer,DRUG: ZW25 (Zanidatamab)|DRUG: Palbociclib|DRUG: Fulvestrant,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,breast,other,Jazz Pharmaceuticals
685,"Canada, United States",Locally Advanced Lung Non-Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|DRUG: Etoposide|RADIATION: Image Guided Radiation Therapy|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|RADIATION: Stereotactic Body Radiation Therapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,NRG Oncology
686,"Australia, Republic of, Turkey, United Kingdom, United States",Non-small Cell Lung Cancer,DRUG: BNT327|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Paclitaxel,23,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II & III,lung/thoracic,checkpoint inhibitor,BioNTech SE
687,"Canada, United States",Advanced Bladder Urothelial Carcinoma|Advanced Renal Pelvis Urothelial Carcinoma|Advanced Ureter Urothelial Carcinoma|Advanced Urethral Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8|Stage III Renal Pelvis and Ureter Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage III Urethral Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis and Ureter Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8,DRUG: Avelumab|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,other,NIH,Government,Phase III,genitourinary,supportive therapy,National Cancer Institute (NCI)
688,France,Non-Small Cell Lung Cancer Metastatic,DRUG: Ipilimumab|DRUG: Nivolumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Intergroupe Francophone de Cancerologie Thoracique
689,"Czechia, France, Germany, Israel, Italy, Norway, Poland, Spain, United Kingdom",Gastric and Esophagogastric Junction Adenocarcinoma,DRUG: Nivolumab and Ipilimumab|OTHER: chemotherapy,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,digestive,checkpoint inhibitor,European Organisation for Research and Treatment of Cancer - EORTC
690,China,"Gastric Cancer|Peritoneal Metastases|Ascites, Malignant","DRUG: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|OTHER: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected",2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Zhejiang Cancer Hospital
691,"France, Germany, Spain, United States",Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer|Esophageal Adenocarcinoma|Esophageal Squamous Cell Cancer|Siewert Type 1 GEJ Cancer|Pancreatic Cancer,DRUG: Futibatinib|DRUG: Pembrolizumab|DRUG: Cisplatin|DRUG: 5-FU|DRUG: Oxaliplatin|DRUG: Leucovorin|DRUG: Levoleucovorin|DRUG: Irinotecan,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,"Taiho Oncology, Inc."
692,"Canada, Guam, United States",Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
693,United States,Extensive Stage Lung Small Cell Carcinoma,DRUG: Atezolizumab|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|RADIATION: Radiation Therapy,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
694,United States,Pancreatic Ductal Adenocarcinoma,DRUG: Neoadjuvant Chemotherapy (NAC)|DRUG: Immunotherapy (pembrolizumab)|DEVICE: Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA),2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"The University of Texas Health Science Center, Houston"
695,China,Locally Advanced Rectal Carcinoma,DRUG: Tislelizumab,23,OTHER,other,OTHER,Other,Phase II & III,digestive,other,Beijing Friendship Hospital
696,United Kingdom,Locally Advanced Gastric Adenocarcinoma|MSI-H/dMMR Gastric Cancer|MSI-H/dMMR Gastroesophageal-junction Cancer,DRUG: Single agent zimberelimab|DRUG: Combination zimberelimab + domvanalimab,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Royal Marsden NHS Foundation Trust
697,United States,Non Small Cell Lung Cancer,DIAGNOSTIC_TEST: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|DRUG: Pembrolizumab|DRUG: Platinum Doublet Chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,University of Miami
698,China,Lung Cancer,DRUG: Tafolecimab|DRUG: Sintilimab|DRUG: Nab paclitaxel|DRUG: Docetaxel|DRUG: Gemcitabine,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Jinghui Wang
699,China,HR+/HER2- Breast Cancer,DRUG: Neoadjuvant Chemotherapy in Combination with Toripalimab|DRUG: Neoadjuvant Chemotherapy,3,OTHER,combination product,OTHER,Other,Phase III,breast,combination product,First Affiliated Hospital of Zhejiang University
700,Hong Kong,HCC,DRUG: Zabadinostat (CXD101) and Geptanolimab|DRUG: Lenvatinib and Sorafenib,2,OTHER,other,OTHER,Other,Phase II,other,other,Stephen Chan Lam
701,Denmark,"Bladder Cancer|Bladder Cancer, Metastatic",DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Jørgen Bjerggaard Jensen
702,"Belgium, United States",Unresectable Metastatic Colorectal Cancer,DRUG: CYAD-101|DRUG: FOLFOX|DRUG: FOLFIRI,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,other,Celyad Oncology SA
703,Republic of,Bile Duct Cancer|Chemotherapy Effect,DRUG: AZD6738|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Seoul National University Hospital
704,"Australia, Canada, New Zealand, Puerto Rico, United States",Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Dinutuximab|DRUG: Isotretinoin|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Sargramostim,3,NIH,other,NIH,Government,Phase III,other,biomarker / diagnostics,National Cancer Institute (NCI)
705,"Belgium, France, Germany, Italy, Japan, Singapore, Spain, Taiwan, United States","Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Esophageal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck",BIOLOGICAL: QEQ278,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,other,Novartis Pharmaceuticals
706,China,Breast Cancer,DRUG: Lvonescimab (AK112),2,OTHER,other,OTHER,Other,Phase II,breast,other,Hubei Cancer Hospital
707,United Kingdom,"Lung Cancer, Nonsmall Cell",DRUG: Pembrolizumab 25 MG/ML [Keytruda],3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Imperial College London
708,Chile,Melanoma Stage IIIc|Melanoma Stage IV,BIOLOGICAL: TRIMELVAX,1,OTHER,other,OTHER,Other,Phase I,skin,other,University of Chile
709,United States,Cervical Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma|HPV (Human Papillomavirus)-Associated Carcinoma,"DRUG: HPV vaccine, Imiquimod, and metformin combination therapy",2,OTHER,cancer vaccine,OTHER,Other,Phase II,gynecologic,cancer vaccine,Baylor College of Medicine
710,"Netherlands, United Kingdom",Renal Cell Carcinoma,DRUG: Neoadjuvant nivolumab|DRUG: Neoadjuvant ipilimumab|DRUG: Neoadjuvant relatlimab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,The Netherlands Cancer Institute
711,"Belgium, Brazil, France, Georgia, Italy, Russian Federation, Spain, United States",Metastatic Colorectal Cancer,DRUG: Botensilimab|DRUG: Balstilimab|DRUG: Standard of Care,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,other,Agenus Inc.
712,United States,Cutaneous Melanoma,DRUG: Pembrolizumab|DRUG: Talimogene Laherparepvec,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,University of Louisville
713,United States,Malignant Melanoma,DRUG: Peginterferon alfa-2b|DRUG: Temozolomide|DRUG: Recombinant interferon alfa-2b,2,OTHER,other,OTHER,Other,Phase II,skin,cytokine / immunomodulator,St. Jude Children's Research Hospital
714,United States,Colorectal Cancer,DRUG: Cemiplimab|DRUG: Fianlimab,2,OTHER,other,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
715,United States,Muscle-Invasive Bladder Carcinoma,BIOLOGICAL: Synthetic long peptide personalized cancer vaccine|DRUG: Poly ICLC|DEVICE: Signatera assay,1,OTHER,cancer vaccine,OTHER,Other,Phase I,genitourinary,cancer vaccine,Washington University School of Medicine
716,United States,Muscle-invasive Urothelial Cancer of the Bladder,BIOLOGICAL: Pembrolizumab|PROCEDURE: Transurethral Resection of Bladder Tumor|DRUG: Gemcitabine|RADIATION: External Beam Radiation Therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,NYU Langone Health
717,China,Triple-Negative Breast Cancer (TNBC),"RADIATION: radiotherapy 5 Gy × 5 fractions, once a day|RADIATION: radiotherapy 8 Gy × 5 fractions, once a day|RADIATION: radiotherapy 8 Gy × 3 fractions, once every other day|RADIATION: radiotherapy 10 Gy× 3 fractions, once every other day|RADIATION: radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)|DRUG: Toripalimab|DRUG: chemotherapy regimen selected by the investigator",2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,Sun Yat-sen University
718,United States,Advanced Merkel Cell Carcinoma|Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Metastatic Merkel Cell Carcinoma|Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8,BIOLOGICAL: Pembrolizumab|RADIATION: Stereotactic Body Radiation Therapy,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,multiple,checkpoint inhibitor,National Cancer Institute (NCI)
719,United States,Pancreatic Adenocarcinoma|Pancreatic Cancer|Pancreatic Adenosquamous Carcinoma,BIOLOGICAL: Autologous DC Therapy,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,other,Diakonos Oncology Corporation
720,Taiwan,Locally Advanced Esophageal Squamous Cell Carcinoma,DRUG: Tiragolumab,12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,National Taiwan University Hospital
721,"Canada, United States",Muscle Invasive Bladder Urothelial Carcinoma|Muscle Invasive Renal Pelvis Urothelial Carcinoma|Muscle Invasive Ureter Urothelial Carcinoma|Muscle Invasive Urethral Urothelial Carcinoma|Stage II Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage IV Bladder Urothelial Carcinoma AJCC v7,PROCEDURE: Biospecimen Collection|OTHER: cfDNA or ctDNA Measurement|PROCEDURE: Computed Tomography|PROCEDURE: Cystoscopy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|OTHER: Questionnaire Administration|BIOLOGICAL: Relatlimab,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
722,Denmark,Pancreatic Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: SBRT|BIOLOGICAL: TGFβ-B-15 peptide,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,"Inna Chen, MD"
723,United States,Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Filgrastim|BIOLOGICAL: Genetically Engineered Lymphocyte Therapy|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Plerixafor|BIOLOGICAL: Rituximab,12,OTHER,other,OTHER,Other,Phase I & II,hematologic,biomarker / diagnostics,City of Hope Medical Center
724,China,Esophageal Squamous Cell Carcinoma Stage II|Esophageal Squamous Cell Carcinoma Stage III,PROCEDURE: Neoadjuvant Chemoradiotherapy|DRUG: Tislelizumab|PROCEDURE: Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended),23,OTHER,other,OTHER,Other,Phase II & III,digestive,radiotherapy,Shanghai Zhongshan Hospital
725,United States,Glioblastoma Multiforme,DRUG: MBG453,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
726,United States,Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,BIOLOGICAL: Atezolizumab|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cemiplimab|PROCEDURE: Computed Tomography|DRUG: Diclofenac Potassium|OTHER: Electronic Health Record Review|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Emory University
727,China,Metastatic Non-Small Cell Lung Cancer|NSCLC Stage IV|OligoProgressive Metastatic Disease,RADIATION: Stereotactic Body Radiotherapy|DRUG: second-line systemic therapy,3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,radiotherapy,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
728,China,Locally Advanced Esophageal Squamous Cell Carcinoma|Sintilimab|Radiotherapy|Concurrent Chemoradiotherapy|Immunonutrition,RADIATION: Radiotherapy|DRUG: Programmed Cell Death Protein 1 Inhibitor|DIETARY_SUPPLEMENT: Immunonutrition support,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
729,United States,Metastatic Breast Cancer,BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,breast,other,Minerva Biotechnologies Corporation
730,United States,"B-NHL|B-Non Hodgkin Lymphoma|Acute Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|B-precursor ALL|B-All|Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|B-Cell Leukemia|Acute Lymphoid Leukemia",BIOLOGICAL: CD19/CD22-CAR-transduced T cells|DRUG: cyclophosphamide|DRUG: fludarabine,12,NIH,adoptive cell therapy,NIH,Government,Phase I & II,hematologic,adoptive cell therapy,National Cancer Institute (NCI)
731,Russian Federation,Anaplastic Thyroid Cancer,DRUG: Pembrolizumab + Lenvatinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"Saint Petersburg State University, Russia"
732,United States,"Diffuse Astrocytoma, IDH-Mutant|Glioblastoma, IDH-wildtype|Brain Metastases, Adult|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Esophageal Squamous Cell Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Merkel Cell Carcinoma|Microsatellite Instability-High Solid Malignant Tumor|Mismatch Repair Deficient Solid Malignant Tumor|Microsatellite Instability-High Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer|Non-small Cell Lung Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Urothelial Carcinoma",DRUG: NEO212 Oral Capsule|DRUG: Ipilimumab|DRUG: Pembrolizumab|DRUG: Nivolumab|DRUG: Regorafenib|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: FOLFIRI Protocol|DRUG: Bevacizumab,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,gynecologic,checkpoint inhibitor,"Neonc Technologies, Inc."
733,Armenia,Non-small Cell Lung Cancer,DRUG: Botensilimab + Balstilimab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Immune Oncology Research Institute
734,China,T-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Antigen-specific T cells CAR-T/CTL and DCvac,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,hematologic,adoptive cell therapy,Shenzhen Geno-Immune Medical Institute
735,United States,"Diffuse Midline Glioma, H3 K27M-Mutant|Recurrent High Grade Glioma",DRUG: Treatment with CD200AR-L,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,brain/CNS,other,OX2 Therapeutics
736,China,B-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Antigen-specific T cells CART/CTL and DCvac,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,Shenzhen Geno-Immune Medical Institute
737,United States,Non-muscle Invasive Bladder Cancer,BIOLOGICAL: BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|BIOLOGICAL: BCG( 50mg/Instillation),12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,genitourinary,other,"ImmunityBio, Inc."
738,United States,Breast Cancer|Metastatic HER2-negative Breast,DRUG: Cyclophosphamide|BIOLOGICAL: Mesothelin-targeted T cells|DRUG: AP1903,1,OTHER,other,OTHER,Other,Phase I,breast,other,Memorial Sloan Kettering Cancer Center
739,United States,Clinical Stage IV Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Metastatic Mucosal Melanoma|Metastatic Ocular Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|RADIATION: Stereotactic Radiosurgery|PROCEDURE: Tumor Treating Fields Therapy,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,skin,checkpoint inhibitor,Emory University
740,China,Nasopharyngeal Cancinoma (NPC)|Nasopharyngeal Cancer,DRUG: QL1706|DRUG: Gemcitabine|DRUG: Cisplatin|RADIATION: Intensity-modulated radiotherapy,3,OTHER,other,OTHER,Other,Phase III,head/neck,radiotherapy,Sun Yat-sen University
741,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Locally Recurrent Head and Neck Squamous Cell Carcinoma|Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma|Locally Recurrent Laryngeal Squamous Cell Carcinoma|Locally Recurrent Oral Cavity Squamous Cell Carcinoma|Locally Recurrent Oropharyngeal Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Melanoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Recurrent Melanoma|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Lip and Oral Cavity Cancer AJCC v8|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Unresectable Melanoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,skin,checkpoint inhibitor,National Cancer Institute (NCI)
742,United States,Lung Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|OTHER: Patient Observation|OTHER: Questionnaire Administration,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
743,China,Lung Cancer|Inoperable Disease,"DRUG: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Second Affiliated Hospital of Guangzhou Medical University
744,China,Extensive Small Cell Lung Cancer,DRUG: Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Qianfoshan Hospital
745,United States,Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer,OTHER: 27T51|DRUG: Cemiplimab|DRUG: Bevacizumab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,gynecologic,checkpoint inhibitor,Regeneron Pharmaceuticals
746,United States,Neuroblastoma,DRUG: Universal Donor (UD) TGFβi NK Cells|DRUG: Temozolomide|DRUG: Irinotecan|DRUG: Dinutuximab|DRUG: GM-CSF,2,OTHER,adoptive cell therapy,OTHER,Other,Phase II,other,adoptive cell therapy,New Approaches to Neuroblastoma Therapy Consortium
747,Japan,Metastatic Breast Cancer,DRUG: Induction therapy,2,OTHER,other,OTHER,Other,Phase II,breast,other,Japan Breast Cancer Research Group
748,Japan,Pancreatic Cancer Stage III|Pancreatic Cancer Stage IV,BIOLOGICAL: TBI-1401(HF10)|DRUG: Gemcitabine|DRUG: Nab-paclitaxel|DRUG: TS-1,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,chemotherapy,Takara Bio Inc.
749,United States,Breast Cancer,DRUG: Pembrolizumab|DRUG: Nab-Paclitaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,NYU Langone Health
750,United States,Chronic Lymphocytic Leukemia,DRUG: IPI-145|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Rituximab,12,OTHER,other,OTHER,Other,Phase I & II,hematologic,other,Dana-Farber Cancer Institute
751,China,Rectal Cancer Patients,COMBINATION_PRODUCT: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|COMBINATION_PRODUCT: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Sun Yat-sen University
752,Japan,Recurrent Triple-Negative Breast Cancer,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Bevacizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Yukinori Ozaki
753,Canada,Renal Cell Carcinoma,DRUG: Fecal Microbiota Transplantation,1,OTHER,other,OTHER,Other,Phase I,genitourinary,other,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
754,Australia,"Glioblastoma Multiforme|Astrocytoma, Grade IV",BIOLOGICAL: Allogeneic cytomegalovirus-specific T cells|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,brain/CNS,checkpoint inhibitor,Queensland Institute of Medical Research
755,"France, Spain",Triple-negative Breast Cancer,DRUG: Pembrolizumab 25 mg/ml|DRUG: Paclitaxel injection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,UNICANCER
756,China,Esophageal Cancer,DRUG: PD-1 monoclonal antibody consolidation therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
757,United States,Cancer Of Prostate,DRUG: M9241|RADIATION: Stereotactic Body Radiation Therapy (SBRT),2,NIH,other,NIH,Government,Phase II,genitourinary,radiotherapy,National Cancer Institute (NCI)
758,United States,Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer,DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
759,"Jordan, Lebanon",Locally Advanced Rectal Cancer,DRUG: COMPOUND 2055269|RADIATION: Radiation Therapy|DRUG: mFOLFOX|PROCEDURE: Total Mesorectal Excision,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Ali Shamseddine
760,Israel,Metastatic Lung Cancer,DRUG: Antibiotics|OTHER: FMT (Fecal Microbiota Transplantation),2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Soroka University Medical Center
761,United States,Advanced Renal Cell Carcinoma,DRUG: Botensilimab|DRUG: Balstilimab|DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,"Michael B. Atkins, MD"
762,United States,Colorectal Cancer|Pancreatic Cancer,DRUG: KRAS Vaccine with Poly-ICLC adjuvant|DRUG: Balstilimab|DRUG: Botensilimab,1,OTHER,cancer vaccine,OTHER,Other,Phase I,digestive,cancer vaccine,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
763,Italy,Triple Negative Breast Cancer Metastatic,DRUG: Ceralasertib|DRUG: Durvalumab|DRUG: Nab-paclitaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,IFOM ETS - The AIRC Institute of Molecular Oncology
764,Australia,Extensive-Stage Small-Cell Lung Cancer,RADIATION: Thoracic Radiotherapy|DRUG: Etoposide with Carboplatin or Cisplatin|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Trans Tasman Radiation Oncology Group
765,United States,Small Cell Carcinoma of the Bladder|High Grade Neuroendocrine Tumors of the Urinary Tract,DRUG: Lurbinectedin|DRUG: Avelumab,2,NIH,other,NIH,Government,Phase II,genitourinary,other,National Cancer Institute (NCI)
766,United States,Colorectal Cancer|Pancreatic Cancer,DRUG: KRAS peptide vaccine|DRUG: Nivolumab|DRUG: Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
767,France,Lung Cancer Metastatic|Renal Cell Carcinoma|Head and Neck Cancer|Triple Negative Breast Cancer|Merkel Cell Carcinoma|Hepatocellular Carcinoma|Melanoma|Urothelial Carcinoma|Colorectal Carcinoma With Microsatellite Instability|Esophageal Squamous Cell Carcinoma|Endometrial Carcinoma|Cervical Cancer|Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma|Basal Cell Carcinoma|Squamous Skin Carcinoma,DRUG: Reduced dose intensity of IO,3,OTHER,other,OTHER,Other,Phase III,gynecologic,other,UNICANCER
768,"Canada, Japan, Puerto Rico, Republic of, United States",Endometrial Clear Cell Adenocarcinoma|Endometrial Dedifferentiated Carcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Mixed Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Endometrial Adenocarcinoma|Recurrent Endometrial Carcinoma|Recurrent Endometrial Clear Cell Adenocarcinoma|Recurrent Endometrial Dedifferentiated Carcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Mixed Cell Adenocarcinoma|Recurrent Endometrial Serous Adenocarcinoma|Recurrent Endometrial Undifferentiated Carcinoma|Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,DRUG: Carboplatin|PROCEDURE: Computed Tomography|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|OTHER: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,gynecologic,checkpoint inhibitor,National Cancer Institute (NCI)
769,China,Small Cell Lung Cancer,DRUG: Serplulimab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Peking Union Medical College Hospital
770,China,Nasopharyngeal Carcinoma|Nasopharyngeal Cancer,DRUG: Adebrelimab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Sun Yat-sen University
771,"Republic of, Taiwan, United States","Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Oleclumab|DRUG: Osimertinib|DRUG: AZD4635,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,lung/thoracic,other,MedImmune LLC
772,"Taiwan, United States","Hepatocellular Carcinoma|Liver Cancer, Adult|Liver Neoplasm|Metastatic Liver Cancer","BIOLOGICAL: ECT204 T cells|DRUG: Regorafenib (STIVARGA®, BAY73-4506)",2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,other,Eureka Therapeutics Inc.
773,United States,"Renal Cell Carcinoma (RCC)|Clear Cell Renal Cell Carcinoma (ccRCC)|Kidney Cancer|Renal Cancer|Renal Cell Carcinoma|Renal Cell Cancer Metastatic|Renal Cell Carcinoma Recurrent|Renal Cell Cancer, Recurrent|Kidney",DRUG: Belzutifan|DRUG: Cabozantinib,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,genitourinary,other,"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
774,United States,Non Small Cell Lung Cancer,BIOLOGICAL: Aglatimagene besadenovec,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,other,"Candel Therapeutics, Inc."
775,"Australia, Austria, Belgium, Canada, France, Italy, Spain, United Kingdom, United States",Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Solid Organ Transplant Complications|Lymphoproliferative Disorders|Allogeneic Hematopoietic Cell Transplant|Stem Cell Transplant Complications,BIOLOGICAL: tabelecleucel,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,other,other,Pierre Fabre Medicament
776,France,Pancreatic Adenocarcinoma|Ampulla of Vater Carcinoma|Adrenocortical Carcinoma|Neuroendocrine Carcinoma|Soft Tissue Sarcoma|Small Bowel Adenocarcinoma|Duodenum Adenocarcinoma|Gastric Adenocarcinoma,DRUG: Dostarlimab|DRUG: Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,UNICANCER
777,United States,Lung Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Ceralasertib|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|PROCEDURE: Echocardiography Test,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
778,Hong Kong,HCC,PROCEDURE: TACE|RADIATION: SBRT|DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,The University of Hong Kong
779,United States,"Non Small Cell Lung Cancer|NSCLC, Stage III|Nsclc",DRUG: Durvalumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Cisplatin|DEVICE: AVENIO ctDNA Surveillance Kit|DRUG: Tremelimumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Maximilian Diehn
780,United States,Pancreatic Cancer|Adenocarcinoma of the Pancreas|Adenocarcinoma,DRUG: Motixafortide|DRUG: Cemiplimab|DRUG: Gemcitabine|DRUG: Nab paclitaxel,2,OTHER,other,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Gulam Manji
781,China,Non-small Cell Lung Cancer Stage III,DRUG: Sintilimab|DRUG: Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,"Shanghai Pulmonary Hospital, Shanghai, China"
782,United States,"Relapsed/Refractory AML|AML, Adult|MDS|Refractory Myelodysplastic Syndromes",BIOLOGICAL: NKX101 - CAR NK cell therapy,1,INDUSTRY,adoptive cell therapy,INDUSTRY,Industry,Phase I,other,adoptive cell therapy,"Nkarta, Inc."
783,United States,Melanoma,BIOLOGICAL: Escalating Doses,1,OTHER,other,OTHER,Other,Phase I,skin,other,Loyola University
784,"Australia, Republic of, United States",Renal Cell Carcinoma,BIOLOGICAL: Pexastimogene Devacirepvec (Pexa-Vec)|BIOLOGICAL: Cemiplimab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,genitourinary,checkpoint inhibitor,"SillaJen, Inc."
785,United States,"Anemia, Iron Deficiency|Melanoma",DRUG: Iron dextran 1000 mg IV,2,OTHER,other,OTHER,Other,Phase II,skin,other,Indiana University
786,China,Rectal Cancer|Advanced Stage Colorectal Cancer|Radiotherapy,DRUG: Adebrelimab Injection combined with radiotherapy and chemotherapy,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,digestive,radiotherapy,Feng Tian
787,Netherlands,Urothelial Carcinoma,DRUG: Avelumab,2,OTHER,other,OTHER,Other,Phase II,other,other,Erasmus Medical Center
788,China,Hepatic Carcinoma,DRUG: Sintilimab|PROCEDURE: Microwave Ablation|PROCEDURE: TACE,1,OTHER,other,OTHER,Other,Phase I,other,other,Shanghai Zhongshan Hospital
789,United States,Spine Metastases,RADIATION: Prophylactic Radiotherapy|DRUG: Standard of care systemic therapy,12,OTHER,other,OTHER,Other,Phase I & II,other,radiotherapy,Baptist Health South Florida
790,United States,Melanoma|Melanoma Stage III,DIAGNOSTIC_TEST: PET Scan|DRUG: Nivolumab|DRUG: Ipilimumab|PROCEDURE: Surgical Resection of Melanoma,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
791,United States,Breast Carcinoma|Colorectal Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Immunotherapy|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|RADIATION: Stereotactic Body Radiation Therapy,1,OTHER,other,OTHER,Other,Phase I,digestive,radiotherapy,City of Hope Medical Center
792,China,Locally Advanced Head and Neck Squamous Cell Carcinoma,DRUG: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,head/neck,checkpoint inhibitor,Ruijin Hospital
793,Germany,Non-small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Tiragolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
794,France,Metastatic Non Small Cell Lung Cancer|Metastatic Bladder Cancer|Metastatic Renal Cell Carcinoma|Metastatic Head and Neck Cancer,DRUG: Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|DRUG: Tiragolumab|RADIATION: Stereotactic body radiation therapy (SBRT),1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,genitourinary,checkpoint inhibitor,Centre Georges Francois Leclerc
795,China,Non-small Cell Lung Cancer Metastatic|First-line Treatment,BIOLOGICAL: CIK cells injection|DRUG: Sintilimab Injection|DRUG: Pemetrexed|DRUG: Albumin paclitaxel|DRUG: Carboplatin,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Tianjin Medical University Cancer Institute and Hospital
796,China,Adenocarcinoma|Stomach Neoplasm|Gastroesophageal-junction Cancer|Oligometastatic Disease|Metastatic Cancer|Metastatic Gastric Cancer|Adenocarcinoma of the Stomach|Gastroesophageal Junction Adenocarcinoma|Metastatic Adenocarcinoma,RADIATION: Radiotherapy targeted to the primary lesion|RADIATION: Radiotherapy targeted to the metastatic lesions|BIOLOGICAL: Anti-PD-1 monoclonal antibody|BIOLOGICAL: Trastuzumab|DRUG: Chemotherapy|PROCEDURE: R0 total/subtotal gastrectomy with D2 lymphadenectomy|PROCEDURE: Metastasectomy|PROCEDURE: Local ablative therapies,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Fudan University
797,United States,Advanced Non-Small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinoma,DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Young TIL,2,NIH,other,NIH,Government,Phase II,lung/thoracic,other,National Cancer Institute (NCI)
798,United States,Non Small Cell Lung Cancer,DRUG: N-803 + Pembrolizumab|DRUG: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|DRUG: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|DRUG: Pembrolizumab|DRUG: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|DRUG: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|DRUG: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,lung/thoracic,checkpoint inhibitor,"ImmunityBio, Inc."
799,United States,Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma,DRUG: Trabectedin|DRUG: Ipilimumab|DRUG: Nivolumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,sarcoma,checkpoint inhibitor,"Sarcoma Oncology Research Center, LLC"
800,United States,Metastatic Breast Cancer|Metastatic Gastrointestinal Carcinoma|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|EGFR Overexpression,BIOLOGICAL: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720,1,OTHER,combination product,OTHER,Other,Phase I,digestive,combination product,Pravin T.P Kaumaya
801,China,Nasopharyngeal Cancer,DRUG: Toripalimab|OTHER: Induction chemotherapy and concurrent chemoradiation,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Fudan University
802,United States,Breast Cancer,DRUG: Pembrolizumab|PROCEDURE: Core Biopsy/Cryoablation|PROCEDURE: Breast Surgery|DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,University of Texas Southwestern Medical Center
803,United States,Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma,BIOLOGICAL: Anti-OX40 Antibody PF-04518600|DRUG: Avelumab|DRUG: Binimetinib|BIOLOGICAL: Utomilumab|DRUG: Liposomal Doxorubicin|DRUG: Sacituzumab Govitecan,2,OTHER,other,OTHER,Other,Phase II,breast,other,"Laura Huppert, MD, BA"
804,China,Triple Negative Breast Cancer,DRUG: Sintilimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide,2,OTHER,other,OTHER,Other,Phase II,breast,chemotherapy,Guangdong Provincial People's Hospital
805,United States,Squamous Cell Carcinoma of the Head and Neck,DRUG: Intratumoral Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,head/neck,checkpoint inhibitor,Providence Health & Services
806,Italy,Breast Cancer|Triple Negative Breast Cancer|Dietary Exposure|Fasting,"DIETARY_SUPPLEMENT: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",2,OTHER,other,OTHER,Other,Phase II,breast,other,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
807,United States,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,DRUG: Chemotherapy|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Ramucirumab,3,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase III,lung/thoracic,checkpoint inhibitor,SWOG Cancer Research Network
808,Italy,Glioblastoma Multiforme,DRUG: Temferon,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,brain/CNS,other,Genenta Science
809,"France, Spain",Melanoma,DRUG: BO-112 plus pembrolizumab|PROCEDURE: Tissue Biopsies,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,skin,checkpoint inhibitor,Highlight Therapeutics
810,United States,Cancer of the Head and Neck,DRUG: INCAGN01876|DRUG: INCMGA00012|BIOLOGICAL: DPV-001,1,OTHER,other,OTHER,Other,Phase I,head/neck,other,Providence Health & Services
811,United States,Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Metastatic Colorectal Cancer (CRC)|Colorectal Cancer Stage IV,PROCEDURE: Pre-Treatment Biopsy|PROCEDURE: On-Treatment Biopsy|DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Bevacizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"University of Colorado, Denver"
812,United States,Glioblastoma (GBM),BIOLOGICAL: DOC1021|PROCEDURE: Tumor resection|DRUG: Temodar (Temozolomide)|RADIATION: SOC cranial radiation,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,brain/CNS,radiotherapy,Diakonos Oncology Corporation
813,"Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hong Kong, India, Italy, Japan, Malaysia, Netherlands, Philippines, Poland, Republic of, Saudi Arabia, Slovakia, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam",Biliary Tract Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab|DRUG: Trastuzumab deruxtecan|DRUG: Rilvegostomig|DIAGNOSTIC_TEST: Agilent HercepTest™ mAb pharmDx|DIAGNOSTIC_TEST: Ventana PD-L1 SP263 assay,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,other,checkpoint inhibitor,AstraZeneca
814,,Melanoma,BIOLOGICAL: pembrolizumab|DRUG: placebo,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,skin,checkpoint inhibitor,Merck Sharp & Dohme LLC
815,"Australia, United States","Lymphoma, Non-Hodgkin|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|Waldenstrom Macroglobulinemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Aggressive Lymphoma|Large-cell Lymphoma",BIOLOGICAL: NKX019,1,INDUSTRY,adoptive cell therapy,INDUSTRY,Industry,Phase I,hematologic,other,"Nkarta, Inc."
816,China,Metastatic Triple-negative Breast Cancer,DRUG: trop2-ADC|DRUG: ADC +anti-angiogenic drug|DRUG: ADC + PD1 monoclonal antibody +anti-angiogenic drug,2,OTHER,other,OTHER,Other,Phase II,breast,other,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
817,United States,Metastatic Melanoma,DRUG: High Dose Interleukin-2 (IL-2)|PROCEDURE: ACT with TIL Infusion|DRUG: Vemurafenib|DRUG: Lymphodepletion,2,OTHER,cytokine / immunomodulator,OTHER,Other,Phase II,skin,cytokine / immunomodulator,H. Lee Moffitt Cancer Center and Research Institute
818,"Guam, United States",Lung Non-Small Cell Carcinoma|Lung Non-Small Cell Squamous Carcinoma|Lung Non-Squamous Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|OTHER: Observation Activity|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed Disodium|OTHER: Questionnaire Administration,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
819,"Ireland, Puerto Rico, United Kingdom, United States","Metastatic Head and Neck Cancer|Recurrent Head and Neck Cancer|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Neoplasms, Head and Neck",COMBINATION_PRODUCT: Pembrolizumab (KEYTRUDA®) and PDS0101,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,head/neck,checkpoint inhibitor,PDS Biotechnology Corp.
820,United States,Glioblastoma Multiforme of Brain,BIOLOGICAL: TVI-Brain-1|PROCEDURE: Standard of Care|RADIATION: Radiotherapy|DRUG: Temozolomide,23,INDUSTRY,other,INDUSTRY,Industry,Phase II & III,brain/CNS,radiotherapy,TVAX Biomedical
821,China,Thymic Carcinoma,OTHER: Envolizumab combined with radiotherapy,2,OTHER,other,OTHER,Other,Phase II,other,radiotherapy,"Shanghai Pulmonary Hospital, Shanghai, China"
822,United States,Breast Cancer,DRUG: HCQ|DRUG: Avelumab|DRUG: Palbociclib,2,OTHER,other,OTHER,Other,Phase II,breast,other,Abramson Cancer Center at Penn Medicine
823,China,Non Small Cell Lung Cancer|Perioperative Complication,DRUG: Modified Si Jun Zi Tang,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,First Affiliated Hospital of Zhejiang University
824,United States,Newly Diagnosed MGMT Unmethylated Glioblastoma,DRUG: D2C7-IT|DRUG: 2141-V11,12,OTHER,other,OTHER,Other,Phase I & II,brain/CNS,other,Darell Bigner
825,United States,CD19+ Acute Leukemia,BIOLOGICAL: Patient Derived CD19 specific CAR T cells also expressing an EGFRt,12,OTHER,other,OTHER,Other,Phase I & II,hematologic,other,Seattle Children's Hospital
826,China,Breast Cancer Metastatic,DRUG: standard of care|RADIATION: radiotherapy + standard of care,3,OTHER,other,OTHER,Other,Phase III,breast,radiotherapy,Chinese Academy of Medical Sciences
827,China,Toripalimab|Surufatinib|Chemoradiotherapy|Limited-stage Small Cell Lung Cancer (LS-SCLC),DRUG: Chemotherapy|DRUG: Immunotherapy|DRUG: Angio-immuno kinase inhibitor|RADIATION: radiotherapy|RADIATION: Prophylactic Cranial Irradiation|DRUG: Consolidation Therapy with Toripalimab and Surufatinib,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Sun Yat-sen University
828,China,High-Risk Localized Soft Tissue Sarcoma,DRUG: Pegylated Liposomal Doxorubicin|DRUG: Doxorubicin|DRUG: Anti-PD-1 monoclonal antibody|RADIATION: Radiotherapy,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,sarcoma,checkpoint inhibitor,Fudan University
829,Italy,Merkel Cell Carcinoma,DRUG: Retifanlimab|DRUG: Cisplatin|DRUG: Etoposide,2,OTHER,other,OTHER,Other,Phase II,other,chemotherapy,Gruppo Oncologico del Nord-Ovest
830,"Puerto Rico, United States",Head and Neck Carcinoma|Adenoid Cystic Carcinoma|Lung Cancer|Non-Small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer|Mesothelioma|Thymic Carcinoma|Cervical Cancer|Ovarian Cancer|Bladder Cancer|Esophageal Cancer|Uterine Cancer|Sarcoma|Any Solid Tumors Progressed After a Prior Immunotherapy|Thymoma|Appendiceal Cancer|Olfactory Neuroblastoma,DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete),1,INDUSTRY,other,INDUSTRY,Industry,Phase I,gynecologic,other,"VM Oncology, LLC"
831,"Australia, Belgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, South Africa, Spain, Turkey, United Kingdom, United States",Metastatic Melanoma|Unresectable Melanoma,DRUG: IO102-IO103|DRUG: Pembrolizumab,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,skin,checkpoint inhibitor,IO Biotech
832,United States,Ovarian Cancer,DRUG: Pembrolizumab|DRUG: ALX148|DRUG: Doxorubicin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,"Alexander B Olawaiye, MD"
833,"Australia, China, Germany, Japan, Portugal, Republic of, Spain, Switzerland, Taiwan, United States",Prostate Cancer,DRUG: AMG 509|DRUG: Abiraterone|DRUG: Enzalutamide,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,other,Amgen
834,United States,Multiple Myeloma,DRUG: Elrantamab|DEVICE: clonoSEQ,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Washington University School of Medicine
835,"Australia, United States",Prostate Cancer,DRUG: STM-416p,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,other,SURGE Therapeutics
836,United States,Renal Cancer|Kidney Cancer|Renal Cell Carcinoma|Inferior Vena Cava Thrombosis,DRUG: Axitinib|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,"University of Colorado, Denver"
837,Canada,Melanoma (Skin),DIETARY_SUPPLEMENT: C-PAN|BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,skin,checkpoint inhibitor,"University Health Network, Toronto"
838,"France, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States",Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Diffuse Large B Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)|Marginal Zone Lymphoma (MZL)|Waldenstrom Macroglobulinemia (WM)|Primary Central Nervous System Lymphoma (PCNSL)|Secondary Central Nervous System Lymphoma (SCNSL),DRUG: NX-5948,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,"Nurix Therapeutics, Inc."
839,"Australia, Canada, China, France, Germany, Italy, Netherlands, Republic of, Spain, Taiwan, United Kingdom, United States",Metastatic Colorectal Cancer,"DRUG: Volrustomig|DRUG: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|DRUG: Bevacizumab",2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,other,AstraZeneca
840,France,Mesotheliomas Pleural|Malignant Pleural Mesothelioma,DEVICE: intrapleural photodynamic therapy with videothoracoscopy|DRUG: Nivolumab Injection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,"University Hospital, Lille"
841,Poland,Small Cell Lung Carcinoma,RADIATION: Palliative Radiotherapy|RADIATION: Radical/Ablative Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Copernicus Memorial Hospital
842,United States,Metastatic Melanoma|Skin Cancer,DRUG: Ipilimumab|DRUG: Nivolumab|PROCEDURE: Cryoablation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Massachusetts General Hospital
843,"Italy, Netherlands, Spain, Switzerland, United Kingdom",Non-Small Cell Lung Cancer|Melanoma,RADIATION: Stereotactic radiosurgery|DRUG: Immune checkpoint inhibitor,3,NETWORK,other,NETWORK,Network,Phase III,lung/thoracic,radiotherapy,ETOP IBCSG Partners Foundation
844,United States,Vulvar Cancer|Vulvar Squamous Cell Carcinoma,DRUG: Cisplatin|DRUG: Pembrolizumab|RADIATION: Radiation Therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,gynecologic,checkpoint inhibitor,Massachusetts General Hospital
845,United States,Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma,DRUG: Pembrolizumab|RADIATION: Stereotactic Body Radiation Therapy (5 days)|PROCEDURE: Surgical Resection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Providence Health & Services
846,United States,Pancreatic Cancer|Adenocarcinoma of the Pancreas|Squamous Cell Carcinoma of Pancreas|Adenosquamous Carcinoma of the Pancreas,DRUG: ZIMBERELIMAB|DRUG: DOMVANALIMAB|DRUG: APX005M|DRUG: FOLFIRI,12,OTHER,other,OTHER,Other,Phase I & II,digestive,other,"James Cleary, MD, PhD"
847,China,Non-Small Cell Lung Cancer,DRUG: SHR-1701 Combined With Fluazopalil,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Hunan Province Tumor Hospital
848,United States,NMIBC|High Risk NMIBC|Non Muscle Invasive Bladder Cancer,DRUG: ZH9,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,other,Prokarium Ltd
849,United States,"Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Cell Cancer, Squamous|Carcinoma, Squamous Cell",DRUG: MEDI0562,1,OTHER,other,OTHER,Other,Phase I,skin,other,Providence Health & Services
850,United States,Squamous Cell Carcinoma of the Head and Neck,DRUG: Nivolumab|DRUG: Lirilumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Dana-Farber Cancer Institute
851,United States,"Cancer of Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck|Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head and Neck",BIOLOGICAL: MK-3475 (neoadjuvant)|PROCEDURE: Surgery|RADIATION: Intensity modulated radiation therapy|RADIATION: Image-guided radiation therapy|DRUG: Cisplatin|BIOLOGICAL: MK-3475 (adjuvant)|PROCEDURE: Peripheral blood,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Washington University School of Medicine
852,"Belgium, Italy, Spain",Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Advanced Non Squamous NSCLC,DRUG: roginolisib|DRUG: Dostarlimab|DRUG: Docetaxel,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,lung/thoracic,other,iOnctura
853,Lebanon,Cancer|Solid Tumor|Thromboembolism|Cardiovascular Diseases|Immune System Diseases|Inflammatory Diseases|Colon Cancer|Breast Cancer|Prostate Cancer|Hepatocellular Carcinoma|Lung Cancer|Chemotherapy|Immunotherapy,DRUG: Palbociclib|DRUG: Rivaroxaban|GENETIC: SNP,1,OTHER,other,OTHER,Other,Phase I,genitourinary,other,Lebanese University
854,United States,Small-cell Lung Cancer|Extensive-stage Small-cell Lung Cancer|Lung Cancer,RADIATION: Ablative Radiation|DRUG: Durvalumab|DRUG: Etoposide|DRUG: Carboplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,University of Chicago
855,United States,Lung Cancer|Small-cell Lung Cancer|Non Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Nab paclitaxel|DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Etoposide|DRUG: Irinotecan|DRUG: Topotecan|DRUG: Lurbinectedin,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Fox Chase Cancer Center
856,United States,Pancreatic Cancer,DRUG: Tislelizumab|DRUG: SX-682,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
857,Italy,"NSCLC, Stage III",DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Fondazione IRCCS Policlinico San Matteo di Pavia
858,"Australia, Austria, Belgium, Czechia, Denmark, France, Greece, Hungary, Ireland, Israel, Italy, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom",Neuroblastoma,DRUG: Vincristine|DRUG: Aldesleukin|DRUG: ch14.18/CHO|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Cisplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: G-CSF|DRUG: Busulfan|DRUG: Melphalan,3,OTHER,other,OTHER,Other,Phase III,other,chemotherapy,St. Anna Kinderkrebsforschung
859,Italy,Colorectal Cancer Metastatic|Microsatellite Stable Colorectal Carcinoma|Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer,BIOLOGICAL: Autologous Dendritic Cell (DC) Vaccine,2,OTHER,cancer vaccine,OTHER,Other,Phase II,digestive,cancer vaccine,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
860,United States,Stage IIB Non-Small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Non-Small Cell Lung Cancer,DEVICE: ViewRay MR-Linear Accelerator|RADIATION: Radiation therapy|DRUG: Paclitaxel|DRUG: Carboplatin AUC|BIOLOGICAL: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Washington University School of Medicine
861,Australia,Melanoma|Brain Metastases,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Melanoma Institute Australia
862,United States,Metastatic Lung Non-Small Cell Squamous Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pevonedistat,2,NIH,other,NIH,Government,Phase II,lung/thoracic,chemotherapy,National Cancer Institute (NCI)
863,China,Non-small Cell Lung Cancer,"DRUG: TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|DRUG: TQB2450 placebo, docetaxel injection, AL2846 matching placebo",3,INDUSTRY,other,INDUSTRY,Industry,Phase III,lung/thoracic,other,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
864,China,Hepatocellular Carcinoma|Immunotherapy|CAR|GPC3 Gene Inactivation|T Cell|Squamous Cell Lung Cancer,BIOLOGICAL: GPC3 and/or TGFβ targeting CAR-T cells,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,digestive,adoptive cell therapy,Second Affiliated Hospital of Guangzhou Medical University
865,Austria,Oropharyngeal Squamous Cell Carcinoma (SCC),BIOLOGICAL: FluBHPVE6E7,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,head/neck,other,BlueSky Immunotherapies GmbH
866,China,Non-Small Cell Lung Cancer,DRUG: Benmelstobart,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,"Shanghai Pulmonary Hospital, Shanghai, China"
867,China,Non Small Cell Lung Cancer Metastatic,DRUG: Pembrolizumab in Combination with Plinabulin and Docetaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Peking Union Medical College Hospital
868,China,Stage III Hepatocellular Cancer (CNLC Staging),DRUG: mFOLFOX7+Camrelizumab+Apatinib,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
869,United States,Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage II Gastric Cancer AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,BIOLOGICAL: Atezolizumab|PROCEDURE: Biospecimen Collection|DRUG: Capecitabine|PROCEDURE: Computed Tomography|DRUG: Docetaxel|PROCEDURE: Echocardiography Test|DRUG: Fluorouracil|DRUG: Leucovorin Calcium|PROCEDURE: Lymphadenectomy|PROCEDURE: Magnetic Resonance Imaging|DRUG: Oxaliplatin|PROCEDURE: Positron Emission Tomography|PROCEDURE: Surgical Procedure,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,digestive,checkpoint inhibitor,National Cancer Institute (NCI)
870,Israel,Non-small Cell Lung Cancer|Melanoma|Renal Cell Carcinoma,DRUG: BMC128|DRUG: Nivolumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,genitourinary,checkpoint inhibitor,Biomica Ltd.
871,Denmark,Metastatic Melanoma,BIOLOGICAL: TILT-123|BIOLOGICAL: TIL|DRUG: Cyclophosphamide|DRUG: Fludarabine,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,skin,other,TILT Biotherapeutics Ltd.
872,Poland,High-Risk Neuroblastoma,COMBINATION_PRODUCT: Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy),1,OTHER,combination product,OTHER,Other,Phase I,other,combination product,Jagiellonian University
873,Australia,Metastatic Merkel Cell Carcinoma,DRUG: Avelumab|RADIATION: External Beam Radiation Therapy (EBRT)|RADIATION: Lutetium-177 (177Lu)-DOTATATE,12,OTHER,other,OTHER,Other,Phase I & II,multiple,radiotherapy,Melanoma and Skin Cancer Trials Limited
874,"Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, India, Italy, Japan, Norway, Poland, Republic of, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States",Biliary Tract Cancer,DRUG: Rilvegostomig|DRUG: Placebo|DRUG: Capecitabine|DRUG: Gemcitabine/Cisplatin|DRUG: S-1 [Tegafur/Oteracil/gimeracil],3,INDUSTRY,other,INDUSTRY,Industry,Phase III,other,chemotherapy,AstraZeneca
875,China,Hypopharyngeal Carcinoma|Immunotherapy|Chemotherapy,DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Capecitabine|DRUG: Camrelizumab,2,OTHER,other,OTHER,Other,Phase II,other,chemotherapy,Eye & ENT Hospital of Fudan University
876,United States,Neuroblastoma,GENETIC: iC9-GD2 T Cells - frozen|GENETIC: iC9-GD2 T Cells - fresh|DRUG: Cytoxan|DRUG: Fludara|DRUG: Keytruda|GENETIC: iC9-GD2 T cells,1,OTHER,other,OTHER,Other,Phase I,other,other,Baylor College of Medicine
877,United States,"B-Cell Chronic Lymphocytic Leukemia|Leukemia, Lymphocytic, Chronic, B-Cell|B-Lymphocytic Leukemia, Chronic",BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Rituximab,12,NIH,other,NIH,Government,Phase I & II,hematologic,other,National Cancer Institute (NCI)
878,China,Osteosarcoma,COMBINATION_PRODUCT: metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy,2,OTHER,combination product,OTHER,Other,Phase II,sarcoma,combination product,Ruijin Hospital
879,United States,Solid Tumor|Non-Small Cell Lung Cancer|Head and Neck Cancer|Melanoma|Gastric Cancer|Renal Cell Carcinoma|Urothelial Carcinoma,DRUG: INBRX-106 - Hexavalent OX40 agonist antibody|DRUG: pembrolizumab 200 mg|DRUG: pembrolizumab 400 mg|DRUG: Carboplatin AUC-5|DRUG: Carboplatin AUC-6|DRUG: Pemetrexed 500 mg/m2|DRUG: Cisplatin 75mg/m2|DRUG: Paclitaxel 200mg/m2|DRUG: Nab paclitaxel 100mg/m2,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,genitourinary,checkpoint inhibitor,"Inhibrx Biosciences, Inc"
880,United States,Lung Atypical Carcinoid Tumor|Lung Neuroendocrine Neoplasm|Lung Non-Small Cell Squamous Carcinoma|Minimally Invasive Lung Adenocarcinoma|Neuroendocrine Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Lung Large Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8,BIOLOGICAL: Nivolumab|RADIATION: Stereotactic Body Radiation Therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,M.D. Anderson Cancer Center
881,United States,Extensive Stage Small Cell Lung Cancer,DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Durvalumab|DRUG: Ceralasertib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Muhammad Furqan
882,China,Unresectable Non-small Cell Lung Cancer,DRUG: neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy|PROCEDURE: surgery|DRUG: Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)|OTHER: Standard Treatment,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,lung/thoracic,chemotherapy,Hua Zhang
883,United States,Melanoma,BIOLOGICAL: young TIL|DRUG: Pembrolizumab|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,skin,checkpoint inhibitor,National Cancer Institute (NCI)
884,Denmark,Malignant Melanoma,DRUG: Pembrolizumab Injection [Keytruda]|DRUG: Ipilimumab Injection [Yervoy]|DRUG: Nivolumab Injection [Opdivo]|DRUG: Encorafenib|DRUG: Binimetinib|DRUG: Dabrafenib|DRUG: Trametinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Inge Marie Svane
885,China,Renal Cell Carcinoma (Kidney Cancer)|Kidney Cancer Metastatic|Renal Cell Carcinoma Metastatic,"RADIATION: Stereotactic body radiotherapy (SBRT)|DRUG: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib",3,OTHER,other,OTHER,Other,Phase III,genitourinary,radiotherapy,Sun Yat-sen University
886,China,"HR-positive,HER2-negative Breast Cancer",DRUG: TORIPALIMAB INJECTION(JS001 )|RADIATION: Stereotactic Body Radiation Therapy (SBRT),2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,First Affiliated Hospital of Zhejiang University
887,United States,Cutaneous Squamous Cell Carcinoma|Skin Cancer|Squamous Cell Carcinoma|Locally Advanced Squamous Cell Carcinoma|Locally Advanced Squamous Cell Carcinoma of the Skin|Locally Advanced Cutaneous Squamous Cell Carcinoma|Locally Advanced Skin Squamous Cell Carcinoma,DRUG: Cemiplimab|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,skin,checkpoint inhibitor,Memorial Sloan Kettering Cancer Center
888,"Belarus, India, Russian Federation",Melanoma|Melanoma (Skin)|Melanoma Stage III|Melanoma Stage IV|Melanoma Unresectable|Melanoma Metastatic|Melanoma Advanced,BIOLOGICAL: BCD-217|BIOLOGICAL: BCD-100|BIOLOGICAL: Placebo,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,skin,other,Biocad
889,"Australia, United States",Prostate Cancer|High-risk Biochemical Recurrence|High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer|Non-metastatic Castration-sensitive Prostate Cancer,DRUG: Xaluritamig,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,other,Amgen
890,Israel,Stage IV Pancreatic Cancer,DRUG: Nivolumab|DRUG: ipilimumab|RADIATION: Stereotactic body radiation therapy|RADIATION: Low dose irradiation,1,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase I,digestive,checkpoint inhibitor,Sheba Medical Center
891,China,Locally Advanced Gastric Carcinoma,"DRUG: Oxaliplatin by arterial infusion plus S-1|DRUG: SOX neoadjuvant|DRUG: Sintilimab neoadjuvant|PROCEDURE: gastrectomy plus D2 lymph node dissection|DRUG: SOX adjuvant, Sequential S-1|DRUG: Sintilimab adjuvant",3,OTHER,other,OTHER,Other,Phase III,digestive,other,Zhejiang University
892,China,Melanoma,"DRUG: tunlametinib|DRUG: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin",3,INDUSTRY,other,INDUSTRY,Industry,Phase III,skin,chemotherapy,"Shanghai Kechow Pharma, Inc."
893,"Canada, Ireland, United States",Metastatic Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Unresectable Renal Cell Carcinoma,BIOLOGICAL: Avelumab|DRUG: Axitinib|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|DRUG: Lenvatinib|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|RADIATION: Stereotactic Ablative Radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,NRG Oncology
894,Singapore,Hepatocellular Carcinoma|Hepatocellular Cancer|Colorectal Cancer|Colorectal Carcinoma|Liver Metastases,BIOLOGICAL: Neoantigen Dendritic Cell Vaccine|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"National Cancer Centre, Singapore"
895,United States,Nonsmall Cell Lung Cancer|Performance Status,"DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nab paclitaxel|OTHER: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|OTHER: QLQ-C30 Global Health/Quality of Life Questionnaire|OTHER: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|DRUG: Pemetrexed",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Wake Forest University Health Sciences
896,United States,Urinary Bladder Cancer,DRUG: gemcitabine + docetaxel,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,University of Arizona
897,China,Locally Advanced Rectal Cancer,RADIATION: node-sparing short-course radiotherapy|DRUG: Sintilimab|DRUG: Capecitabine|DRUG: Oxaliplatin|PROCEDURE: TME surgery|PROCEDURE: watch and wait,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Jinhua Central Hospital
898,China,TNBC - Triple-Negative Breast Cancer,DRUG: LM-108|DRUG: Toripalimab|DRUG: Eribulin|DRUG: Nab paclitaxel,2,OTHER,other,OTHER,Other,Phase II,breast,chemotherapy,Fudan University
899,"Germany, Switzerland",Non-small Cell Lung Cancer|NSCLC,DRUG: Durvalumab|RADIATION: Radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Swiss Group for Clinical Cancer Research
900,China,Esophageal Squamous Cell Carcinoma|Oligometastatic Disease|Radiotherapy,COMBINATION_PRODUCT: PD-1 inhibitor+/- chemotherapy combined with local therapy|DRUG: systemic therapy alone,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,Fudan University
901,China,MCRC,"DRUG: Thymalfasin (Thymosin alpha 1, Ta1)|DRUG: Regorafenib (BAY 73-4506)|DRUG: Tislelizumab (BGB-A317)",2,OTHER,other,OTHER,Other,Phase II,other,other,Beijing Friendship Hospital
902,China,Rectal Adenocarcinoma|High-Risk Cancer|MSS,RADIATION: Short-Course Radiotherapy|DRUG: PD-1 monoclonal antibody|DRUG: mFOLFOX6 regimen|DRUG: Cetuximab|DRUG: Bevacizumab|PROCEDURE: Surgical resection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Sixth Affiliated Hospital, Sun Yat-sen University"
903,United States,"Kita-kyushu Lung Cancer Antigen 1, Human",DRUG: IL-2 (Aldesleukin)|DRUG: Cyclophosphamide|BIOLOGICAL: KK-LC-1 TCR|DRUG: Fludarabine,1,NIH,adoptive cell therapy,NIH,Government,Phase I,lung/thoracic,adoptive cell therapy,National Cancer Institute (NCI)
904,United States,Diffuse Large B Cell Lymphoma (DLBCL),BIOLOGICAL: bbT369,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,Regeneron Pharmaceuticals
905,"Australia, Brazil, Canada, France, Germany, Italy, Netherlands, Republic of, Spain, United States",Merkel Cell Carcinoma,DRUG: KRT-232|DRUG: Avelumab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,other,other,"Kartos Therapeutics, Inc."
906,Netherlands,"Carcinoma, Non-Small-Cell Lung",DRUG: Durvalumab|RADIATION: low-dose PCI,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Association NVALT Studies
907,China,Head and Neck Cancer,DRUG: Toripalimab|RADIATION: Radiation Therapy|DRUG: Cisplatin,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Tianjin Medical University Cancer Institute and Hospital
908,United States,Non-small Cell Lung Cancer Stage III,DRUG: Cemiplimab-Rwlc,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Georgetown University
909,China,"Carcinoma, Non-Small-Cell Lung",RADIATION: SBRT|DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Sun Yat-sen University
910,United States,Non Small Cell Lung Cancer,RADIATION: Stereotactic radiation therapy|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,University of Texas Southwestern Medical Center
911,"France, Italy, Japan, Republic of, Taiwan, United States",Pharmacokinetics of Zolbetuximab|Gastric Cancer|Gastro-esophageal Junction (GEJ) Cancer|Pharmacokinetics of Oxaliplatin|Pharmacokinetics of Fluorouracil Bolus (5-FU),DRUG: zolbetuximab|DRUG: oxaliplatin|DRUG: leucovorin|DRUG: fluorouracil|DRUG: Pembrolizumab|DRUG: folinic acid|DRUG: nivolumab|DRUG: Docetaxel,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,"Astellas Pharma Global Development, Inc."
912,China,Advanced NSCLC,RADIATION: Radiotherapy|DRUG: PD-1 inhibitor|DRUG: Neoantigen-loaded DC vaccine,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,The First Affiliated Hospital of Nanchang University
913,United States,Glioblastoma,DRUG: INCMGA00012|DRUG: INCAGN01876|DRUG: SRS|PROCEDURE: Brain surgery,2,OTHER,other,OTHER,Other,Phase II,brain/CNS,other,University of Pennsylvania
914,United States,Metastatic Pancreatic Ductal Adenocarcinoma,DRUG: Botensilimab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,chemotherapy,Agenus Inc.
915,United States,Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic/Pylomyxoid Astrocytoma|Brain Tumor|Glioma|Brain Cancer|Glioblastoma|Glioblastoma Multiforme,DRUG: rQNestin|DRUG: Cyclophosphamide|PROCEDURE: Stereotactic biopsy,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Dana-Farber Cancer Institute
916,China,Multiple Myeloma,BIOLOGICAL: KQ-2003 CAR-T cells,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,hematologic,adoptive cell therapy,Shanxi Province Cancer Hospital
917,United States,Lung Non-Small Cell Carcinoma|Pleural Disorder,DRUG: Porfimer Sodium|PROCEDURE: Video-Assisted Thoracic Surgery|DRUG: Photodynamic Therapy|DEVICE: Intraoperative PDT,1,OTHER,other,OTHER,Other,Phase I,lung/thoracic,other,Roswell Park Cancer Institute
918,Spain,Urothelial Bladder Carcinoma,DRUG: Sacituzumab govitecan|DRUG: Zimberelimab|DRUG: Domvanalimab,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Fundación para el Progreso de la Oncología en Cantabria
919,China,Head and Neck Cancer,BIOLOGICAL: Tislelizumab|DRUG: Afatinib,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,West China Hospital
920,United States,Small Cell Lung Cancer|SCLC|Extensive Stage Small Cell Lung Cancer,DRUG: Durvalumab|DRUG: Monalizumab|DRUG: Carboplatin or Cisplatin|DRUG: Etoposide,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Hirva Mamdani
921,United States,Glioblastoma Multiforme,BIOLOGICAL: VBI-1901|DRUG: Carmustine|DRUG: Lomustine,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,brain/CNS,other,VBI Vaccines Inc.
922,China,Locally Advanced Rectal Cancer (LARC)|Immunotherapy|Radiotherapy|Total Neoadjuvant Therapy|Anal Function Preservation,DRUG: Anti-PD-1 antibody drug named Serplulimab|RADIATION: Radiotherapy|DRUG: Chemotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,West China Hospital
923,United States,Metastatic Pancreatic Ductal Adenocarcinoma|Metastatic Pancreatic Cancer,RADIATION: Stereotactic Body Radiation Therapy|DRUG: Botensilimab|DRUG: Balstilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Benjamin Spieler
924,United States,Recurrent Glioblastoma IDH Wildtype,DRUG: D2C7-IT|DRUG: 2141 V11,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Darell Bigner
925,China,Non-small Cell Lung Cancer|Cardiovascular Complication,"DRUG: Multiple cardiovascular drugs related to ""Golden Triangle""",3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,other,Sun Yat-sen University
926,Russian Federation,Bone Sarcoma|Embryonal Rhabdomyosarcoma|Alveolar Rhabdomyosarcoma,DRUG: dinutuximab beta,3,OTHER,other,OTHER,Other,Phase III,sarcoma,other,N.N. Petrov National Medical Research Center of Oncology
927,China,Advanced NSCLC,RADIATION: Radiotherapy|DRUG: PD-1 inhibitor|DRUG: Neoantigen-based peptide vaccine,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,The First Affiliated Hospital of Nanchang University
928,United States,"Human Papilloma Virus|Warts|Warts, Genital|Condyloma|Condylomata Acuminata",BIOLOGICAL: nonavalent human papillomavirus vaccine,12,OTHER,cancer vaccine,OTHER,Other,Phase I & II,other,cancer vaccine,"University of California, San Francisco"
929,France,Advanced Biliary Tract Carcinoma,DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,GERCOR - Multidisciplinary Oncology Cooperative Group
930,United States,Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma (RCC)|Stage II Renal Pelvis Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8,BIOLOGICAL: Pembrolizumab|DRUG: Tivozanib|PROCEDURE: Biospecimen Collection|PROCEDURE: MRI|PROCEDURE: Computed Tomography|PROCEDURE: Biopsy|OTHER: Questionnaire Administration,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,genitourinary,checkpoint inhibitor,Alliance for Clinical Trials in Oncology
931,"Canada, Hong Kong, United States",Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7,DRUG: Atezolizumab|PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cetuximab|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Docetaxel|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|OTHER: Survey Administration,23,NIH,checkpoint inhibitor,NIH,Government,Phase II & III,head/neck,checkpoint inhibitor,National Cancer Institute (NCI)
932,Israel,Metastatic or Locally Advanced NSCLC,DRUG: Durvalumab|DRUG: Tremelimumab|RADIATION: Low dose irradiation,2,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase II,multiple,checkpoint inhibitor,Sheba Medical Center
933,China,Non-small Cell Lung Cancer,DRUG: Cadonilimab (AK104),2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Xin-Hua Xu
934,"Australia, Netherlands, United States",Malignant Melanoma Stage III,DRUG: Neoadjuvant ipilimumab + nivolumab|DRUG: Adjuvant nivolumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,skin,checkpoint inhibitor,The Netherlands Cancer Institute
935,Russian Federation,Advanced or Metastatic NSCLC,DRUG: Ceralasertib|DRUG: Durvalumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,multiple,checkpoint inhibitor,AstraZeneca
936,United States,Bladder Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8,PROCEDURE: Biopsy of Bladder|PROCEDURE: Biospecimen Collection|DRUG: Cisplatin|PROCEDURE: Computed Tomography|PROCEDURE: Cystoscopy|BIOLOGICAL: Durvalumab|DRUG: Fluorouracil|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mitomycin|OTHER: Patient Observation|RADIATION: Radiation Therapy,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
937,"France, Germany, Spain",Multiple Myeloma,DRUG: SLAMF7 CAR-T,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,hematologic,adoptive cell therapy,Wuerzburg University Hospital
938,United States,B Acute Lymphoblastic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|OTHER: Laboratory Biomarker Analysis,1,OTHER,other,OTHER,Other,Phase I,hematologic,biomarker / diagnostics,City of Hope Medical Center
939,Canada,"Lung Cancer, Nonsmall Cell",DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,McGill University Health Centre/Research Institute of the McGill University Health Centre
940,Japan,"Lymphoblastic Leukemia, Acute Adult",BIOLOGICAL: TBI-1501,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,Takara Bio Inc.
941,United States,Recurrent Oligodendroglioma|Progressive Oligodendroglioma,BIOLOGICAL: TTRNA-DC vaccines with GM-CSF|BIOLOGICAL: Autologous Hematopoietic Stem cells (HSCs)|BIOLOGICAL: TTRNA-xALT|DRUG: Td vaccine,1,OTHER,cancer vaccine,OTHER,Other,Phase I,brain/CNS,cancer vaccine,University of Florida
942,Italy,Clear Cell RCC,GENETIC: Temferon|BIOLOGICAL: Pembrolizumab|DRUG: Cabozantinib,12,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I & II,other,checkpoint inhibitor,Genenta Science
943,United States,Glioblastoma,DRUG: ITI-1001,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,brain/CNS,other,"Immunomic Therapeutics, Inc."
944,United States,Osteogenic Sarcoma Recurrent,DRUG: Iscador*P,2,OTHER,other,OTHER,Other,Phase II,sarcoma,other,Hackensack Meridian Health
945,China,AML (Acute Myelogenous Leukemia)|NK Cell|CD123+ Acute Myeloid Leukemia,DRUG: Donor-derived CD123-CD16 bispecific antibody-modified NK cells,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,hematologic,adoptive cell therapy,Chunji Gao
946,United States,Glioblastoma Multiforme of Brain|Anaplastic Astrocytoma of Brain|Gliosarcoma of Brain,BIOLOGICAL: C134,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,University of Alabama at Birmingham
947,China,Recurrent Glioblastoma,"GENETIC: Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.",1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Beijing Tiantan Hospital
948,United States,Platinum-resistant Ovarian Cancer|Platinum-refractory Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|High-grade Serous Ovarian Cancer|Endometrioid Ovarian Cancer|Ovarian Clear Cell Carcinoma,"BIOLOGICAL: olvimulogene nanivacirepvec|DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin|DRUG: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|DRUG: Bevacizumab (or biosimilar)",3,INDUSTRY,other,INDUSTRY,Industry,Phase III,gynecologic,chemotherapy,Genelux Corporation
949,United States,Fallopian Tube Endometrioid Tumor|Fallopian Tube High Grade Serous Adenocarcinoma|Malignant Ovarian Endometrioid Tumor|Ovarian High Grade Serous Adenocarcinoma|Platinum-Sensitive Fallopian Tube Carcinoma|Platinum-Sensitive Ovarian Carcinoma|Platinum-Sensitive Primary Peritoneal Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Serous Adenocarcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|BIOLOGICAL: Tremelimumab,2,NIH,other,NIH,Government,Phase II,gynecologic,other,National Cancer Institute (NCI)
950,United States,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Marginal Zone Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Recurrent Central Nervous System Lymphoma|Refractory Central Nervous System Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|DRUG: Fludarabine Phosphate,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,hematologic,adoptive cell therapy,Fred Hutchinson Cancer Center
951,United States,Advanced Pancreatic Ductal Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer,DRUG: AGEN1423|DRUG: Botensilimab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,Bruno Bockorny
952,China,De-escalated Radiotherapy; Head and Neck Cancer,"RADIATION: Continuous, hyperfractionated, accelerated radiotherapy(CHART)",2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
953,United States,CD 19+ Acute Leukemia,BIOLOGICAL: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC),1,OTHER,other,OTHER,Other,Phase I,hematologic,other,Seattle Children's Hospital
954,United States,Hepatocellular Carcinoma|Cirrhosis|Portal Hypertension,DRUG: Durvalumab|DRUG: Tremelimumab|PROCEDURE: Liver Transplant,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Davendra Sohal
955,China,Extensive-stage Small-cell Lung Cancer,RADIATION: Thoracic Radiotherapy,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,lung/thoracic,radiotherapy,Henan Cancer Hospital
956,China,Gastric or Gastroesophageal Junction Adenocarcinoma,COMBINATION_PRODUCT: neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab),2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Jiangsu Cancer Institute & Hospital
957,United States,B-Cell Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia,DRUG: Tecartus,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,H. Lee Moffitt Cancer Center and Research Institute
958,Germany,Glioblastoma,"BIOLOGICAL: Autologous, tumor lysate-loaded, mature dendritic cells (DC)|DRUG: standard therapy",2,OTHER,other,OTHER,Other,Phase II,brain/CNS,other,"Heinrich-Heine University, Duesseldorf"
959,United States,Non-muscle Invasive Bladder Cancer With Carcinoma in Situ,DRUG: Nadofaragene Firadenovec|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Pembrolizumab,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,genitourinary,checkpoint inhibitor,Ferring Pharmaceuticals
960,United States,Follicular Lymphoma,DRUG: Rituximab|BIOLOGICAL: Neo Vax|DRUG: Pembrolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,hematologic,checkpoint inhibitor,Dana-Farber Cancer Institute
961,United States,Non Small Cell Lung Cancer Stage,RADIATION: Hypo-Fractionation|RADIATION: Standard-Fractionation,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,University of Kansas Medical Center
962,"Australia, United Kingdom, United States",Extensive-stage Small-cell Lung Cancer,DRUG: BNT327|DRUG: Atezolizumab|DRUG: Etoposide|DRUG: Carboplatin,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,lung/thoracic,checkpoint inhibitor,BioNTech SE
963,United States,Endometrial Cancer|ARID1A Gene Mutation|Recurrent Endometrial Carcinoma,DRUG: Avelumab|DRUG: M1774,2,OTHER,other,OTHER,Other,Phase II,gynecologic,other,"Panagiotis Konstantinopoulos, MD, PhD"
964,"Belgium, Brazil, France, Germany, Italy, Russian Federation, Spain, Switzerland, United Kingdom, United States",Advanced Melanoma,DRUG: Botensilimab|DRUG: Balstilimab,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,skin,other,Agenus Inc.
965,China,"Lymphoma, B-Cell",BIOLOGICAL: CD19-CD22 CAR-T cells,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,hematologic,adoptive cell therapy,Shanxi Province Cancer Hospital
966,Republic of,Advanced Hepatocellular Carcinoma (HCC),RADIATION: Particle beam radiation therapy,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,digestive,radiotherapy,"National Cancer Center, Korea"
967,China,Esophageal Squamous Cell Carcinoma,DRUG: Tirelizumab|DRUG: Nab paclitaxel|DRUG: Carboplatin|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Ruijin Hospital
968,United States,Esophageal Adenocarcinoma|Gastric Adenocarcinoma,DRUG: Nal-IRI|DRUG: Oxaliplatin|DRUG: 5-FU|DRUG: Trastuzumab|DRUG: Pembrolizumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"University of Wisconsin, Madison"
969,United States,Merkel Cell Carcinoma,DRUG: Pembrolizumab|DRUG: Lutetium Lu 177 dotatate,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Weill Medical College of Cornell University
970,United States,Leukemia,BIOLOGICAL: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,Seattle Children's Hospital
971,United States,T-Cell Lymphoma|Peripheral T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Recurrent|Peripheral T-Cell Lymphoma Recurrent,BIOLOGICAL: LB1901,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,Legend Biotech USA Inc
972,China,Advanced Hepatocellular Carcinoma,PROCEDURE: Palliative Hepatectomy|DRUG: Durvalumab|DRUG: Lenvatinib,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,Zhiyong Huang
973,China,Non-Small Cell Lung Cancer|RET Driver Mutation|BRAF V600 Mutation|Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation|MET Amplification|MET Exon 14 Skipping Mutation,BIOLOGICAL: Toripalimab|DRUG: Nab paclitaxel|DRUG: Pemetrexed|DRUG: Carboplatin,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Guangdong Provincial People's Hospital
974,"Puerto Rico, United States",Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Cyclophosphamide|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|OTHER: Genetic Testing|PROCEDURE: Mammography|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,breast,checkpoint inhibitor,National Cancer Institute (NCI)
975,"Republic of, Singapore, United States",Advanced Solid Tumor|Clear Cell Renal Cell Carcinoma|Hepatocellular Carcinoma|Non-small Cell Lung Cancer,DRUG: CHS-388|DRUG: Pembrolizumab|DRUG: Toripalimab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,genitourinary,checkpoint inhibitor,"Coherus Biosciences, Inc."
976,United States,Locally Advanced Pancreatic Adenocarcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7,BIOLOGICAL: Falimarev|BIOLOGICAL: Inalimarev|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Sargramostim,1,NIH,other,NIH,Government,Phase I,digestive,biomarker / diagnostics,National Cancer Institute (NCI)
977,Sweden,Uveal Melanoma|Liver Metastases,DEVICE: PHP|DRUG: IPI1/NIVO3|DRUG: IPI3/NIVO1,3,OTHER_GOV,other,OTHER_GOV,Government,Phase III,digestive,other,Vastra Gotaland Region
978,"Israel, Poland, Republic of, Spain, Taiwan, United States",Diffuse Large B-cell Lymphoma,DRUG: Mosunetuzumab Intravenous (IV)|DRUG: Mosunetuzumab Subcutaneous (SC)|DRUG: Polatuzumab Vedotin|DRUG: Tocilizumab,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,Hoffmann-La Roche
979,United States,Advanced Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC V8|Stage IV Hepatocellular Carcinoma AJCC V8|Unresectable Hepatocellular Carcinoma,PROCEDURE: Computed Tomography|DRUG: Gallium Ga 68 Gozetotide|PROCEDURE: Positron Emission Tomography,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Mayo Clinic
980,United States,Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Ipatasertib|BIOLOGICAL: Pembrolizumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,head/neck,checkpoint inhibitor,National Cancer Institute (NCI)
981,United States,Pleural Biphasic Mesothelioma|Pleural Sarcomatoid Mesothelioma,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|PROCEDURE: Surgical Procedure|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Alliance for Clinical Trials in Oncology
982,China,Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer,DRUG: adebrelimab and chemotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Zhejiang Cancer Hospital
983,"Denmark, Finland, Norway, Republic of, Sweden",MCL|Mantle Cell Lymphoma,DRUG: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma,2,NETWORK,other,NETWORK,Network,Phase II,hematologic,other,Nordic Lymphoma Group
984,Australia,Metastatic Triple Negative Breast Cancer,DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Gemcitabine|DRUG: Carboplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,"Peter MacCallum Cancer Centre, Australia"
985,"Belgium, Canada, Czechia, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States",Metastatic NSCLC - Non-Small Cell Lung Cancer|Locally Advanced NSCLC - Non-Small Cell Lung Cancer,DRUG: inupadenant|DRUG: Placebo|DRUG: Carboplatin|DRUG: Pemetrexed,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,chemotherapy,iTeos Therapeutics
986,"France, Italy, Spain",Metastatic Non Small Cell Lung Cancer,DRUG: Tedopi|DRUG: Nivolumab|DRUG: Docetaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Fondazione Ricerca Traslazionale
987,United States,Hepatocellular Cancer|Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma,DRUG: durvalumab|DRUG: Doxorubicin-Eluting Beads|PROCEDURE: TACE|DRUG: bevacizumab|DRUG: Tremelimumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,digestive,checkpoint inhibitor,National Cancer Institute (NCI)
988,United States,Metastatic Pancreatic Cancer,DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Irinotecan|DRUG: Capecitabine|DRUG: Pembrolizumab|DRUG: Olaparib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
989,United States,Advanced Melanoma|Unresectable Melanoma,DRUG: Nivolumab|DRUG: Axitinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Yana Najjar
990,China,Esophagogastric Junction Adenocarcinoma,DRUG: Sintilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sun Yat-sen University
991,Belgium,Recurrent Glioblastoma,DRUG: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|PROCEDURE: Neurosurgery and intracavitary injection nivolumab and ipililumab|DRUG: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,brain/CNS,checkpoint inhibitor,Universitair Ziekenhuis Brussel
992,United States,Squamous Cell Carcinoma|the Nasal Cavity|Paranasal Sinuses,DRUG: Pembrolizumab|DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Carboplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,M.D. Anderson Cancer Center
993,United States,Recurrent Glioblastoma Multiforme|Progressive Glioblastoma Multiforme|Anaplastic Astrocytoma or Gliosarcoma,BIOLOGICAL: M032 (NSC 733972),1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,University of Alabama at Birmingham
994,United Kingdom,Primary CNS Lymphoma,BIOLOGICAL: CD19CAR T-cells,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,"University College, London"
995,France,Head and Neck Mucosal Melanomas,DRUG: Pembrolizumab|PROCEDURE: Surgery|RADIATION: IMRT|DRUG: Lenvatinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,"Gustave Roussy, Cancer Campus, Grand Paris"
996,United States,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,DRUG: Standard Therapy|DRUG: AMG 386 with or without Trastuzumab|DRUG: AMG 479 (Ganitumab) plus Metformin|DRUG: MK-2206 with or without Trastuzumab|DRUG: AMG 386 and Trastuzumab|DRUG: T-DM1 and Pertuzumab|DRUG: Pertuzumab and Trastuzumab|DRUG: Ganetespib|DRUG: ABT-888|DRUG: Neratinib|DRUG: PLX3397|DRUG: Pembrolizumab - 4 cycle|DRUG: Talazoparib plus Irinotecan|DRUG: Patritumab and Trastuzumab|DRUG: Pembrolizumab - 8 cycle|DRUG: SGN-LIV1A|DRUG: Durvalumab plus Olaparib|DRUG: SD-101 + Pembrolizumab|DRUG: Tucatinib plus trastuzumab and pertuzumab|DRUG: Cemiplimab|DRUG: Cemiplimab plus REGN3767|DRUG: Trilaciclib with or without trastuzumab + pertuzumab|DRUG: SYD985 ([vic-]trastuzumab duocarmazine)|DRUG: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|DRUG: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|DRUG: Amcenestrant|DRUG: Amcenestrant + Abemaciclib|DRUG: Amcenestrant + Letrozole|DRUG: ARX788|DRUG: ARX788 + Cemiplimab|DRUG: VV1 + Cemiplimab|DRUG: Datopotamab deruxtecan|DRUG: Datopotamab deruxtecan + Durvalumab|DRUG: Zanidatamab|DRUG: Lasofoxifene|DRUG: Z-endoxifen|DRUG: ARV-471|DRUG: ARV-471 + Letrozole|DRUG: ARV-471 + Abemaciclib|DRUG: Endoxifen + Abemaciclib|DRUG: Rilvegostomig + TDXd|DRUG: Dan222 + Niraparib|DRUG: Sarilumab + Cemiplimab + Paclitaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,breast,checkpoint inhibitor,QuantumLeap Healthcare Collaborative
997,China,HCC|Precision Therapy,DRUG: HAIC + Tislelizumab +lenvatinib,1,OTHER,other,OTHER,Other,Phase I,other,other,Chen Xiaoping
998,"Australia, Canada, Puerto Rico, United States",Primary Mediastinal Large B-Cell Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|PROCEDURE: Echocardiography Test|DRUG: Etoposide Phosphate|BIOLOGICAL: Filgrastim|PROCEDURE: Lumbar Puncture|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pegfilgrastim|PROCEDURE: Positron Emission Tomography|DRUG: Prednisolone|DRUG: Prednisone|RADIATION: Radiation Therapy|BIOLOGICAL: Rituximab|BIOLOGICAL: Rituximab and Hyaluronidase Human|DRUG: Vincristine Sulfate,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,hematologic,checkpoint inhibitor,National Cancer Institute (NCI)
999,"Italy, Spain",Colon Cancer Stage II|Colon Cancer Stage III,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Folinic acid|DRUG: Fluorouracil|DRUG: Temozolomide|DRUG: Irinotecan|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Panitumumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,IFOM ETS - The AIRC Institute of Molecular Oncology
1000,United States,Metastatic Melanoma,OTHER: Radiation therapy and high-dose IL-2|DRUG: High-dose IL-2,2,OTHER,cytokine / immunomodulator,OTHER,Other,Phase II,skin,cytokine / immunomodulator,Providence Health & Services
1001,United Kingdom,Advanced Cancer|Non Small Cell Lung Cancer,DRUG: Tepotinib|DRUG: Pembrolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,lung/thoracic,checkpoint inhibitor,"Institute of Cancer Research, United Kingdom"
1002,Germany,Polycythemia Vera (PV)|Essential Thrombocythemia (ET),DRUG: Ruxolitinib|DRUG: BAT,2,OTHER,other,OTHER,Other,Phase II,other,other,RWTH Aachen University
1003,United States,Metastatic Pancreatic Adenocarcinoma,"DRUG: Nivolumab (Cohort A)|DRUG: Ipilimumab (Cohort A, B and C)|DRUG: Hydroxychloroquine (HCQ) (Cohort B)|DRUG: Nab-paclitaxel (nP) (Cohort A, B and C)|DRUG: Gemcitabine (gem) (Cohort A, B and C)|DRUG: NG350A (Cohort C)",1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,digestive,checkpoint inhibitor,"Cancer Insight, LLC"
1004,China,Glioma,BIOLOGICAL: IL13Rα2 CAR-T,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,brain/CNS,adoptive cell therapy,Yang Zhang
1005,"Italy, Netherlands, Republic of, Spain, United States",Non-small Cell Lung Cancer,DRUG: encorafenib|DRUG: binimetinib,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,other,Pfizer
1006,United States,Low Grade Glioma|High Grade Glioma,"DRUG: Trametinib and Nivolumab|DRUG: Dabrafenib, trametinib, nivolumab",12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,brain/CNS,checkpoint inhibitor,Ann & Robert H Lurie Children's Hospital of Chicago
1007,United States,Glioblastoma|Malignant Glioma|Recurrent Glioma|Refractory Glioma|WHO Grade III Glioma,BIOLOGICAL: HER2(EQ)BBζ/CD19t+ T cells|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,biomarker / diagnostics,City of Hope Medical Center
1008,United States,Advanced Melanoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Acral Lentiginous Melanoma|Unresectable Melanoma|Unresectable Mucosal Melanoma,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|OTHER: Patient Observation|BIOLOGICAL: Pembrolizumab,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,skin,checkpoint inhibitor,ECOG-ACRIN Cancer Research Group
1009,United States,Non Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Ramucirumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Fox Chase Cancer Center
1010,Belgium,Malignant Pleural Mesothelioma,BIOLOGICAL: Dendritic cell vaccination|DRUG: Atezolizumab|DRUG: Platinum/pemetrexed based chemotherapy,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,"University Hospital, Antwerp"
1011,"Austria, Belgium, France, Italy, Spain, United Kingdom, United States",Epstein-Barr Virus (EBV)-Associated Diseases|EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)|EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)|EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)|EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Solid Organ Transplant Complications|Lymphoproliferative Disorders|Allogeneic Hematopoietic Cell Transplant|Stem Cell Transplant Complications|EBV+ Sarcomas|Leiomyosarcoma,BIOLOGICAL: Tabelecleucel,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,brain/CNS,other,Atara Biotherapeutics
1012,United States,Advanced Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v8,BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DRUG: Sitravatinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,M.D. Anderson Cancer Center
1013,China,Non-small Cell Lung Cancer|Older People|Carbon Ion Radiotherapy|Radiotherapy Side Effect,RADIATION: carbon ion radiotherapy|OTHER: targeted therapy|OTHER: single regimen chemotherapy in sequence with radiotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Jian Chen
1014,"Belgium, France, Italy, Netherlands, Spain",NSCLC Stage IV,DRUG: Cemiplimab|DRUG: Placebo,2,NETWORK,other,NETWORK,Network,Phase II,other,checkpoint inhibitor,European Organisation for Research and Treatment of Cancer - EORTC
1015,United States,"Pediatric Sarcoma, Refractory|Pediatric Sarcoma, Relapsed",BIOLOGICAL: GEM/DOX + TGFBi expanded NK cells,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,sarcoma,adoptive cell therapy,Nationwide Children's Hospital
1016,Germany,Intrahepatic Cholangiocarcinoma,DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
1017,"France, Italy, Spain, United Kingdom",Melanoma,BIOLOGICAL: MB097|BIOLOGICAL: Pembrolizumab|DRUG: Vancomycin,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,skin,checkpoint inhibitor,Microbiotica Ltd
1018,United States,Locally Advanced Alveolar Soft Part Sarcoma|Metastatic Alveolar Soft Part Sarcoma|Locally Advanced Non Small Cell Lung Cancer|Metastatic Non Small Cell Lung Cancer|Locally Advanced Small Cell Lung Cancer|Metastatic Small Cell Lung Cancer|Locally Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma|Locally Advanced Melanoma|Metastatic Melanoma,DRUG: Atezolizumab,1,NIH,checkpoint inhibitor,NIH,Government,Phase I,digestive,checkpoint inhibitor,National Cancer Institute (NCI)
1019,China,Vinorelbine,DRUG: vinorelbine,2,OTHER,other,OTHER,Other,Phase II,other,other,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
1020,United States,Head Neck Cancer|Metastatic Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharynx Squamous Cell Carcinoma|Hypopharynx Squamous Cell Carcinoma|Larynx Squamous Cell Carcinoma,DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Wake Forest University Health Sciences
1021,United States,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Richter Syndrome|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,DRUG: Atezolizumab|PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Oxaliplatin|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab,1,NIH,checkpoint inhibitor,NIH,Government,Phase I,hematologic,checkpoint inhibitor,National Cancer Institute (NCI)
1022,France,Hepatocellular Carcinoma by BCLC Stage,DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,UNICANCER
1023,China,Oral Squamous Cell Carcinoma,DRUG: Camrelizumab plus TP|DRUG: TP,3,OTHER,other,OTHER,Other,Phase III,head/neck,other,"Hospital of Stomatology, Wuhan University"
1024,United States,Peritoneal Malignant Mesothelioma,BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Cytoreductive Surgery|DRUG: Hyperthermic Intraperitoneal Chemotherapy|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,lung/thoracic,checkpoint inhibitor,National Cancer Institute (NCI)
1025,"Australia, United States",Melanoma,DRUG: mRNA-4157|BIOLOGICAL: Pembrolizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,skin,checkpoint inhibitor,"ModernaTX, Inc."
1026,United States,Recurrent Glioblastoma,"BIOLOGICAL: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|BIOLOGICAL: RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)",1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,University of Florida
1027,United States,Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head-and-neck Squamous-cell Carcinoma,DRUG: Cetuximab|OTHER: Questionnaire administration|OTHER: Quality of life assessment,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Wake Forest University Health Sciences
1028,Hong Kong,Hepatocellular Carcinoma,DRUG: Durvalumab|DRUG: Tremelimumab|RADIATION: Yttrium-90 radioembolisation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,The University of Hong Kong
1029,China,Renal Cell Carcinoma|Radiotherapy|Immune Checkpoint Inhibitor,RADIATION: High-dose Radiotherapy (HDRT)|RADIATION: Low-dose Radiotherapy (LDRT)|DRUG: Anti-PD-1 monoclonal antibody,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,"Jinling Hospital, China"
1030,United States,Metastatic Urothelial Carcinoma|Unresectable Urothelial Carcinoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Emavusertib|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography,1,NIH,checkpoint inhibitor,NIH,Government,Phase I,multiple,checkpoint inhibitor,National Cancer Institute (NCI)
1031,United Kingdom,Non-small Cell Lung Cancer,DRUG: MPDL3280A|DRUG: Vemurafenib|DRUG: Alectinib|DRUG: Trastuzumab emtansine,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,"University College, London"
1032,China,Advanced Triple-negative Breast Cancer,DRUG: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy|DRUG: debry single antibody + VEX metronomic chemotherapy,2,OTHER,other,OTHER,Other,Phase II,breast,radiotherapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
1033,China,Esophageal Squamous Cell Carcinoma|Efficacy|Toxicity,DRUG: Induction Immunotherapy-Toripalimab|DRUG: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|RADIATION: Radiotherapy|DRUG: Apatinib|DRUG: Capecitabine,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sun Yat-sen University
1034,United Kingdom,Gastric Adenocarcinoma|Oesophageal Adenocarcinoma,DRUG: FLOT-A,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Royal Marsden NHS Foundation Trust
1035,"Australia, Belgium, Canada, France, Israel, Italy, Malaysia, Netherlands, Philippines, Poland, Republic of, Singapore, Spain, Taiwan, Thailand, Turkey, United States",Locally Advanced or Metastatic Non-Small Cell Lung Cancer,DRUG: T-DXd|BIOLOGICAL: Durvalumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Volrustomig|DRUG: Rilvegostomig,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,lung/thoracic,checkpoint inhibitor,AstraZeneca
1036,Germany,"ALL, Recurrent, Adult",DRUG: Blinatumomab|DRUG: Venetoclax,12,OTHER,other,OTHER,Other,Phase I & II,other,other,Goethe University
1037,United States,EGFR Gene Mutation|Glioblastoma|MGMT-Unmethylated Glioblastoma|Recurrent Glioblastoma,BIOLOGICAL: E-SYNC T Cells|DRUG: Cyclophosphamide (non-investigational)|DRUG: Fludarabine (non-investigational)|PROCEDURE: Leukapheresis|PROCEDURE: Surgical resection,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,"Hideho Okada, MD, PhD"
1038,France,Squamous Cell Carcinoma of the Anus Stage III,BIOLOGICAL: Blood sample collection|PROCEDURE: Biopsy,2,OTHER,other,OTHER,Other,Phase II,other,other,Centre Hospitalier Universitaire de Besancon
1039,China,MSI-H,DRUG: Sintilimab|DRUG: IBI310&Sintilimab|PROCEDURE: Radical surgery,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,other,other,Innovent Biologics (Suzhou) Co. Ltd.
1040,United States,Rectal Adenocarcinoma,DRUG: LY2157299|DRUG: Capecitabine|DRUG: Fluorouracil|PROCEDURE: Tumor specific mesorectal excision,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Providence Health & Services
1041,"Canada, United States",Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Renal Pelvis Urothelial Carcinoma|Locally Advanced Ureter Urothelial Carcinoma|Locally Advanced Urethral Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Bladder Urothelial Carcinoma|Recurrent Renal Pelvis Urothelial Carcinoma|Recurrent Ureter Urothelial Carcinoma|Recurrent Urethral Urothelial Carcinoma|Recurrent Urothelial Carcinoma|Stage IIIB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|DRUG: Enfortumab Vedotin|DRUG: Erdafitinib|PROCEDURE: Multigated Acquisition Scan,1,NIH,other,NIH,Government,Phase I,genitourinary,other,National Cancer Institute (NCI)
1042,Republic of,Non-small Cell Lung Cancer,DRUG: Bojungikki-tang(BJIKT)|DRUG: Pembrolizumab,2,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase II,lung/thoracic,checkpoint inhibitor,Korea Institute of Oriental Medicine
1043,United States,"Leukemia, Myeloid, Acute",BIOLOGICAL: VCAR33,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,Vor Biopharma
1044,China,Adjuvant Radiotherapy,RADIATION: Adjuvant radiotherapy|OTHER: Observation,2,OTHER,other,OTHER,Other,Phase II,other,radiotherapy,Zhejiang Cancer Hospital
1045,Poland,"Neoadjuvant|Immunotherapy|Sarcoma,Soft Tissue|Radiation Therapy","DRUG: Pembrolizumab, Eftilagimod alpha",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,sarcoma,checkpoint inhibitor,Maria Sklodowska-Curie National Research Institute of Oncology
1046,France,Soft Tissue Sarcoma Adult|Advanced Cancer,DRUG: Association of Nivolumab + Relatlimab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,sarcoma,checkpoint inhibitor,Institut Bergonié
1047,China,Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer,DRUG: Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Yunnan Cancer Hospital
1048,Netherlands,"Acute Myeloid Leukemia Refractory|Acute Myeloid Leukemia, Relapsed, Adult",BIOLOGICAL: UCB-NK cells|DRUG: IL-2,12,OTHER,adoptive cell therapy,OTHER,Other,Phase I & II,hematologic,adoptive cell therapy,Radboud University Medical Center
1049,United States,Lung Adenocarcinoma|Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,BIOLOGICAL: Ipilimumab|PROCEDURE: Local Consolidation Therapy|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy|PROCEDURE: Therapeutic Conventional Surgery,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,M.D. Anderson Cancer Center
1050,China,Hepatocellular Carcinoma,RADIATION: Stereotactic body radiotherapy|DRUG: Sintilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sun Yat-sen University
1051,"Canada, United States",Leukemia|Lymphoma,BIOLOGICAL: Patient-derived CD19- and CD22 specific CAR,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,Seattle Children's Hospital
1052,United States,Melanoma Stage III|Melanoma Stage IV,DRUG: SX-682|BIOLOGICAL: Pembrolizumab,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,skin,checkpoint inhibitor,"Syntrix Biosystems, Inc."
1053,France,HNSCC,DRUG: Cetuximab|DRUG: avelumab|DRUG: Cisplatin|RADIATION: IMRT,3,OTHER,other,OTHER,Other,Phase III,other,radiotherapy,Groupe Oncologie Radiotherapie Tete et Cou
1054,"France, Italy, Spain",Non-small Cell Lung Cancer Stage III,COMBINATION_PRODUCT: durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|COMBINATION_PRODUCT: Durvalumab plus radiotherapy|BIOLOGICAL: durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Mario Negri Institute for Pharmacological Research
1055,United States,Bile Duct Cancer|Cholangiocarcinoma|Cholangiocarcinoma Non-resectable|Cholangiocarcinoma Metastatic|Metastatic Intrahepatic Cholangiocarcinoma,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab|RADIATION: Yttrium-90,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,multiple,checkpoint inhibitor,Beth Israel Deaconess Medical Center
1056,United States,Head and Neck Cancer|Cervical Cancer|Non-small Cell Carcinoma|Melanoma|Ovarian Cancer|Anogenital Cancers|HPV - Anogenital Human Papilloma Virus Infection|HPV-Related Cervical Carcinoma|HPV-Related Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Malignancy|HPV-Related Adenocarcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Associated Vaginal Adenocarcinoma|HPV-Related Endocervical Adenocarcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Verrucous Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV Positive Rectal Squamous Cell Carcinoma,BIOLOGICAL: TSC-204-A0201|BIOLOGICAL: TSC-204-C0702|BIOLOGICAL: TSC-200-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-204-C0702|BIOLOGICAL: TSC-204-A0201 + TSC-200-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-200-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-203-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-203-A0201|BIOLOGICAL: TSC-200-A0201 + TSC-203-A0201|BIOLOGICAL: TSC-203-A0201|BIOLOGICAL: TSC-204-A0101|BIOLOGICAL: TSC-201-B0702|BIOLOGICAL: TSC-204-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-204-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-204-C0702 + TSC-204-A0101|BIOLOGICAL: TSC-204-C0702 + TSC-201-B0702|BIOLOGICAL: TSC-200-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-200-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-203-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-203-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-202-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-202-A0201|BIOLOGICAL: TSC-200-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-203-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-204-A0101 + TSC-202-A0201|BIOLOGICAL: TSC-201-B0702 + TSC-202-A0201,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,gynecologic,other,"TScan Therapeutics, Inc."
1057,United States,Metastatic Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v8,PROCEDURE: Cytoreductive Nephrectomy|DRUG: Active Comparator,3,NETWORK,other,NETWORK,Network,Phase III,genitourinary,other,SWOG Cancer Research Network
1058,United States,Mesothelioma,DRUG: Durvalumab / tremelimumab|DRUG: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,lung/thoracic,checkpoint inhibitor,Baylor College of Medicine
1059,United States,Metastatic Renal Cell Carcinoma,DRUG: Evolocumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,M.D. Anderson Cancer Center
1060,United States,Clear Cell Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma Metastatic,DRUG: Selenomethionine (SLM)|DRUG: Axitinib|DRUG: Pembrolizumab,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,genitourinary,checkpoint inhibitor,Mohammed Milhem
1061,Australia,NSCLC,RADIATION: Radiotherapy|DRUG: SoC systemic therapy,1,OTHER,other,OTHER,Other,Phase I,other,radiotherapy,"Peter MacCallum Cancer Centre, Australia"
1062,China,Gastroesophageal Junction Adenocarcinoma,RADIATION: Sintilimab combined with chemotherapy and local treatment|COMBINATION_PRODUCT: Sintilimab combined with chemotherapy only,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Jiangsu Cancer Institute & Hospital
1063,"Finland, Germany, Netherlands, Norway, Sweden",Acute Myeloid Leukemia in Remission,BIOLOGICAL: DCP-001,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,hematologic,other,Mendus
1064,China,"TNBC, Triple Negative Breast Cancer",DRUG: Neoadjuvant chemotherapy combined with Toripalimab,2,OTHER,other,OTHER,Other,Phase II,breast,chemotherapy,First Affiliated Hospital of Zhejiang University
1065,United States,Small Cell Carcinoma of the Bladder|Small Cell Carcinoma of the Urinary Tract|Squamous Cell Carcinoma of the Bladder|Squamous Cell Carcinoma of the Urinary Tract|Primary Adenocarcinoma of the Bladder|Primary Adenocarcinoma of the Urinary Tract|Renal Medullary Carcinoma|Squamous Cell Carcinoma of the Penis,DRUG: Sacituzumab govitecan|DRUG: Atezolizumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
1066,United States,Non-hodgkin Lymphoma|Hodgkin Lymphoma,"DRUG: DOC Group B|DRUG: Pv-COMRAD 1 and 2 Group B|DRUG: Pv-R-CYM 1 and 2 Group B|DRUG: DOC Group C|DRUG: MAD CPR 1 and 2|DRUG: Pv-R CYVE 1 and 2|DRUG: Pv-R CYVE-MTX 1 and 2|DRUG: MAD CP|DRUG: Pv-Cytarabine/etoposide|DRUG: AD CP|DRUG: Bv-AVD-R 1 and 2: COHORT IIa|DRUG: Bv-NVD-R, Cycle 1-2|DRUG: Bv-NVD-R, Cycle 1-4 SER|DRUG: Bv-AVD-R|DRUG: Bv-NVD-R, Cycle 1-4 RER|DRUG: Bv-NAVD-R, Cycle 1-2|RADIATION: Involved Site Radiation Therapy",2,OTHER,other,OTHER,Other,Phase II,hematologic,radiotherapy,New York Medical College
1067,China,Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,DRUG: Serplulimab|DRUG: Lenvatinib|DRUG: Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,Qilu Hospital of Shandong University
1068,China,NSCLC Stage IV,RADIATION: SBRT or LDRT|DRUG: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Fudan University
1069,United States,"Colorectal Cancer|Hematologic Malignancy|Rectum Cancer|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Syndrome|Plasma Cell Myeloma|Gastric Cancer|Esophageal Cancer|Esophagus Cancer|Gastric Cancer, Metastatic|Unresectable Esophageal Cancer|Metastatic Esophageal Cancer",DRUG: Vactosertib|DRUG: Fludarabine Phosphate|DRUG: Cyclophosphamide|DRUG: IL-2|DRUG: Natural Killer Cells,1,OTHER,cytokine / immunomodulator,OTHER,Other,Phase I,digestive,cytokine / immunomodulator,David Wald
1070,China,Hepatocellular Carcinoma,PROCEDURE: FOLFOX-HAIC|DRUG: Camrelizumab|DRUG: Apatinib,3,OTHER,other,OTHER,Other,Phase III,digestive,other,Sun Yat-sen University
1071,United States,Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Fluorouracil|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,3,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase III,head/neck,checkpoint inhibitor,ECOG-ACRIN Cancer Research Group
1072,United States,Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|BIOLOGICAL: Pembrolizumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,digestive,checkpoint inhibitor,National Cancer Institute (NCI)
1073,"Canada, Puerto Rico, United States",Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma,PROCEDURE: Biospecimen Collection|DRUG: Brentuximab Vedotin|PROCEDURE: Computed Tomography|DRUG: Dacarbazine|DRUG: Doxorubicin Hydrochloride|BIOLOGICAL: Filgrastim|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pegfilgrastim|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy|DRUG: Vinblastine Sulfate,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,hematologic,checkpoint inhibitor,National Cancer Institute (NCI)
1074,China,"Leukemia, B-cell",BIOLOGICAL: CART-19/22,12,INDUSTRY,other,INDUSTRY,Industry,Phase I & II,hematologic,other,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd"
1075,Canada,"Mesothelioma, Malignant",DRUG: Cyclophosphamide|DRUG: Tremelimumab|DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,"University Health Network, Toronto"
1076,China,"SCLC, Limited Stage",DRUG: Durvalumab|DRUG: Chemotherapy drug of EP regimen|RADIATION: radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Hebei Medical University Fourth Hospital
1077,China,Esophageal Squamous Cell Carcinoma,DRUG: Tislelizumab,1,OTHER,other,OTHER,Other,Phase I,digestive,other,Affiliated Cancer Hospital of Shantou University Medical College
1078,United States,High-risk Smoldering Multiple Myeloma|Smoldering Multiple Myeloma|Multiple Myeloma,DRUG: Teclistamab|DRUG: Lenalidomide|DRUG: Dexamethasone,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,"Irene Ghobrial, MD"
1079,China,Esophageal Squamous Cell Carcinoma|Oligometastatic Disease,DRUG: PD-1 combined with SBRT,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Sun Yat-sen University
1080,United States,Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Cancer|Recurrent Head and Neck Cancer|Metastatic Head-and-neck Squamous-cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma,BIOLOGICAL: PD-L1 t-haNK|DRUG: Cetuximab|BIOLOGICAL: N-803,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Glenn J. Hanna
1081,China,Locally Advanced Esophageal Squamous Cell Carcinoma,DRUG: S-1|DRUG: Toripalimab|RADIATION: Intensity-modulated radiotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sun Yat-sen University
1082,China,NSCLC,RADIATION: SBRT+LDRT|DRUG: Toripalimab|DRUG: Chemotherapy drug|DRUG: Toripalimab,2,OTHER,other,OTHER,Other,Phase II,other,radiotherapy,Shanghai Chest Hospital
1083,United States,Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma|Recurrent Skin Squamous Cell Carcinoma|Resectable Head and Neck Cutaneous Squamous Cell Carcinoma|Resectable Skin Squamous Cell Carcinoma|Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cemiplimab|PROCEDURE: Computed Tomography|RADIATION: Image Guided Radiation Therapy|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|PROCEDURE: Surgical Procedure|PROCEDURE: Surgical Procedure,3,NIH,other,NIH,Government,Phase III,skin,checkpoint inhibitor,National Cancer Institute (NCI)
1084,China,Head and Neck Squamous Cell Carcinoma,DRUG: Anti-PD-1 monoclonal antibody|OTHER: Postoperative CCRT,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
1085,France,Small Cell Lung Carcinoma,DRUG: Durvalumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,UNICANCER
1086,Switzerland,NSCLC Stage IV,DRUG: Atezolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Oncology Institute of Southern Switzerland
1087,United States,Prostate Cancer Patients on Active Surveillance,"DRUG: Poly-ICLC intramuscular (IM) injection|DRUG: Poly-ICLC, Intertumoral (IT) injection",2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Ashutosh Kumar Tewari
1088,United States,Hepatocellular Carcinoma Non-resectable,COMBINATION_PRODUCT: Fluorine-18 fluorocholine,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Queen's Medical Center
1089,United States,High-grade Glioma,BIOLOGICAL: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,University of Florida
1090,"Belgium, France, Italy, Spain, United Kingdom","Carcinoma, Squamous Cell of Head and Neck",DRUG: Afatinib|DRUG: Palbociclib|DRUG: standard of care|DRUG: IPH2201|DRUG: Durvalumab|DRUG: Niraparib|DRUG: INCAGN01876,2,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase II,head/neck,checkpoint inhibitor,European Organisation for Research and Treatment of Cancer - EORTC
1091,United States,Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC V8,BIOLOGICAL: Durvalumab|RADIATION: Radiation Therapy|PROCEDURE: Biospecimen Collection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Mayo Clinic
1092,United States,Metastatic Melanoma|Advanced Locoregional Melanoma|Metastatic Renal Cell Carcinoma|Clear Cell Histology,DRUG: Pembrolizumab|DRUG: Aldesleukin,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
1093,United States,Melanoma Stage III|Melanoma Stage IV|Inoperable Disease,DRUG: Interleukin-2|DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
1094,China,Head and Neck Squamous Cell Carcinoma,DRUG: Tislelizumab-jsgr|DRUG: Cisplatin|DRUG: Albumin-Bound Paclitaxel|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Beijing Tongren Hospital
1095,United States,Lymphoplasmacytic Lymphoma,BIOLOGICAL: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|OTHER: Laboratory Biomarker Analysis,1,OTHER,cancer vaccine,OTHER,Other,Phase I,hematologic,cancer vaccine,M.D. Anderson Cancer Center
1096,"Australia, United States",Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma,DRUG: Prednisone|DRUG: Vincristine|DRUG: Daunorubicin|DRUG: Pegaspargase|DRUG: Erwinase®|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Dasatinib|DRUG: Methotrexate|DRUG: Blinatumomab|DRUG: Ruxolitinib|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Etoposide|DRUG: Clofarabine|DRUG: Vorinostat|DRUG: Idarubicin|DRUG: Nelarabine|DRUG: Thioguanine|DRUG: Asparaginase Erwinia chrysanthemi (recombinant)-rywn|DRUG: Calaspargase Pegol,23,OTHER,other,OTHER,Other,Phase II & III,hematologic,other,St. Jude Children's Research Hospital
1097,"Australia, United States","Triple Negative Breast Cancer|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle Cell Lymphoma|Bladder Cancer|Uveal Melanoma, Recurrent|Cervix Cancer|Carcinoma in Situ|Head and Neck Squamous Cell Carcinoma|Skin Cancer|Metastatic Cancer|Tumor, Solid|Tumor Recurrence",DRUG: ONM-501|DRUG: Cemiplimab,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,genitourinary,checkpoint inhibitor,"OncoNano Medicine, Inc."
1098,"Australia, Belgium, Italy, Malaysia, Poland, Republic of, Romania, Spain, Taiwan, United Kingdom, United States",Head and Neck Squamous Cell Carcinoma (HNSCC),DRUG: INBRX-106|DRUG: Pembrolizumab,23,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II & III,head/neck,checkpoint inhibitor,"Inhibrx Biosciences, Inc"
1099,"Australia, United States",Glioblastoma|Malignant Glioma|Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent Grade III Glioma|Grade III Glioma,BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,brain/CNS,checkpoint inhibitor,"Sabine Mueller, MD, PhD"
1100,China,Hepatocellular Carcinoma,DRUG: Sintilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Xin-Hua Xu
1101,United States,Pancreatic Adenocarcinoma,DRUG: Nivolumab|PROCEDURE: Irreversible Electroporation,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,University of Louisville
1102,Italy,Pleural Mesothelioma,DRUG: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Istituto Oncologico Veneto IRCCS
1103,United States,Sarcoma,DRUG: Palbociclib|DRUG: Pembrolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,sarcoma,checkpoint inhibitor,John Rieth
1104,China,Non Small Cell Lung Cancer|Brain Metastases|Stereotactic Radiation|Immunotherapy,DRUG: Cadonilimab combined with SRS,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,other,Rongrong Zhou
1105,United States,Diarrhea|Enterocolitis,BIOLOGICAL: SER-155,1,OTHER,other,OTHER,Other,Phase I,other,other,Memorial Sloan Kettering Cancer Center
1106,United States,"Grade I Meningioma, Adult|Grade II Meningioma, Adult|Grade III Meningioma, Adult|Recurrent Meningioma",DRUG: Pembrolizumab|PROCEDURE: Stereotactic Radiosurgery,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"Nancy Ann Oberheim Bush, MD"
1107,"United Kingdom, United States",Non-small Cell Lung Cancer,DRUG: BNT327|DRUG: Docetaxel,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,other,BioNTech SE
1108,Belarus,B-cell Acute Lymphoblastic Leukemia|Lymphoblastic B-Cell Lymphoma,BIOLOGICAL: CD19 CAR-T-cells|DRUG: Tocilizumab,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,hematologic,adoptive cell therapy,"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology"
1109,China,Head and Neck Squamous Cell Carcinoma,DRUG: Ivonescimab combined with TP|DRUG: Cadonilimab combined with TP|DRUG: Penpulimab combined with TP,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Lei Liu
1110,"Georgia, Germany, Republic of, Spain, Taiwan, Turkey, United States",Advanced Non-Small Cell Lung Cancer,DRUG: BNT116|DRUG: Cemiplimab,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,lung/thoracic,checkpoint inhibitor,Regeneron Pharmaceuticals
1111,United States,Fibrolamellar Hepatocellular Carcinoma,DRUG: Durvalumab|DRUG: DRP-104,12,OTHER,checkpoint inhibitor,OTHER,Other,Phase I & II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1112,"Belarus, Russian Federation",Melanoma Stage III|Melanoma (Skin),BIOLOGICAL: BCD-217|BIOLOGICAL: anti-PD1|PROCEDURE: Excision of the primary lesion|PROCEDURE: Regional lymphadenectomy,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,skin,other,Biocad
1113,China,T-lymphoblastic Lymphoma|T-ALL,BIOLOGICAL: CAR-T,1,INDUSTRY,adoptive cell therapy,INDUSTRY,Industry,Phase I,hematologic,adoptive cell therapy,"Hebei Senlang Biotechnology Inc., Ltd."
1114,United States,Metastatic Castration-resistant Prostate Cancer,DRUG: Testosterone Cypionate|DRUG: Sipuleucel-T,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Yale University
1115,United States,Microsatellite Stable Rectal Carcinoma|Locally Advanced Rectal Adenocarcinoma,DRUG: Balstilimab|DRUG: Botensilimab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Memorial Sloan Kettering Cancer Center
1116,Italy,Mesotheliomas Pleural,DRUG: Atezolizumab 1200 mg in 20 ML Injection|DRUG: Placebo,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Gruppo Oncologico Italiano di Ricerca Clinica
1117,"Canada, United States",Metastatic Undifferentiated Pleomorphic Sarcoma|Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Unresectable Undifferentiated Pleomorphic Sarcoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Diagnostic Imaging Testing|DRUG: Doxorubicin|PROCEDURE: Echocardiography Test|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Pembrolizumab,3,NIH,checkpoint inhibitor,NIH,Government,Phase III,sarcoma,checkpoint inhibitor,National Cancer Institute (NCI)
1118,United States,Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma,DRUG: Pembrolizumab|DRUG: Axitinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,H. Lee Moffitt Cancer Center and Research Institute
1119,China,Cervical Cancer|Neoadjuvant Chemoimmunotherapy|Radical Hysterectomy|Extrafascial Hysterectomy,DRUG: Cadonilimab|DRUG: Paclitaxel-albumin|DRUG: Cisplatin|PROCEDURE: Extrafascial hysterectomy|PROCEDURE: Radical hysterectomy|PROCEDURE: Cone biopsy,2,OTHER,other,OTHER,Other,Phase II,gynecologic,chemotherapy,Tongji Hospital
1120,United States,Esophageal Adenocarcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,DRUG: OBP-301|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Weill Medical College of Cornell University
1121,France,Lung Adenocarcinoma|Cryotherapy Effect,DEVICE: Cryoablation|DRUG: Pembrolizumab|DRUG: Pemetrexed|DRUG: Carboplatin,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,lung/thoracic,checkpoint inhibitor,Institut Bergonié
1122,"France, Israel, United Kingdom, United States",Glioblastoma,DEVICE: Optune® device|DRUG: Temozolomide|DRUG: Pembrolizumab|DRUG: Placebo,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,brain/CNS,checkpoint inhibitor,NovoCure GmbH
1123,"Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Republic of, Romania, Saudi Arabia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States","Carcinoma, Non-Small-Cell Lung",DRUG: Adagrasib|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Placebo|DRUG: Cisplatin,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,lung/thoracic,checkpoint inhibitor,Mirati Therapeutics Inc.
1124,"Canada, United States",Head and Neck Squamous Cell Carcinoma (HNSCC),DRUG: Pembrolizumab|RADIATION: Stereotactic Body Radiation Therapy (SBRT),2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"RTOG Foundation, Inc."
1125,United States,NSCLC,DRUG: Atezolizumab|DRUG: Tiragolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"Alliance Foundation Trials, LLC."
1126,China,Renal Cell Carcinoma Stage I,DRUG: Volonib combined with Everolimus Formation,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Sun Yat-sen University
1127,China,Nasopharyngeal Carcinoma,DRUG: GP combine with Tislelizumab neoadjuvant therapy+CCRT,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Sun Yat-sen University
1128,Italy,Head and Neck Squamous Cell Carcinoma (HNSCC)|Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer,DRUG: Cetuximab/avelumab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Gruppo Oncologico del Nord-Ovest
1129,Italy,Head and Neck Squamous Cell Carcinoma,DRUG: Niraparib,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Gruppo Oncologico del Nord-Ovest
1130,France,Head and Neck Squamous Cell Carcinoma,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"Gustave Roussy, Cancer Campus, Grand Paris"
1131,"Australia, Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Lithuania, Netherlands, Norway, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom",High-Risk Neuroblastoma|Patient With Insufficient Response Chemoimmunotherapy,DRUG: Vincristine|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Vindesine|DRUG: Dacarbazine|DRUG: Ifosfamide|DRUG: Doxorubicin|DRUG: Busulfan|DRUG: Melphalan|DRUG: Thiotepa|RADIATION: Radiotherapy|DRUG: Dinutuximab Beta|DRUG: Cisplatin|DRUG: Temozolomide 100 MG|DRUG: Irinotecan|DRUG: Cyclophosphamid,3,OTHER,other,OTHER,Other,Phase III,other,radiotherapy,"Gustave Roussy, Cancer Campus, Grand Paris"
1132,United States,Neuroblastoma|Diffuse Intrinsic Pontine Glioma,BIOLOGICAL: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT),1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,University of Florida
1133,China,"Sarcoma|Sarcoma,Soft Tissue|Sarcoma of Bone",COMBINATION_PRODUCT: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT),2,OTHER,combination product,OTHER,Other,Phase II,sarcoma,combination product,Ruijin Hospital
1134,United States,Platinum-Resistant Lung Small Cell Carcinoma|Platinum-Sensitive Lung Small Cell Carcinoma|Recurrent Extensive Stage Lung Small Cell Carcinoma|Refractory Extensive Stage Lung Small Cell Carcinoma,BIOLOGICAL: Durvalumab|DRUG: Lurbinectedin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,lung/thoracic,checkpoint inhibitor,Mayo Clinic
1135,China,Locally Advanced Esophageal Squamous Cell Carcinoma,"DRUG: Toripalimab (240mg day1, Q3W*3cycle)",2,OTHER,other,OTHER,Other,Phase II,digestive,other,"Nanfang Hospital, Southern Medical University"
1136,China,Esophageal Squamous Cell Carcinoma (ESCC),DRUG: Induction chemoimmunotherapy|RADIATION: Hypofractionated Radiation Therapy|RADIATION: Conventional Fractionated Radiation Therapy|DRUG: Concurrent Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sun Yat-sen University
1137,United States,Squamous Cell Carcinoma of the Head and Neck|Oropharynx|Human Papillomavirus Viruses|Drug Therapy|Cancer Vaccine,DRUG: Docetaxel|DRUG: Cisplatin|DRUG: PRGN-2009,2,NIH,other,NIH,Government,Phase II,head/neck,chemotherapy,National Cancer Institute (NCI)
1138,United States,Multiple Myeloma,DRUG: Carfilzomib|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Daratumumab|PROCEDURE: autologous hematopoietic cell transplantation,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Memorial Sloan Kettering Cancer Center
1139,Malaysia,NSCLC (Non-small Cell Lung Carcinoma)|First Line Therapy|Locally Advanced/Metastatic NSCLC,"DRUG: Nivolumab 40mg|DRUG: Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel",3,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase III,lung/thoracic,checkpoint inhibitor,Dr Arvindran A/L Alaga
1140,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Therapies,DRUG: Cardenilimab Combined With Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,Li Zhang
1141,United States,Glioblastoma Multiforme|Glioblastoma,BIOLOGICAL: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,University of Florida
1142,United States,Diffuse Large-Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|High-grade B-cell Lymphoma (HGBCL)|Follicular Lymphoma,BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)|BIOLOGICAL: CD19 targeted CAR T Cell Therapy,2,OTHER,cancer vaccine,OTHER,Other,Phase II,hematologic,cancer vaccine,H. Lee Moffitt Cancer Center and Research Institute
1143,United States,NSCLC Stage IV|NSCLC Stage IIIB,DRUG: Ipatasertib,2,OTHER,other,OTHER,Other,Phase II,other,other,"Jun Zhang, MD, PhD"
1144,China,Intrahepatic Cholangiocarcinoma|Transarterial Chemoembolization|Apatinib|PD-1 Antibody,COMBINATION_PRODUCT: DEB-TACE combined with apatinib and PD-1 antibody,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Sichuan Cancer Hospital and Research Institute
1145,United States,Adult Glioblastoma|High Grade Glioma|WHO Grade III or IV Malignant Glioma,"BIOLOGICAL: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)",1,OTHER,cancer vaccine,OTHER,Other,Phase I,brain/CNS,cancer vaccine,University of Florida
1146,"Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom, United States",Uveal Melanoma,BIOLOGICAL: IMCgp100|DRUG: Dacarbazine|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Pembrolizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,skin,checkpoint inhibitor,Immunocore Ltd
1147,Germany,Classical Hodgkin Lymphoma,DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,University of Cologne
1148,United States,Adult Grade III Lymphomatoid Granulomatosis|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|PROCEDURE: autologous hematopoietic stem cell transplantation|OTHER: laboratory biomarker analysis,1,OTHER,other,OTHER,Other,Phase I,genitourinary,biomarker / diagnostics,City of Hope Medical Center
1149,"Germany, Hungary, Poland, Spain, Turkey, United Kingdom, United States",Non-Small Cell Lung Cancer,BIOLOGICAL: BNT116|BIOLOGICAL: Cemiplimab|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Paclitaxel|BIOLOGICAL: BNT316|BIOLOGICAL: anti-B7-H3 antibody conjugated to topoisomerase I inhibitor|BIOLOGICAL: anti-HER3 antibody conjugated to topoisomerase I inhibitor,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,lung/thoracic,checkpoint inhibitor,BioNTech SE
1150,"Turkey, United States","Carcinoma, Non-Small-Cell Lung",DRUG: JNJ-90301900|BIOLOGICAL: Durvalumab|RADIATION: Concurrent Chemo/Radiation Therapy (cCRT)|DRUG: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin|DRUG: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,lung/thoracic,checkpoint inhibitor,Johnson & Johnson Enterprise Innovation Inc.
1151,United States,Actinic Keratosis,PROCEDURE: Biopsy|DRUG: Calcipotriene|DRUG: Fluorouracil,2,OTHER,other,OTHER,Other,Phase II,other,other,University of Arizona
1152,United States,Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8,DRUG: Atezolizumab|PROCEDURE: Conventional Surgery|DRUG: Fluorouracil|DRUG: Oxaliplatin|DRUG: Tiragolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,M.D. Anderson Cancer Center
1153,United States,Metastatic Nasopharyngeal Carcinoma|Recurrent Nasopharyngeal Carcinoma|Stage IV Nasopharyngeal Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,head/neck,checkpoint inhibitor,National Cancer Institute (NCI)
1154,Italy,Cholangiocarcinoma,DRUG: Durvalumab 1120 mg|DRUG: Durvalumab 1500 mg|DRUG: Tremelimumab i.v. at 300 mg|COMBINATION_PRODUCT: Cisplatin (CDDP) 25 mg/mq i.v|COMBINATION_PRODUCT: Gemcitabine (GEM) 1000 mg/mq i.v.,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,"National Cancer Institute, Naples"
1155,Germany,Newly Diagnosed H3-mutated Glioma,DRUG: Tecentriq 1200 MG in 20 ML Injection|BIOLOGICAL: H3K27M peptide vaccine|OTHER: Imiquimod (5%),1,OTHER,cancer vaccine,OTHER,Other,Phase I,brain/CNS,cancer vaccine,German Cancer Research Center
1156,"Australia, Canada",Metastatic Renal Cell Carcinoma,DRUG: Ipilimumab/ Nivolumab|RADIATION: SBRT + Ipilimumab/Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Ontario Clinical Oncology Group (OCOG)
1157,China,Nasopharyngeal Carcinoma|De-escalation Therapy,DRUG: Full course of PD-1/PD-L1 blockades|DRUG: Cisplatin-based induction chemotherapy|RADIATION: Standard-dose IMRT|RADIATION: Gradient Fractionated IMRT|DRUG: Concurrent Chemotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,head/neck,checkpoint inhibitor,Sun Yat-sen University
1158,China,Pancreatic Adenocarcinoma Metastatic,DRUG: Penpulimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Gemcitabine,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
1159,United States,"Juvenile Myelomonocytic Leukemia|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Undifferentiated Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Myelodysplastic Syndrome|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Mixed Phenotype Acute Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Biphenotypic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Minimal Residual Disease|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Leukemia",BIOLOGICAL: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|OTHER: Laboratory Biomarker Analysis,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,hematologic,adoptive cell therapy,Fred Hutchinson Cancer Center
1160,"China, Hong Kong, Italy, Japan, Republic of, Singapore, Spain, Taiwan, United States",Hepatocellular Carcinoma,BIOLOGICAL: Tremelimumab|BIOLOGICAL: Durvalumab|BIOLOGICAL: Bevacizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,MedImmune LLC
1161,"Finland, Norway, Sweden","NSCLC, Stage I",DRUG: Durvalumab,2,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase II,other,checkpoint inhibitor,Vastra Gotaland Region
1162,China,Head and Neck Squamous Carcinoma,RADIATION: SBRT+immunochemotherpy|DRUG: Immunochemotherapy|DRUG: cetuximab+immunochemotharpy,2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Jiang Feng
1163,China,Esophageal Squamous Cell Carcinoma,DRUG: Tislelizumab|RADIATION: Low-dose radiotherapy|DRUG: Nab-paclitaxel|DRUG: Cisplatin,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sichuan University
1164,United States,Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Metastatic Breast Cancer|Metastatic Non-Small Cell Lung Carcinoma,RADIATION: Stereotactic Body Radiotherapy/SBRT|DRUG: Systemic Therapy/Standard of Care,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Memorial Sloan Kettering Cancer Center
1165,"Australia, Norway, Sweden",Melanoma Stage Iv,DRUG: Ipilimumab|DRUG: Nivolumab|RADIATION: Stereotactic Radiotherapy|OTHER: Salvage therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,skin,checkpoint inhibitor,Melanoma Institute Australia
1166,"Belgium, France, Italy, Japan, Poland, Republic of, Spain, Taiwan, Turkey, United States",Advanced or Metastatic NSCLC,DRUG: Datopotamab deruxtecan|DRUG: Durvalumab|DRUG: Carboplatin|DRUG: AZD2936|DRUG: MEDI5752|DRUG: AZD7789,1,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase I,multiple,checkpoint inhibitor,AstraZeneca
1167,United States,Lung Cancer Metastatic|EGFR Gene Mutation,DRUG: Osimertinib|DRUG: Alisertib,1,OTHER,other,OTHER,Other,Phase I,lung/thoracic,other,Collin Blakely
1168,"Australia, Republic of, Taiwan, United States",Hepatocellular Carcinoma,DRUG: SRF388|DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Placebo,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,"Coherus Biosciences, Inc."
1169,China,Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma,DRUG: Adebrelimab|DRUG: Apatinib|DRUG: Tegafur,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
1170,Netherlands,Colon Carcinoma,DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Celecoxib 200mg|DRUG: BMS-986253|DRUG: BMS-986016,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,The Netherlands Cancer Institute
1171,China,Nasopharyngeal Cancinoma (NPC)|SBRT|Immunotherapy,DRUG: SBRT combined with Nimotuzumab followed by Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,The First Affiliated Hospital of Xiamen University
1172,"Canada, Hong Kong, Singapore, United States",Metastatic Nasopharyngeal Carcinoma|Recurrent Nasopharyngeal Carcinoma|Stage IV Nasopharyngeal Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Relatlimab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,head/neck,checkpoint inhibitor,National Cancer Institute (NCI)
1173,United States,Advanced Gastric Adenocarcinoma,DRUG: Paclitaxel|DRUG: Olaparib|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1174,Italy,Cutaneous Squamous Cell Carcinoma,DRUG: Cemiplimab,2,OTHER,other,OTHER,Other,Phase II,other,checkpoint inhibitor,Fondazione Melanoma Onlus
1175,United States,Hairy Cell Leukemia|Hairy Cell Leukemia Variant,BIOLOGICAL: CD22CART cell infusion,1,NIH,other,NIH,Government,Phase I,hematologic,other,National Cancer Institute (NCI)
1176,United States,Neoplasms|High Grade Glioma|Glioblastoma Multiforme|Malignant Glioma of Brain|Anaplastic Astrocytoma of Brain|High-grade Glioma|Anaplastic Glioma|Giant Cell Glioblastoma,BIOLOGICAL: Biological G207,2,NETWORK,other,NETWORK,Network,Phase II,brain/CNS,other,Pediatric Brain Tumor Consortium
1177,United States,Non-Muscle Invasive Bladder Urothelial Carcinoma|Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma|Stage I Bladder Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Fluorouracil|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mitomycin|BIOLOGICAL: Pembrolizumab|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,genitourinary,checkpoint inhibitor,National Cancer Institute (NCI)
1178,China,Esophagogastric Junction Adenocarcinoma,DRUG: Adebrelimab (anti-PD-L1) + XELOX,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Ruijin Hospital
1179,China,Hepatocellular Carcinoma,DRUG: HAIC+STRIDE+Len,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Sulai Liu
1180,"Australia, Austria, Belgium, Brazil, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Republic of, Romania, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States","Carcinoma, Non-Small-Cell Lung",DRUG: Olomorasib|DRUG: Pembrolizumab|DRUG: Durvalumab|DRUG: Placebo,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,lung/thoracic,checkpoint inhibitor,Eli Lilly and Company
1181,France,Localized Oesogastric Adenocarcimona|MSI and or dMMR,DRUG: Nivolumab 10 MG/ML|DRUG: Ipilimumab 200 MG in 40 ML Injection,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,GERCOR - Multidisciplinary Oncology Cooperative Group
1182,Russian Federation,Primary Mediastinal Lymphoma,DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide Phosphate|DRUG: Prednisolone|DRUG: Rituximab|DRUG: Vincristine Sulfate|DRUG: Filgrastim|DRUG: Pegfilgrastim|DRUG: Nivolumab 40 mg in 4 ml Injection,3,NETWORK,checkpoint inhibitor,NETWORK,Network,Phase III,hematologic,checkpoint inhibitor,"National Research Center for Hematology, Russia"
1183,China,Cholangiocarcinoma,COMBINATION_PRODUCT: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil,2,OTHER,combination product,OTHER,Other,Phase II,other,combination product,West China Hospital
1184,"Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Malaysia, New Zealand, Norway, Poland, Republic of, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States",Hepatocellular Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Placebo,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,digestive,checkpoint inhibitor,Merck Sharp & Dohme LLC
1185,"Mexico, United States",Borderline Resectable Pancreatic Adenocarcinoma,BIOLOGICAL: Aglatimagene besadenovec|RADIATION: Chemoradiation|RADIATION: Stereotactic body radiation therapy|PROCEDURE: Surgery,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,digestive,radiotherapy,"Candel Therapeutics, Inc."
1186,United States,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Tisagenlecleucel,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Memorial Sloan Kettering Cancer Center
1187,United States,Glioblastoma|Malignant Glioma|Recurrent Glioblastoma|Recurrent Glioma,DRUG: CARv3-TEAM-E T cells,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,"Marcela V. Maus, M.D.,Ph.D."
1188,China,Esophageal Squamous Cell Carcinoma,DRUG: Serplulimab|DRUG: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)|DRUG: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)|RADIATION: Radiotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Fujian Medical University Union Hospital
1189,China,Liver Carcinoma|Hepatic Cell Carcinoma,BIOLOGICAL: CAR-GPC3 T cells,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,digestive,other,"Shanghai Ming Ju Biotechnology Co., Ltd."
1190,China,Nasopharyngeal Carcinoma,"DRUG: Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|DRUG: Apatinib, Camrelizumab|DRUG: Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|DRUG: Chemotherapy (gemcitabine/ capecitabine/ docetaxel)",2,OTHER,other,OTHER,Other,Phase II,head/neck,chemotherapy,Sun Yat-sen University
1191,Australia,Endometrial Cancer Stage I|Mmr Deficiency|Endometrioid Endometrial Adenocarcinoma|Immune-related Adverse Event,DRUG: Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI],2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,gynecologic,other,Queensland Centre for Gynaecological Cancer
1192,United States,Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Ambiguous Lineage Leukemia or Lymphoma|Myeloma,DRUG: FLT,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,University of Oklahoma
1193,United States,"Myeloma-Multiple|Myeloma, Plasma-Cell",DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells,1,NIH,other,NIH,Government,Phase I,hematologic,other,National Cancer Institute (NCI)
1194,United States,Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Carcinoma|Head and Neck Cancer Stage IV|Head and Neck Cancer Stage III|HPV-Related Carcinoma|HPV-Related Malignancy|HPV-Related Squamous Cell Carcinoma,DRUG: IPI-549,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,Ezra Cohen
1195,United States,T-cell Acute Lymphoblastic Leukemia|T-Cell Acute Lymphoblastic Lymphoma,DRUG: Daratumumab,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,New York Medical College
1196,Netherlands,Gastric Adenocarcinoma|Esophageal Adenocarcinoma,DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Retifanlimab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
1197,China,Esophageal Squamous Cell Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Cisplatin|RADIATION: neoadjuvant chemoradiotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,digestive,checkpoint inhibitor,Tianjin Medical University Cancer Institute and Hospital
1198,China,Nasopharyngeal Carcinoma,DRUG: camrelizumab|RADIATION: stereotactic body radiotherapy,3,OTHER,other,OTHER,Other,Phase III,head/neck,radiotherapy,Sun Yat-sen University
1199,France,Adenocarcinoma - GEJ|Gastric Adenocarcinoma,DRUG: Dostarlimab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,GERCOR - Multidisciplinary Oncology Cooperative Group
1200,Australia,Cutaneous Squamous Cell Carcinoma,DRUG: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Melanoma Institute Australia
1201,France,Squamous Cell Anal Carcinoma|Metastatic Squamous Cell Carcinoma,BIOLOGICAL: Sample collection,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Centre Hospitalier Universitaire de Besancon
1202,"Argentina, Australia, Brazil, Chile, China, Costa Rica, Czechia, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Malaysia, Mexico, Philippines, Portugal, Republic of, Romania, South Africa, Spain, Turkey, Ukraine, United States","Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: pembrolizumab/vibostolimab|BIOLOGICAL: durvalumab|DRUG: cisplatin|DRUG: pemetrexed|DRUG: etoposide|DRUG: carboplatin|DRUG: paclitaxel|RADIATION: thoracic radiotherapy,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,lung/thoracic,checkpoint inhibitor,Merck Sharp & Dohme LLC
1203,United States,Melanoma Stage III|Melanoma Stage IV|Skin Cancer Stage III|Skin Cancer Stage IV|Drug-Induced Colitis|Drug Toxicity|Immune-related Adverse Event,DRUG: Infliximab|DRUG: Methylprednisolone|DRUG: Prednisone,2,OTHER,other,OTHER,Other,Phase II,skin,other,Massachusetts General Hospital
1204,United Kingdom,Acute Lymphoblastic Leukemia,PROCEDURE: Leukapheresis|RADIATION: Total Body Irradiation (TBI)|DRUG: Lymphodepletion with Fludarabine|DRUG: Lymphodepletion with Cyclophosphamide|BIOLOGICAL: CD19+CD22 CAR T-cells,1,OTHER,other,OTHER,Other,Phase I,hematologic,radiotherapy,"University College, London"
1205,China,SBRT,COMBINATION_PRODUCT: SBRT+chemoimmunotherapy,2,OTHER,combination product,OTHER,Other,Phase II,other,combination product,Sun Yat-sen University
1206,United States,Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma,DRUG: XL092|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Karie Runcie
1207,"Australia, Brazil, Canada, Colombia, Denmark, France, Israel, Norway, Portugal, Republic of, Romania, Spain, Taiwan, United Kingdom, United States",Squamous Cell Carcinoma of Head and Neck,DRUG: Lenvatinib|BIOLOGICAL: Pembrolizumab|DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Cetuximab|DRUG: Lenvatinib,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,head/neck,checkpoint inhibitor,Merck Sharp & Dohme LLC
1208,United States,High Grade Glioma|Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma,BIOLOGICAL: PEP-CMV|DRUG: Temozolomide|BIOLOGICAL: Tetanus Diphtheria Vaccine,2,OTHER,cancer vaccine,OTHER,Other,Phase II,brain/CNS,cancer vaccine,Nationwide Children's Hospital
1209,China,Adrenocortical Carcinoma,DRUG: Triprolizumab|DEVICE: rodiotherapy,2,OTHER,other,OTHER,Other,Phase II,other,other,Sun Yat-sen University
1210,Indonesia,Hepatocellular Carcinoma,DRUG: Autologous Natural Killer Cell Therapy|DEVICE: Clinimacs Plus,1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,digestive,adoptive cell therapy,Dr Cipto Mangunkusumo General Hospital
1211,China,Lung Squamous Cell Carcinoma,RADIATION: low-dose radiation therapy and stereotactic body radiation therapy|DRUG: chemotherapy|DRUG: Sintilimab,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,radiotherapy,Sichuan University
1212,China,Untreated Mantle Cell Lymphoma,DRUG: zanubrutinib and rituximab|DRUG: zanubrutinib and rituximab|DRUG: BEAM pretreatment|DRUG: zanubrutinib maintenance,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,The First Affiliated Hospital of Soochow University
1213,China,Collecting Duct Carcinoma,DRUG: PD-(L)1 inhibitor|DRUG: Axitinib,2,OTHER,other,OTHER,Other,Phase II,other,other,Peking University Cancer Hospital & Institute
1214,"Australia, Austria, Belgium, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States",Advanced Melanoma,DRUG: Tebentafusp|DRUG: Tebentafusp with Pembrolizumab|DRUG: Investigators Choice,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,skin,checkpoint inhibitor,Immunocore Ltd
1215,China,Hepatocellular Carcinoma,DRUG: Donafenib + Envafolimab,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,digestive,other,Anhui Provincial Hospital
1216,China,Rectal Adenocarcinoma,DRUG: Adebrelimab|DRUG: Oxaliplatin|DRUG: Capecitabine|RADIATION: Short-course Radiation|PROCEDURE: Biopsy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sir Run Run Shaw Hospital
1217,China,Melanoma of Skin|Acral Melanoma|Stage II Melanoma,DRUG: Toripalimab combined with Endostar,2,OTHER,other,OTHER,Other,Phase II,skin,other,Fudan University
1218,United States,Small Cell Neuroendocrine Carcinoma of Bladder|Bladder Cancer|Urothelial Carcinoma Bladder,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|PROCEDURE: Cystectomy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1219,Germany,Hepatocellular Carcinoma Non-resectable|HCC,DRUG: Tremelimumab|DRUG: Durvalumab|PROCEDURE: Y-90 SIRT|PROCEDURE: DEB-TACE,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
1220,China,Nasopharyngeal Carcinoma|De-escalation Therapy,DRUG: Cisplatin-based induction chemotherapy|DRUG: Full course of PD-1/PD-L1 blockades|RADIATION: Reduced-dose IMRT|RADIATION: Standard-dose IMRT|DRUG: Concurrent Chemotherapy,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,head/neck,checkpoint inhibitor,Sun Yat-sen University
1221,China,Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy,"DRUG: AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally",2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,genitourinary,checkpoint inhibitor,RenJi Hospital
1222,Australia,Cutaneous Squamous Cell Carcinoma of the Head and Neck|Head and Neck Cancer,DRUG: Pembrolizumab,2,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase II,head/neck,checkpoint inhibitor,Queensland Health
1223,United States,"Lymphoma|Lymphoma, Large B-Cell, Diffuse",DRUG: Glofitamab|DRUG: Polatuzumab|DRUG: Rituximab|DRUG: Doxorubicin Hydrochloride|DRUG: Cyclophosphamide|DRUG: Prednisone,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,"Jennifer Crombie, MD"
1224,United States,Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia,DRUG: Asparaginase Erwinia chrysanthemi|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration|DRUG: Calaspargase Pegol|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin|DRUG: Dexamethasone|DRUG: Doxorubicin|PROCEDURE: Echocardiography Test|PROCEDURE: FDG-Positron Emission Tomography|DRUG: Leucovorin|DRUG: Levoleucovorin|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methylprednisolone|PROCEDURE: Multigated Acquisition Scan|DRUG: Prednisolone|DRUG: Prednisone|DRUG: Therapeutic Hydrocortisone|DRUG: Thioguanine|DRUG: Venetoclax|DRUG: Vincristine,2,NIH,other,NIH,Government,Phase II,hematologic,other,National Cancer Institute (NCI)
1225,United States,B Cell Leukemia,BIOLOGICAL: Autologous CD19 CAR+ EGFTt + T cells,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,Seattle Children's Hospital
1226,Italy,Colorectal Cancer|Resectable Colorectal Carcinoma,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Panitumumab|DRUG: Botensilimab|DRUG: Balstilimab|DRUG: Sotorasib|DRUG: Vorbipiprant|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Gruppo Oncologico del Nord-Ovest
1227,"Denmark, France, United Kingdom",Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma,DRUG: Nivolumab cohort 1|DRUG: Nivolumab cohort 2,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,hematologic,checkpoint inhibitor,"Gustave Roussy, Cancer Campus, Grand Paris"
1228,China,Hepatocellular Carcinoma,DRUG: Tislelizumab + Sitravatinib,2,OTHER_GOV,other,OTHER_GOV,Government,Phase II,digestive,other,Anhui Provincial Hospital
1229,China,Gastric/Gastroesophageal Junction Adenocarcinoma,DRUG: Paclitaxel for injection (albumin-bound)|DRUG: Adebrelimab|DRUG: Apatinib mesylate,2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,The First Affiliated Hospital of Xiamen University
1230,"Guam, United States",Skin Angiosarcoma|Skin Radiation-Related Angiosarcoma|Visceral Angiosarcoma,PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: FDG-Positron Emission Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,skin,checkpoint inhibitor,National Cancer Institute (NCI)
1231,China,Esophageal Squamous Cell Carcinoma (ESCC)|Neoantigen-loaded Dendritic Cell Vaccine|Immune Checkpoint Inhibitors (ICIs),BIOLOGICAL: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac),2,OTHER,cancer vaccine,OTHER,Other,Phase II,digestive,cancer vaccine,Sichuan University
1232,United States,"B Cell Lymphoma|Lymphoma|Lymphoma, B-Cell|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma",DRUG: Pembrolizumab|DRUG: R-CHOP Protocol,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,hematologic,checkpoint inhibitor,University of Chicago
1233,"Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Hong Kong, Hungary, Italy, Japan, Norway, Poland, Republic of, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom, United States",Hodgkin Lymphoma,DRUG: brentuximab vedotin|DRUG: doxorubicin|DRUG: bleomycin|DRUG: vinblastine|DRUG: dacarbazine,3,INDUSTRY,other,INDUSTRY,Industry,Phase III,hematologic,other,Takeda
1234,China,"Carcinoma, Non-Small-Cell Lung",DRUG: Sugemalimab and Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,lung/thoracic,chemotherapy,Hunan Cancer Hospital
1235,United States,"Newly Diagnosed Glioblastoma|Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype|Gliosarcoma|Glioblastoma Multiforme",DRUG: Balstilimab|DRUG: Botensilimab|DRUG: Liposomal Doxorubicin|DEVICE: Sonocloud-9 (SC-9),2,OTHER,other,OTHER,Other,Phase II,brain/CNS,other,Northwestern University
1236,Germany,Esophagus Adenocarcinoma,DRUG: Durvalumab|DRUG: FLOT|DRUG: mFOLFOX-6|RADIATION: Radiotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
1237,United States,Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia,BIOLOGICAL: Anti-CD33 CAR T-cells|PROCEDURE: Lymphodepletion Therapy,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,City of Hope Medical Center
1238,China,Nasopharyngeal Carcinoma,"DRUG: Camrelizumab, gemcitabin, cisplatin|RADIATION: Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy",2,OTHER,other,OTHER,Other,Phase II,head/neck,radiotherapy,Sun Yat-sen University
1239,China,NSCLC|Neoadjuvant Immunotherapy|Low Dose Radiotherapy|Sintilimab,RADIATION: Experimental|DRUG: Active comparator,2,OTHER,other,OTHER,Other,Phase II,other,radiotherapy,Anhui Provincial Cancer Hospital
1240,United States,Glioblastoma,DRUG: Bevacizumab|DRUG: PD-L1 t-haNK|DRUG: N-803,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,brain/CNS,checkpoint inhibitor,"ImmunityBio, Inc."
1241,China,Esophageal Squamous Cell Carcinoma (ESCC)|Immunotherapy,RADIATION: low-dose involved-field radiotherapy combined with immunochemotherapy,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Sichuan University
1242,Russian Federation,"Acute Lymphoblastic Leukemia, Pediatric|ALL, Infants",COMBINATION_PRODUCT: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.,3,OTHER,combination product,OTHER,Other,Phase III,hematologic,combination product,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology"
1243,United States,"B-Cell Chronic Lymphocytic Leukemia|B-Lymphocytic Leukemia, Chronic|Chronic Lymphocytic Leukemia|Leukemia, Chronic Lymphatic|Leukemia, Chronic Lymphocytic, B-Cell|Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphocytic Leukemia, Chronic, B Cell|Lymphocytic Leukemia, Chronic, B-Cell",DRUG: Ibrutinib|DRUG: Fludarabine|DRUG: Pembrolizumab,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,hematologic,checkpoint inhibitor,"National Heart, Lung, and Blood Institute (NHLBI)"
1244,United Kingdom,Renal Cell Carcinoma,DRUG: Durvalumab|DRUG: Tremelimumab,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,genitourinary,checkpoint inhibitor,"University College, London"
1245,"Denmark, Norway, Sweden",Soft Tissue Sarcoma Adult|Angiosarcoma|Undifferentiated Pleomorphic Sarcoma,DRUG: Propranolol|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,sarcoma,checkpoint inhibitor,Niels Junker
1246,China,Nasopharyngeal Carcinoma,DRUG: Anrotinib plus Tirelizumab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,"Zhongshan People's Hospital, Guangdong, China"
1247,United States,T Cell Non-Hodgkin Lymphoma,DRUG: Senza5 CART5,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,Vittoria Biotherapeutics
1248,China,Epithelial Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma,COMBINATION_PRODUCT: DCVAC/OvCa|COMBINATION_PRODUCT: Placebo,2,OTHER,combination product,OTHER,Other,Phase II,gynecologic,combination product,Peking University Third Hospital
1249,United States,Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|Pancreatic Ductal Adenocarcinoma,DRUG: Pembrolizumab|DRUG: Defactinib,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,The University of Texas Health Science Center at San Antonio
1250,China,Hepatocellular Carcinoma,RADIATION: Stereotactic body radiotherapy|DRUG: Adebrelimab|DRUG: Lenvatinib,2,OTHER,other,OTHER,Other,Phase II,digestive,radiotherapy,Mian XI
1251,China,Advanced Urothelial Carcinoma|Probiotics|Immunotherapy,DRUG: Probiotics Compound (Biolosion)|DRUG: Nab-paclitaxel|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Disitamab vedotin|DRUG: Enfortumab Vedotin|DRUG: Pembrolizumab|DRUG: Toripalimab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Sun Yat-sen University
1252,China,Esophageal Squamous Cell Carcinoma,RADIATION: Intensity-modulated radiotherapy (IMRT)|DRUG: Tislelizumab|DRUG: Cisplatin|DRUG: Nab paclitaxel,3,OTHER,other,OTHER,Other,Phase III,digestive,radiotherapy,Renmin Hospital of Wuhan University
1253,China,Head and Neck Squamous Cell Carcinoma,DRUG: Pembrolizumab combined with Chemotherapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Yuankai Shi
1254,France,HCC - Hepatocellular Carcinoma,DRUG: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Assistance Publique - Hôpitaux de Paris
1255,United States,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma,BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|OTHER: Laboratory Biomarker Analysis,1,OTHER,other,OTHER,Other,Phase I,hematologic,biomarker / diagnostics,City of Hope Medical Center
1256,China,Recurrent Nasopharyngeal Carcinoma,DRUG: Toripalimab,3,OTHER,other,OTHER,Other,Phase III,head/neck,other,Cancer Hospital of Guangxi Medical University
1257,China,Esophageal Squamous Cell Carcinoma,DRUG: Adebrelimab|DRUG: Dalpiciclib 100mg|DRUG: Dalpiciclib 150mg,1,OTHER,other,OTHER,Other,Phase I,digestive,other,West China Hospital
1258,Spain,"Lung Diseases|Carcinoma, Non-Small-Cell Lung|Resectable Lung Non-Small Cell Carcinoma",DRUG: Zimberelimab|DRUG: Sacituzumab govitecan|DRUG: Cisplatin|DRUG: Carboplatin,3,OTHER,other,OTHER,Other,Phase III,lung/thoracic,chemotherapy,Fundación GECP
1259,United States,Hepatocellular Carcinoma,BIOLOGICAL: RP2|BIOLOGICAL: Bevacizumab|BIOLOGICAL: Atezolizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,Replimune Inc.
1260,China,Advanced Hepatocellular Carcinoma,DRUG: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Tianjin Medical University Cancer Institute and Hospital
1261,Australia,Melanoma,DRUG: Standard therapy or clinical trial|DRUG: Matched targeted therapy|DRUG: Trametinib and / or supportive care|DRUG: CDK4/6 and MEK inhibitor|DRUG: Compassionate Access Targeted Therapy,2,OTHER,other,OTHER,Other,Phase II,skin,other,Melanoma Institute Australia
1262,China,Radiotherapy|PD-1 Inhibitor|Capecitabine|Nasopharyngeal Carcinoma,RADIATION: SBRT radiotherapy + Conventionally fractionated radiotherapy|DRUG: PD-1 inhibitor|DRUG: Capecitabine,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,"Fifth Affiliated Hospital, Sun Yat-Sen University"
1263,China,Esophageal Squamous Cell Carcinoma,DRUG: QL1706,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Tianjin Medical University Cancer Institute and Hospital
1264,China,Precursor B-Cell Acute Lymphoblastic Leukemia,DRUG: Blinatumomab plus Reduced-dose Chemotherapy,2,OTHER,other,OTHER,Other,Phase II,hematologic,chemotherapy,First Affiliated Hospital of Zhejiang University
1265,"Canada, United States",Nodular Lymphocyte Predominant B-Cell Lymphoma|Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma|Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|BIOLOGICAL: Mosunetuzumab|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab|BIOLOGICAL: Rituximab and Hyaluronidase Human,2,NIH,other,NIH,Government,Phase II,hematologic,other,National Cancer Institute (NCI)
1266,United States,Relapsed B-Cell Acute Lymphoblastic Leukemia,PROCEDURE: leukapheresis or collection of PBMCs|DRUG: cyclophosphamide based chemotherapy regimens|BIOLOGICAL: modified T cells,1,OTHER,other,OTHER,Other,Phase I,hematologic,chemotherapy,Memorial Sloan Kettering Cancer Center
1267,China,Rectal Squamous Cell Carcinoma,COMBINATION_PRODUCT: PD-1 and CRT,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,"Sixth Affiliated Hospital, Sun Yat-sen University"
1268,China,Esophageal Squamous Cell Carcinoma,"DRUG: Adebrelimab: 20mg/kg day1, Q3W, 3 times",2,OTHER,other,OTHER,Other,Phase II,digestive,other,"Nanfang Hospital, Southern Medical University"
1269,United States,Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC),DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Dan Zandberg
1270,China,Nasopharyngeal Carcinoma,DRUG: PD-1 blocking antibody|DRUG: Gemcitabine|DRUG: Cisplatin (80 mg/m2)|RADIATION: Reduced-dose Intensity-modulated radiotherapy|RADIATION: Conventional-dose Intensity-modulated radiotherapy|DRUG: Cisplatin (100 mg/m2)|DRUG: Capecitabine,3,OTHER,checkpoint inhibitor,OTHER,Other,Phase III,head/neck,checkpoint inhibitor,Sun Yat-sen University
1271,United States,Advanced Non-squamous Non-small-cell Lung Cancer|Advanced Squamous Non-Small Cell Lung Carcinoma|Metastatic Non-squamous Non Small Cell Lung Cancer|Metastatic Squamous Non-Small Cell Lung Carcinoma|Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Stage III|Non-small Cell Lung Cancer Stage IV|Non-small Cell Lung Cancer Recurrent,"BIOLOGICAL: Olvimulogene nanivacirepvec|DRUG: Platinum chemotherapy: carboplatin or cisplatin|DRUG: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC|DRUG: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab|DRUG: Docetaxel",2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,lung/thoracic,checkpoint inhibitor,Genelux Corporation
1272,"Australia, Austria, Belgium, Brazil, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Norway, Singapore, Spain, Switzerland, Taiwan, United Kingdom, United States",Non-Hodgkin Lymphoma,DRUG: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|DRUG: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT),3,INDUSTRY,other,INDUSTRY,Industry,Phase III,hematologic,chemotherapy,Novartis Pharmaceuticals
1273,China,Head and Neck Squamous Cell Carcinoma,DRUG: Camrelizumab|DRUG: Dalpiciclib 100mg|DRUG: Dalpiciclib 150mg,1,OTHER,other,OTHER,Other,Phase I,head/neck,other,West China Hospital
1274,United States,"Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Neoplasms, Head and Neck|Unresectable Head and Neck Squamous Cell Carcinoma",COMBINATION_PRODUCT: Combination Treatment of PDS0101 and Pembrolizumab|DRUG: Pembrolizumab Monotherapy,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,head/neck,checkpoint inhibitor,PDS Biotechnology Corp.
1275,Israel,Esophageal Squamous Cell Carcinoma,DRUG: Cisplatin|DRUG: 5-FU|RADIATION: Radiation therapy|DRUG: Cetuximab|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Baruch Brenner
1276,Italy,"Myasthenia Gravis, Generalized",DRUG: Rituximab|OTHER: Placebo,3,OTHER,other,OTHER,Other,Phase III,other,other,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1277,"Israel, Puerto Rico, United States",B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration and Biopsy|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|PROCEDURE: Echocardiography Test|PROCEDURE: Electrocardiography|PROCEDURE: Lumbar Puncture|DRUG: Mesna|DRUG: Methotrexate|PROCEDURE: Multigated Acquisition Scan|DRUG: Ponatinib Hydrochloride|DRUG: Prednisone|DRUG: Vincristine Sulfate,3,NIH,other,NIH,Government,Phase III,hematologic,other,National Cancer Institute (NCI)
1278,Australia,Extramedullary Myeloma,BIOLOGICAL: Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent,1,OTHER,combination product,OTHER,Other,Phase I,hematologic,combination product,"Peter MacCallum Cancer Centre, Australia"
1279,China,Renal Cell Carcinoma (RCC),DRUG: Toripalimab|DRUG: Lenvatinib,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,"Jinling Hospital, China"
1280,China,Gastric or Gastroesophageal Junction Adenocarcinoma,DRUG: LM-302+Candonilimab+Capecitabine,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Shanghai Zhongshan Hospital
1281,Canada,Non-small Cell Carcinoma,DRUG: Binimetinib|DRUG: Pembrolizumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,other,checkpoint inhibitor,"University Health Network, Toronto"
1282,United States,Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma,DRUG: VG161|DRUG: Nivolumab Injection [Opdivo],2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,Virogin Biotech Canada Ltd
1283,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Therapy,"COMBINATION_PRODUCT: Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|PROCEDURE: Esophagectomy|OTHER: sample",2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
1284,United States,Multiple Myeloma|Smoldering Multiple Myeloma,DRUG: Ciltacabtagene Autoleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Dana-Farber Cancer Institute
1285,China,Clinical IVb Stage Oral Squamous Cell Carcinomas Patients,DRUG: Adebrelimab,2,OTHER,other,OTHER,Other,Phase II,head/neck,other,"Hospital of Stomatology, Wuhan University"
1286,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Chemoimmunotherapy|Adjuvant Therapy,DRUG: Tislelizumab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,Guo Xufeng
1287,United States,Hodgkin's Lymphoma|Non-Hodgkin Lymphoma,GENETIC: CAR T Cells,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,Baylor College of Medicine
1288,United States,Multiple Myeloma,DRUG: Cyclophosphamide|DRUG: Ciltacabtagene Autoleucel|RADIATION: Total body irradiation,1,OTHER,other,OTHER,Other,Phase I,hematologic,radiotherapy,Washington University School of Medicine
1289,France,Advanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma,DRUG: Bintrafusp alfa|DRUG: Doxorubicin,2,OTHER,other,OTHER,Other,Phase II,sarcoma,other,Institut Bergonié
1290,China,Myelodysplastic Syndromes|Dendritic Cell|Hypomethylating Agents|Immunotherapy,BIOLOGICAL: DC vaccine,1,OTHER,cancer vaccine,OTHER,Other,Phase I,other,cancer vaccine,Affiliated Hospital to Academy of Military Medical Sciences
1291,Israel,Advanced Glioblastoma|Metastatic Melanoma in the Central Nervous System|MGMT-Unmethylated Glioblastoma,DRUG: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|DRUG: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO],2,OTHER_GOV,checkpoint inhibitor,OTHER_GOV,Government,Phase II,skin,checkpoint inhibitor,Sheba Medical Center
1292,China,Neoadjuvant Immunotherapy,DRUG: tislelizumab+disitamab-vedotin,2,OTHER,other,OTHER,Other,Phase II,other,other,Tianjin Medical University Second Hospital
1293,United Kingdom,"Leukemia, Lymphoblastic, Acute, Lymphoma",BIOLOGICAL: CD19CAT-41BBZ CAR T-cells,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,"University College, London"
1294,China,Diffuse Large B Cell Lymphoma,DRUG: autologous hematopoietic stem cell,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Ruijin Hospital
1295,Italy,Follicular Lymphoma,RADIATION: Radiotherapy|OTHER: Radiotherapy plus Obinutuzumab,3,OTHER,other,OTHER,Other,Phase III,hematologic,radiotherapy,Fondazione Italiana Linfomi - ETS
1296,United States,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,PROCEDURE: CS1-CAR T Therapy|DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: Leukapheresis,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,City of Hope Medical Center
1297,Italy,Sinonasal Undifferentiated Carcinoma,DRUG: Pembrolizumab|DRUG: Cisplatin|DRUG: Docetaxel|DRUG: Carboplatin,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Istituti Clinici Scientifici Maugeri SpA
1298,China,Relapsed/Refractory Multiple Myeloma|Plasma Cell Leukemia,DRUG: CAR-GPRC5D,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,"Nanjing IASO Biotechnology Co., Ltd."
1299,United States,Hepatocellular Carcinoma,DRUG: Nivolumab|DRUG: Relatlimab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1300,United States,"Follicular Lymphoma|Low Grade Non-Hodgkin's Lymphoma, Adult",DRUG: Epcoritamab|DRUG: Rituximab,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,"Reid Merryman, MD"
1301,China,Relapsed/Refractory Multiple Myeloma|Plasma Cell Leukemia,DRUG: CAR-T (CAR-GPRC5D),1,OTHER,adoptive cell therapy,OTHER,Other,Phase I,hematologic,adoptive cell therapy,Chunrui Li
1302,United Kingdom,Relapsed Follicular Lymphoma|Refractory Follicular Lymphoma,DRUG: Epcoritamab|DRUG: Lenalidomide|DRUG: Rituximab|DRUG: Obinutuzumab|DRUG: Bendamustine|DRUG: Vincristine|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Prednisone|DRUG: Investigation agent 2|DRUG: Investigation agent 3,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,University of Birmingham
1303,China,Cadonilimab|Clear Cell Renal Cell Carcinoma|Neoadjuvant Therapy,DRUG: Cadonilimab Combined With Lenvatinib,2,OTHER,other,OTHER,Other,Phase II,genitourinary,other,Sun Yat-sen University
1304,United States,Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma,DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|RADIATION: Proton Beam Radiation Therapy,2,NIH,checkpoint inhibitor,NIH,Government,Phase II,head/neck,checkpoint inhibitor,National Cancer Institute (NCI)
1305,United States,Myelodysplastic Syndromes,DRUG: SX-682|DRUG: Decitabine,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,other,other,"Syntrix Biosystems, Inc."
1306,"Canada, Denmark, France, Italy, Spain, United Kingdom, United States",Relapsed or Refractory Classical Hodgkin Lymphoma,DRUG: Sabestomig (AZD7789),1,INDUSTRY,other,INDUSTRY,Industry,Phase I,hematologic,other,AstraZeneca
1307,China,Clear Cell Renal Cell Carcinoma,DRUG: 68Ga-NY104 PET/CT|DRUG: 18F-FDG PET/CT|RADIATION: Radiation Therapy|DRUG: Systemic therapy,2,OTHER,other,OTHER,Other,Phase II,genitourinary,radiotherapy,Peking Union Medical College Hospital
1308,United States,Urothelial Carcinoma Bladder,DRUG: Sasanlimab|RADIATION: Stereotactic Body Radiation Therapy|PROCEDURE: Radical Cystectomy + pelvic lymph node dissection + urinary diversion,2,OTHER,other,OTHER,Other,Phase II,genitourinary,radiotherapy,The Methodist Hospital Research Institute
1309,Italy,Intrahepatic Cholangiocarcinoma,RADIATION: radioembolization with Y-90|DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,other,checkpoint inhibitor,Francesco De Cobelli
1310,United States,"Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-Mutant",BIOLOGICAL: rHSC-DIPGVax|DRUG: Balstilimab|DRUG: Zalifrelimab,1,OTHER,other,OTHER,Other,Phase I,brain/CNS,other,Ann & Robert H Lurie Children's Hospital of Chicago
1311,"Australia, Austria, Czechia, Germany, Israel, Italy, Slovakia, Switzerland","Acute Lymphoblastic Leukemia, Pediatric",DRUG: Blinatumomab|DRUG: Bortezomib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin|DRUG: Myocet|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Etoposide|DRUG: Fludarabine Phosphate|DRUG: Ifosfamide|DRUG: 6-Mercaptopurine|DRUG: Methotrexate|DRUG: Pegaspargase|DRUG: Prednisolone|DRUG: Tioguanin|DRUG: Vincristine|DRUG: Vindesine|DRUG: Erwinase,3,OTHER,other,OTHER,Other,Phase III,hematologic,other,Martin Schrappe
1312,"Canada, Italy, Spain",Hepatocellular Carcinoma,DRUG: Tremelimumab,2,OTHER,other,OTHER,Other,Phase II,digestive,other,"University Health Network, Toronto"
1313,Canada,Relapsed or Refractory CD19+ B-cell Lymphoma|Relapsed or Refractory Chronic Lymphocytic Leukemia|Relapsed or Refractory Small Lymphocytic Lymphoma,BIOLOGICAL: TBI-2001|DRUG: Cyclophosphamide|DRUG: Fludarabine,1,OTHER,other,OTHER,Other,Phase I,hematologic,other,"University Health Network, Toronto"
1314,China,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: ICAR19 CAR-T cells,1,INDUSTRY,adoptive cell therapy,INDUSTRY,Industry,Phase I,hematologic,adoptive cell therapy,"Immune Cell, Inc."
1315,United States,Follicular Lymphoma|Marginal Zone Lymphoma|Indolent Non-hodgkin Lymphoma,DRUG: Obinutuzumab|DRUG: Glofitamab,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,"Reid Merryman, MD"
1316,United States,"Soft Tissue Sarcoma|Sarcoma,Soft Tissue",DRUG: Talimogene Laherparepvec|RADIATION: Neoadjuvant Radiation|PROCEDURE: Surgery,2,OTHER,other,OTHER,Other,Phase II,sarcoma,radiotherapy,John Rieth
1317,"Spain, United States",Monoclonal Gammopathy of Undetermined Significance (MGUS)|Smoldering Multiple Myeloma (SMM),DRUG: Linvoseltamab,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,hematologic,other,Regeneron Pharmaceuticals
1318,"Malaysia, Singapore",B Lymphoblastic Leukemia,DRUG: Prednisolone|DRUG: Dexamethasone|DRUG: Vincristine|DRUG: Methotrexate|DRUG: L-Asparaginase|DRUG: Pegylated asparaginase|DRUG: Erwinase|DRUG: Dasatinib|DRUG: Imatinib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Thioguanine|DRUG: Rituximab|DRUG: Doxorubicin|DRUG: Fludarabine,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,"National University Hospital, Singapore"
1319,China,C-staged Hepatocellular Carcinoma in BCLC Classification,COMBINATION_PRODUCT: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab,2,OTHER,combination product,OTHER,Other,Phase II,digestive,combination product,Sun Yat-sen University
1320,Russian Federation,Hodgkin Lymphoma,DRUG: Prolgolimab|DRUG: Combination with prolgolimab and bendamustine,2,OTHER,combination product,OTHER,Other,Phase II,hematologic,combination product,St. Petersburg State Pavlov Medical University
1321,United States,Fibrolamellar Hepatocellular Carcinoma (FLC),DRUG: DNAJB1-PRKACA peptide vaccine|DRUG: Nivolumab|DRUG: Ipilimumab,1,OTHER,checkpoint inhibitor,OTHER,Other,Phase I,digestive,checkpoint inhibitor,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1322,"Australia, Canada, France, Hungary, New Zealand, Poland, Romania, Serbia, Spain, United States",Relapsed Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-cell Lymphoma,DRUG: DPX-Survivac|DRUG: Pembrolizumab|DRUG: CPA,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,hematologic,checkpoint inhibitor,"ImmunoVaccine Technologies, Inc. (IMV Inc.)"
1323,United States,"Leukemia, B-Cell",GENETIC: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy,1,OTHER,other,OTHER,Other,Phase I,hematologic,chemotherapy,Baylor College of Medicine
1324,United States,Squamous Cell Carcinoma of Head and Neck,DRUG: Combination 5-azacytidine and nivolumab|DRUG: 5-azacytidine|DRUG: Nivolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,head/neck,checkpoint inhibitor,Barbara Burtness
1325,Spain,Squamous Cell Carcinoma of the Anal Canal,DRUG: Atezolizumab plus Tiraglolumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,digestive,checkpoint inhibitor,Grupo Espanol Multidisciplinario del Cancer Digestivo
1326,United States,T-Cell Lymphoma,DRUG: Brentuximab vedotin|DRUG: Pembrolizumab,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,hematologic,checkpoint inhibitor,Yale University
1327,"Japan, Taiwan, United States",Recurrent Head and Neck Squamous Cell Carcinoma,COMBINATION_PRODUCT: ASP-1929 Photoimmunotherapy|BIOLOGICAL: Pembrolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: 5-fluorouracil|DRUG: Paclitaxel|DRUG: Docetaxel,3,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase III,head/neck,checkpoint inhibitor,"Rakuten Medical, Inc."
1328,United Kingdom,Diffuse Large B Cell Lymphoma,DRUG: Pembrolizumab|DRUG: Rituximab|DRUG: Ifosfamide|DRUG: Carboplatin|DRUG: Etoposide,2,OTHER,checkpoint inhibitor,OTHER,Other,Phase II,hematologic,checkpoint inhibitor,University of Southampton
1329,Denmark,"Hepatitis, Drug-Induced",DRUG: Mycophenolate Mofetil|DRUG: Solu-Medrol|DRUG: Ursodeoxycholic acid|DRUG: Prednisone tablet,2,OTHER,other,OTHER,Other,Phase II,other,other,Inge Marie Svane
1330,China,Primary Mediastinal Diffuse Large B-cell Lymphoma,"DRUG: Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)",2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Sun Yat-sen University
1331,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Treatment,"DRUG: Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib|PROCEDURE: Esophagectomy|OTHER: Collecting samples from participant",2,OTHER,other,OTHER,Other,Phase II,digestive,chemotherapy,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
1332,United States,Metastatic Soft Tissue Sarcoma|Advanced Soft Tissue Sarcoma,DRUG: Balstilimab|DRUG: Zalifrelimab|DRUG: Doxorubicin|DRUG: Botensilimab,2,OTHER,other,OTHER,Other,Phase II,sarcoma,other,"University of Colorado, Denver"
1333,"Puerto Rico, United States",Hepatocellular Carcinoma,DRUG: Atezolizumab|DRUG: Bevacizumab,2,INDUSTRY,checkpoint inhibitor,INDUSTRY,Industry,Phase II,digestive,checkpoint inhibitor,"Genentech, Inc."
1334,New Zealand,"Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Transformed Non-Hodgkin Lymphoma",DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: WZTL-002 CAR T-cells,2,OTHER,other,OTHER,Other,Phase II,hematologic,other,Malaghan Institute of Medical Research
1335,United States,MuSK Myasthenia Gravis,BIOLOGICAL: MuSK-CAART,1,INDUSTRY,other,INDUSTRY,Industry,Phase I,other,other,Cabaletta Bio
1336,Australia,"HIV|Organ Transplantation|Lymphoma, Non-Hodgkin|Chronic Lymphocytic Leukemia|Multiple Myeloma|COVID-19 Vaccines",BIOLOGICAL: Pfizer Bivalent COVID-19 Vaccine|BIOLOGICAL: Moderna Bivalent mRNA vaccine,3,OTHER_GOV,cancer vaccine,OTHER_GOV,Government,Phase III,hematologic,cancer vaccine,Bayside Health
1337,"Canada, United States",Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B Cell Lymphoma|High Grade B-cell Lymphoma (HGBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Lymphoma|Central Nervous System Lymphoma|Mantle Cell Lymphoma (MCL)|Richter Transformation,BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Bendamustine,2,INDUSTRY,other,INDUSTRY,Industry,Phase II,hematologic,other,Miltenyi Biomedicine GmbH
1338,Norway,Glioblastoma,Autologous cancer stem cell mRNA transfected dendritic cells,12,Hospital/Clinic/Other health care facility,cancer vaccine,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,brain/CNS,cancer vaccine,Oslo University Hospital HF
1339,Netherlands,BRAF V600 mutation–positive unresectable or metastatic melanoma,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules, YERVOY 5 mg/ml concentrate for solution for infusion, Mektovi 15 mg film-coated tablets",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,skin,other,European Organisation For Research And Treatment Of Cancer
1340,France,pleural mesothelioma,ivonescimab,12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,Intergroupe Francophone De Cancerologie Thoracique
1341,Spain,Non-small cell lung cancer,"Placebo, CEMIPLIMAB",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,checkpoint inhibitor,European Organisation For Research And Treatment Of Cancer
1342,Spain,MSS and MSI colorectal and endometrial tumors,"DURVALUMAB, TREMELIMUMAB",12,Laboratory/Research/Testing facility,checkpoint inhibitor,Laboratory/Research/Testing facility,Academic,Phase I & II,gynecologic,checkpoint inhibitor,Vall D Hebron Institute Of Oncology
1343,Italy,"Cancer in the stomach or in the junction between the stomach and the oesophagus, without metastases in other organs and surgically resectable, with microsatellite instability and no EBV infection.","DURVALUMAB, TREMELIMUMAB",12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,digestive,checkpoint inhibitor,Gruppo Oncologico Del Nord Ovest
1344,Spain,Sarcomas,"Allogeneic peripheral blood-derived CD56+ natural killer cells, co-cultured with K562-mb15-41BBI cell line",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,sarcoma,other,"Hospital Universitario La Paz, Hospital Universitario La Paz"
1345,Hungary,"Neoplasms, Head and Neck",JEMPERLI 500 mg concentrate for solution for infusion,12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,head/neck,other,Glaxosmithkline Research & Development Limited
1346,France,Renal Cell Carcinoma,"IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Educational Institution,other,Educational Institution,Academic,Phase I & II,genitourinary,other,University College London
1347,Netherlands,"non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A","Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,"Universitaetsklinikum Essen AöR, Universitaetsklinikum Essen AöR"
1348,Netherlands,"Pancreatic cancer, Borderline resectable pancreatic cancer (BRPC)","Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Folikabi 10 mg/ml oplossing voor injectie/infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml, concentraat voor oplossing voor infusie",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Amsterdam UMC
1349,France,Unresectable stage III Non-Small Cell Lung Cancer,"LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN, PACLITAXEL",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,chemotherapy,Intergroupe Francophone De Cancerologie Thoracique
1350,France,Advanced Non-Small Cell Lung Cancer,"Carboplatine Hikma 450 mg/45 ml oplossing voor infusie, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quemliclustat, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatine Hikma 450 mg/45 ml Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml solution pour perfusion, Zimberelimab, CISPLATINE TEVA 1 mg/ml KONZENTRAT ZUR HERSTELLUNG EINER INFUSIONSLÖSUNG",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,chemotherapy,Gilead Sciences Inc.
1351,Netherlands,"dMMR tumors consisting of but not limited to; Colorectal cancer, oesophageal cancer, GEJ-cancer, Gastric cancer, Duodenal and small bowel cancer, endometrial cancer, breastcancer, prostate cancer and sarcoma. 
pMMR tumors: To be defined","BOTENSILIMAB, BALSTILIMAB",12,Laboratory/Research/Testing facility,other,Laboratory/Research/Testing facility,Academic,Phase I & II,gynecologic,other,Netherlands Cancer Institute
1352,Belgium,"Advanced-stage, relapsed/refractory cancer",KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,other,other,Imcheck Therapeutics
1353,Poland,HER2 negative breast cancer,"Paclitaxelum Accord, 6 mg/ml, koncentrat do sporządzania roztworu do infuzji, Carbomedac, 10 mg/ml, koncentrat do sporządzania roztworu do infuzji, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Natrium Chloratum 0,9% Baxter, roztwór do infuzji",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,breast,chemotherapy,Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
1355,Austria,Non-Small-Cell Lung Cancer,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib",12,Educational Institution,other,Educational Institution,Academic,Phase I & II,lung/thoracic,other,Medizinische Universitaet Innsbruck
1356,France,Metastatic non-small cell lung cancer (NSCLC),"Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Trajenta 5 mg film-coated tablets, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib",12,"Pharmaceutical company, Pharmaceutical company",other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,"F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG"
1359,Italy,Merkel cell carcinoma without metastases in other organs and surgically resectable,"ZYNYZ 500 mg concentrate for solution for infusion, CARBOPLATIN, ETOPOSIDE, CISPLATIN",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,other,chemotherapy,Gruppo Oncologico Del Nord Ovest
1360,Portugal,"Lung Cancer, Non-Small Cell","KEYTRUDA 25 mg/mL concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion",12,"Pharmaceutical company, Pharmaceutical company",other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,"Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited"
1361,France,Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.,"CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,breast,checkpoint inhibitor,Unicancer
1362,France,malignant pleural mesothelioma,"Gliolan 30 mg/ml powder for oral solution., OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Centre Hospitalier Universitaire De Lille
1363,Denmark,cancer,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Odense University Hospital
1365,France,Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer,"NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED",12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,checkpoint inhibitor,Intergroupe Francophone De Cancerologie Thoracique
1366,France,Synchronous oligometastatic non-small cell lung cancer (NSCLC),"CARBOPLATINE KABI 10 mg/ml, solution à diluer pour perfusion, YERVOY 5 mg/ml concentrate for solution for infusion, PACLITAXEL SANDOZ 6 mg/ml, solution à diluer pour perfusion, LIBTAYO 350 mg concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatine Accord 1 mg/ml concentraat voor oplossing voor infusie, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,chemotherapy,Institut Gustave Roussy
1367,France,"Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy","IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Unicancer
1368,France,MSI/dMMR tumors or EBV+ gastric cancer,KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Centre Leon Berard
1369,Spain,Resectable Non-small cell lung cancer,OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,Fundacion GECP
1370,Austria,Hepatocellular Carcinoma (Morpheus-Neo HCC),"Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, Tecentriq 1,200 mg concentrate for solution for infusion, RO7247669",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,F. Hoffmann-La Roche AG
1371,Germany,"Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)","Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung",12,Pharmaceutical company,adoptive cell therapy,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,chemotherapy,Swiss Group for Clinical Cancer Research
1372,Belgium,"Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC)","Tecentriq 1 200 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Oncobax®-AK, KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,genitourinary,other,Everimmune
1373,Italy,Adrenocortical carcinoma,"Lysodren 500 mg tablets, LIBTAYO 350 mg concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
1374,France,"MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IMMUNE INFILTRATE","KEYTRUDA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, CAPECITABINE BIOGARAN 500 mg, comprimé pelliculé, Avastin 25 mg/ml concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Fondation Franc.Cancerologie Digestive
1375,Netherlands,Cutaneous squamous cell carcinoma,"YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
1376,France,Cancer,"NIVOLUMAB, PEMBROLIZUMAB",1,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I,other,checkpoint inhibitor,Centre Hospitalier Regional De Marseille
1377,Spain,Triple negative breast cancer,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,breast,chemotherapy,"Unicancer, Institut Gustave Roussy"
1378,Italy,thyroid cancers,KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb
1379,France,Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer,"OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,gynecologic,chemotherapy,Unicancer
1380,Denmark,Colorectal Cancer,"Influvactetra, injektionsvæske, suspension i fyldt injektionssprøjte, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Influvac Tetra Saison 2024/2025 Injektionssuspension in einer Fertigspritze Influenza-Impfstoff aus Oberflächenantigen (inaktiviert)",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Zealand University Hospital
1381,Hungary,"Advanced epithelial ovarian, fallopian tube or peritoneal carcinoma","Powder for solution for infusion, Oregovomab",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,gynecologic,other,Canariabio Inc.
1382,Spain,peritoneal metastases of colorectal cancer,Mitomicina Accord 40 mg polvo para solución inyectable y para perfusión EFG,1,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I,digestive,other,Hospital Universitario De Fuenlabrada
1383,France,"Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Unicancer
1384,Italy,patients affected by small cell lung cancer (SCLC),Tecentriq 1 200 mg concentrate for solution for infusion,12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
1385,Italy,"Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)","PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB",12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,checkpoint inhibitor,Fondazione Centro Nazionale Di Adroterapia Oncologica
1386,France,Early and metastatic triple negative breast cancer,"CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Tecentriq 1,200 mg concentrate for solution for infusion, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, 68Ga-FAPI-46, Doxorubicin Accord Healthcare 2 mg/ml solution à diluer pour perfusion, Tiragolumab, Abraxane 5 mg/ml powder for dispersion for infusion.",12,"Laboratory/Research/Testing facility, Hospital/Clinic/Other health care facility",other,Laboratory/Research/Testing facility,Academic,Phase I & II,breast,chemotherapy,"Institut Curie, Institut Curie"
1387,Belgium,type B3 thymoma and thymic carcinoma,"IPILIMUMAB, NIVOLUMAB",12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,other,checkpoint inhibitor,European Organisation For Research And Treatment Of Cancer
1388,Germany,Male and female adult patients with locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment,"CISPLATIN, CARBOPLATIN, ETOPOSIDE, Tecentriq 1 200 mg concentrate for solution for infusion",12,Educational Institution,other,Educational Institution,Academic,Phase I & II,lung/thoracic,chemotherapy,Technische Universitaet Dresden
1389,Bulgaria,"Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients","MEDI4736 Placebo, DURVALUMAB",12,"Patient organisation/association, Patient organisation/association, Patient organisation/association, Educational Institution, Pharmaceutical company",checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,checkpoint inhibitor,"NVALT-studies Stichting, Intergroupe Francophone De Cancerologie Thoracique, Fundacion GECP, Queen's University, Clinipace Global Limited"
1390,France,"Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies","Zimberelimab, CALCIUM FOLINATE, FLUOROURACIL, OXALIPLATIN, DOMVANALIMAB, Quemliclustat",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,other,other,Arcus Biosciences Inc.
1391,Czechia,Endometrial cancer,"-, PACLITAXEL, DOXORUBICIN, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, MK-2870, -, -",12,Pharmaceutical company,combination product,Pharmaceutical company,Industry,Phase I & II,gynecologic,combination product,Merck Sharp & Dohme LLC
1392,France,Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC),"Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,head/neck,checkpoint inhibitor,Institut Gustave Roussy
1393,Italy,"Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer","KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,head/neck,other,Gruppo Oncologico Del Nord Ovest
1394,Norway,KRAS G12C-mutated non-small cell lung cancer,SOTORASIB,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Vestre Viken HF
1395,France,Metastatic or unresectable advanced rare sarcomas,"IPILIMUMAB, NIVOLUMAB, PAZOPANIB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,sarcoma,checkpoint inhibitor,Centre Leon Berard
1396,Netherlands,Cervical Cancer,,1,Hospital/Clinic/Other health care facility,unknown,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I,gynecologic,unknown,Amsterdam UMC
1398,Italy,Stage IIB-IIIB (N2) resectable non small cell lung cancer,"IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, CARBOPLATIN, CISPLATIN, PACLITAXEL, PEMETREXED",12,Laboratory/Research/Testing facility,other,Laboratory/Research/Testing facility,Academic,Phase I & II,lung/thoracic,chemotherapy,ETOP IBCSG Partners Foundation
1399,Norway,Non-small cell lung cancer (Stage IV),"Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Oslo University Hospital HF
1400,Italy,Non Small Cell Lung Cancer,DURVALUMAB,12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,checkpoint inhibitor,Fondazione IRCCS Policlinico San Matteo
1401,France,Soft Tissue Sarcoma,Tecentriq 1 200 mg concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,sarcoma,other,Centre Antoine Lacassagne
1402,France,"Poor general status, Non small cell lung cancer",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,Intergroupe Francophone De Cancerologie Thoracique
1403,Portugal,"Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases)","KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline Solution",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,skin,other,Merck Sharp & Dohme LLC
1404,Italy,Locoregional Hepatocellular Carcinoma (HCC),"INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, BEVACIZUMAB, MYCOPHENOLATE MOFETIL, Placebo",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,AstraZeneca AB
1405,Netherlands,"Resectable intermediate to high-risk clear cell RCC (according to RECIST 1.1) that can be biopsied, no history of distant metastases, naïve for CTLA-4/PD-1/PD-L1/LAG-3 directed immunotherapy, and more than 18 years old","RELATLIMAB, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
1408,France,"Non-small cell lung cancer (NSCLC):
- Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or
- Metastatic NSCLC","S095024/Sym024, S095018/Sym023, S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,Institut De Recherches Internationales Servier IRIS
1409,Italy,Endometrial cancer,"IMFINZI 50 mg/mL concentrate for solution for infusion., Ogivri 150 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Akynzeo 300 mg/0.5 mg hard capsules, Ogivri 420 mg powder for concentrate for solution for infusion, CARBOPLATINO Pfizer 10 mg/ml soluzione per infusione, Paclitaxel Kabi 6 mg/ml concentrato per soluzione per infusione, Akynzeo 300 mg/0.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tecentriq 1 200 mg concentrate for solution for infusion, Akynzeo 300 mg/0.5 mg hard capsules, JEMPERLI 500 mg concentrate for solution for infusion, Decadron “4 mg/1 ml Soluzione iniettabile”, Akynzeo 300 mg/0.5 mg hard capsules",1,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I,gynecologic,chemotherapy,Fondazione IRCCS Istituto Nazionale Dei Tumori
1410,France,Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.,"CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,chemotherapy,Institut Bergonie
1411,Spain,Extensive-disease small cell lung cancer and high SLFN11-expression,"IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion.",12,"Laboratory/Research/Testing facility, Laboratory/Research/Testing facility",other,Laboratory/Research/Testing facility,Academic,Phase I & II,lung/thoracic,other,"ETOP IBCSG Partners Foundation, ETOP IBCSG Partners Foundation"
1412,Netherlands,locally advanced urothelial cancer.,Bavencio 20 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,multiple,other,Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
1413,Germany,"non-small cell lung cancer stages IIIA (N2) and selected resectable
stages IIIB",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Universitaetsklinikum Essen AöR
1414,France,KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma,,1,Pharmaceutical company,unknown,Pharmaceutical company,Industry,Phase I,digestive,unknown,Amal Therapeutics S.A.
1415,France,Non small cell lung cancer,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,Intergroupe Francophone De Cancerologie Thoracique
1416,Austria,Advanced non small lung cancer,Allegra 120 mg Filmtabletten,12,Educational Institution,other,Educational Institution,Academic,Phase I & II,lung/thoracic,other,Medical University Of Vienna
1417,France,"Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer
(except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO]
combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel
cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability
[MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer,
gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or
squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in
partial response) after 6 months of standard IO treatment (monotherapy or previously in
combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination
with pemetrexed or bevacizumab or TKI).","AVELUMAB, DURVALUMAB, NIVOLUMAB, NIVOLUMAB, ATEZOLIZUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, DOSTARLIMAB, PEMBROLIZUMAB, CEMIPLIMAB, CEMIPLIMAB, PEMBROLIZUMAB, DURVALUMAB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,gynecologic,checkpoint inhibitor,Unicancer
1418,Norway,Non-small cell lung cancer (NSCLC),IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Vaestra Goetalandsregionen
1419,Belgium,Resectable peritoneal metastases of a colorectal origin,"Avastin 25 mg/ml concentrate for solution for infusion., Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie, Xeloda 150 mg film-coated tablets, 5-Fluorouracil Sandoz 50 mg/ml koncentrátum oldatos infúzióhoz, IRINOTECAN MYLAN GENERICS 20 mg/ml concentrato per soluzione per infusione",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Catharina Ziekenhuis Stichting
1420,France,advanced non-squamous non-small cell lung cancer,"BEVACIZUMAB, PACLITAXEL, Tecentriq 1,200 mg concentrate for solution for infusion",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,chemotherapy,Intergroupe Francophone de Cancerologie Thoracique
1421,Denmark,Esophageal Cancer,"Trazimera 150 mg powder for concentrate for solution for infusion, FLUOROURACIL, CAPECITABINE, PEMBROLIZUMAB, CAPECITABINE, OXALIPLATIN",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,checkpoint inhibitor,"Rigshospitalet, Frederiksberg Hospital"
1423,Italy,Squamous cell carcinoma of head and neck,PEMBROLIZUMAB,12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,head/neck,checkpoint inhibitor,European Organisation For Research And Treatment Of Cancer
1424,Netherlands,"HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor","Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,other,Universitair Medisch Centrum Groningen
1425,Italy,stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC),"Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Carboplatino Hikma 10 mg/ml soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Tevimbra 100 mg concentrate for solution for infusion",12,Laboratory/Research/Testing facility,other,Laboratory/Research/Testing facility,Academic,Phase I & II,lung/thoracic,chemotherapy,Fondazione Ricerca Traslazionale
1426,Germany,Intermediate stage hepatocellular carcinoma (HCC),"TREMELIMUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
1427,Germany,Colorectal liver metastases (CRLM),"Tecentriq 840 mg concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab, Tecentriq 840 mg concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Universitaetsklinikum Essen AöR
1429,Belgium,Glioblastoma grade IV,WT1 LAMP mRNA DC,12,Hospital/Clinic/Other health care facility,cancer vaccine,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,brain/CNS,cancer vaccine,Antwerp University Hospital
1430,France,The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter.,"IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, CISPLATINE VIATRIS 1 mg/1 ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentrátum oldatos infúzióhoz",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,chemotherapy,Centre Hospitalier Universitaire De Nimes
1431,Finland,cutaneous malignant melanoma,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,other,Uppsala University Hospital
1432,Italy,Extensive-Stage Small-Cell Lung Cancer (ES SCLC),"Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Olaparib, CARBOPLATINO TEVA 10 mg/ml, Olaparib",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,chemotherapy,Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
1433,Italy,locally advanced cholangiocarcinoma,"DURVALUMAB, CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., TREMELIMUMAB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,multiple,checkpoint inhibitor,IRCCS Istituto Nazionale Tumori Fondazione Pascale
1434,Germany,"T1-T2N0 esophageal adenocarcinoma including gastroesophageal
junction (GEJ) with indication for radical surgery","5-FU medac 50 mg/ml, Injektionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
1435,Belgium,Non-small cell lung cancer,"Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,Gilead Sciences Inc.
1436,France,Resectable mucosal melanomas,"LENVIMA 10 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,other,Institut Gustave Roussy
1437,Norway,Colorectal cancer,"Adrenalin Aguettant 1 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte, Kalsiumfolinat Pfizer 10 mg/ml injeksjonsvæske, oppløsning, OPDIVO 10 mg/mL concentrate for solution for infusion., Dexamethasone Krka 4 mg tabletter, Solu-Cortef 250 mg pulver og væske til injeksjonsvæske, oppløsning i tokammerhetteglass, Fluorouracil Accord 50 mg/ml injeksjons-/infusjonsvæske, oppløsning, Ondansetron Bluefish 8 mg tabletter, filmdrasjerte, Paracet 1 g tabletter, Metoclopramide Accord 10 mg tabletter, Oxaliplatin Fresenius Kabi 5 mg/ml konsentrat til infusjonsvæske, oppløsning",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Akershus University Hospital
1438,Belgium,Oropharyngeal Squamous Cell Carcinoma,"IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,head/neck,chemotherapy,European Organisation For Research And Treatment Of Cancer
1439,Spain,Non-small cell lung cancer (NSCLC),OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,Fundacion GECP
1440,Spain,"Nonsquamous non-small cell lung cancer, Nonsquamous non-small cell lung cancer","Inupadenant HCl, Placebo to Inupadenant, Inupadenant HCl",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,iTeos Belgium
1441,Sweden,Oral squamous cell carcinoma (OSCC),OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,head/neck,other,Karolinska University Hospital
1442,Italy,HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC),"Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,head/neck,other,Gruppo Oncologico Del Nord Ovest
1443,Italy,"Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or
refuse to receive cisplatin-based chemotherapy","OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., SODIO CLORURO BAXTER S.P.A. 0,9% Soluzione per infusione, Visugromab (CTL-002), OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,genitourinary,other,CatalYm GmbH
1444,Germany,"Patients (18-75 years) with metastatic and/or refractory soft-tissue
sarcoma after failure of anthracycline-containing 1st line therapy or with
contraindications to anthracyclines (CD13 positivity: grade >/= 1+)","tTF-NGR, TRABECTEDIN",12,"Educational Institution, Educational Institution",other,Educational Institution,Academic,Phase I & II,sarcoma,other,"Universitaet Muenster, Universitaet Muenster"
1445,Italy,Advanced cancer of the stomach or the gastroesophageal junction,"OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., ASP8951",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,Astellas Pharma Global Development Inc.
1446,Germany,hepatocellular carcinoma,"DURVALUMAB, TREMELIMUMAB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,checkpoint inhibitor,Klinikum der Universitaet Muenchen AöR
1447,Belgium,Completely resected Stage IIb/c melanoma,"5% Dextrose for Injection; Solution for injection, 0.9% sodium chloride injection. Solution for injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,skin,other,Bristol Myers Squibb International Corporation
1448,Sweden,colorectal cancer,,1,Pharmaceutical company,unknown,Pharmaceutical company,Industry,Phase I,digestive,unknown,NEOGAP Therapeutics AB
1449,France,Kidney cancer,"NIVOLUMAB, IPILIMUMAB",12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,genitourinary,checkpoint inhibitor,ARTIC
1450,Germany,Advanced stage intrahepatic biliary tract cancer (BTC),"IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,other,other,Institut fuer Klinische Krebsforschung IKF GmbH
1451,Netherlands,castration-resistant prostate cancer,"YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,other,Stichting Radboud universitair medisch centrum
1452,Belgium,metastatic clear cell Renal Carcinoma Cell,GOZETOTIDE,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,other,Cliniques Universitaires Saint-Luc
1453,France,Breast cancer,"Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung, Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,breast,chemotherapy,Institut Curie
1454,Portugal,Non-Small Cell Lung Cancer (NSCLC),IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
1456,France,Unresectable locally advanced or metastatic colorectal cancer,"OXALIPLATIN, Leukine, CALCIUM FOLINATE, FLUOROURACIL, ENDOXAN 50 mg, comprimé enrobé, STC-1010",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,Brenus Pharma
1457,France,Advanced liver cancers,"RO7247669, RO7791094, RoActemra 20 mg/mL concentrate for solution for infusion, ADG126, RO7790118, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO7790118",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,F. Hoffmann-La Roche AG
1458,Italy,Hepatocellular carcinoma,"CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Humanitas Mirasole S.p.A.
1459,Italy,ADVANCED TRIPLE NEGATIVE BREAST CANCER,"DURVALUMAB, Ceralasertib, PACLITAXEL ALBUMIN-BOUND",12,Laboratory/Research/Testing facility,checkpoint inhibitor,Laboratory/Research/Testing facility,Academic,Phase I & II,breast,checkpoint inhibitor,IFOM Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
1460,France,Non small cell lung cancer,"PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED",12,Patient organisation/association,checkpoint inhibitor,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,checkpoint inhibitor,Intergroupe Francophone De Cancerologie Thoracique
1461,France,Patients with a confirmed diagnosis of ovarian small cell carcinoma.,"ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Etoposide 20 mg/ml  Concentrate for solution for infusion  , Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion",12,Laboratory/Research/Testing facility,other,Laboratory/Research/Testing facility,Academic,Phase I & II,gynecologic,chemotherapy,Asso De Recherche Cancers Gynecologiques
1462,Netherlands,Stage III melanoma,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,other,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
1463,Portugal,High risk (TILs-positive) HR-/HER2- (triple negative) breast cancer,"CARBOPLATIN, EPIRUBICIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEGFILGRASTIM, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, FILGRASTIM",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,breast,chemotherapy,Champalimaud Clinical Centre
1464,Denmark,"Borderline resectable, locally advanced or metastatic pancreatic cancer (BRPC, LAPC or mPC)","OPDIVO 10 mg/mL concentrate for solution for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, GEMCITABINE HYDROCHLORIDE",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Region Hovedstaden
1465,Poland,Resectable soft tissue sarcomas,"IMP321, KEYTRUDA 25 mg/mL concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,sarcoma,other,Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
1466,Italy,recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC),"AVELUMAB, Erbitux 5 mg/mL solution for infusion",12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,head/neck,other,Gruppo Oncologico Del Nord Ovest
1467,Germany,Limited Disease Small Cell Lung Cancer,"IMFINZI 50 mg/mL concentrate for solution for infusion., ETOPOSIDE, CARBOPLATIN, CISPLATIN",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,chemotherapy,Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
1468,Italy,"Cutaneaous Squamous Cell Carcinoma, surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma",CEMIPLIMAB,12,"Laboratory/Research/Testing facility, Laboratory/Research/Testing facility",other,Laboratory/Research/Testing facility,Academic,Phase I & II,other,checkpoint inhibitor,"Fondazione Melanoma Onlus, Fondazione Melanoma Onlus"
1469,Netherlands,"Small-cell lung cancer, extensive stage",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Educational Institution,other,Educational Institution,Academic,Phase I & II,lung/thoracic,other,Norwegian University Of Science And Technolology
1470,France,Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell Lung Cancer.,"TEDOPI, DOCETAXEL",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,OSE Immunotherapeutics
1472,Czechia,Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation,"BENDAMUSTINE, VENETOCLAX, OBINUTUZUMAB, VENETOCLAX, CYCLOPHOSPHAMIDE, FLUDARABINE, VENETOCLAX, RITUXIMAB, ACALABRUTINIB",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,hematologic,other,Acerta Pharma B.V.
1473,Netherlands,"NSCLC, synchronous oligo-metastatic","IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Laboratory/Research/Testing facility,other,Laboratory/Research/Testing facility,Academic,Phase I & II,multiple,other,ETOP IBCSG Partners Foundation
1474,Italy,melanoma brain metastases,"YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,other,Melanoma Institute Australia
1475,Germany,"Sarcoma, Melanoma, Non-small cell lung cancer, Colorectal cancer, Triple negative breast cancer",,1,Pharmaceutical company,unknown,Pharmaceutical company,Industry,Phase I,digestive,unknown,Valo Therapeutics Oy
1476,Germany,"Immune related adverse events induced by treatment with
immunotherapy",UVADEX 20 Mikrogramm/ml Lösung zur Modifikation einer Blutfraktion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Medical Center - University Of Freiburg
1477,Poland,Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE),,1,Pharmaceutical company,unknown,Pharmaceutical company,Industry,Phase I,lung/thoracic,unknown,AstraZeneca AB
1478,Germany,Melanoma,"PEMBROLIZUMAB, NIVOLUMAB, IPILIMUMAB, DACARBAZINE",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,checkpoint inhibitor,"Universitaetsklinikum Erlangen AöR, Universitaetsklinikum Erlangen AöR"
1479,Italy,Head and neck cancer,"CETUXIMAB, TEPOTINIB",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,head/neck,other,"Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia"
1480,Belgium,"Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma","CETUXIMAB, CISPLATIN, TRETINOIN",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,head/neck,chemotherapy,Centre Leon Berard
1482,Italy,advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated,"OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL, Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL, SIMVASTATIN, CAPECITABINE",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,IRCCS Istituto Nazionale Tumori Fondazione Pascale
1483,France,cell penile carcinoma,AVELUMAB,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,other,Centre Hospitalier Regional Universitaire
1484,Spain,Resectable Non-small cell lung cancer Pancoast tumor,OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,other,Patient organisation/association,Patient Organisation,Phase I & II,lung/thoracic,other,Fundacion GECP
1486,France,metastatic clear cell renal cancer with progressive disease after 2 lines of therapy in the advanced/metastatic setting including at least 1 line of anti-VEGFR and 1 line of immunotherapy.,,12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",unknown,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,unknown,"Centre Leon Berard, Centre Leon Berard, Centre Leon Berard"
1487,Belgium,inoperable pleural mesothelioma,"YERVOY 5 mg/ml concentrate for solution for infusion, Armisarte 25 mg/ml concentrate for solution for infusion, Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie, OPDIVO 10 mg/mL concentrate for solution for infusion., Carboplatine Fresenius Kabi 10 mg/ml concentraat voor oplossing voor infusie",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,chemotherapy,Antwerp University Hospital
1488,Spain,Bladder Cancer,"Domvanalimab, Zimberelimab, Trodelvy 200 mg powder for concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,other,Fundacion Para El Progreso De La Oncologia En Cantabria
1489,Romania,Recurrent or advanced/metastatic solid tumors who are immunotherapy naive and may or may not have been treated with prior therapy for their disease.,INCB099280,12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,multiple,other,Incyte Corp.
1490,Spain,Non-muscle invasive bladder cancer,MITOMYCIN,1,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I,genitourinary,other,Presurgy S.L.
1491,France,metastatic gastric cancer,JEMPERLI 500 mg concentrate for solution for infusion,12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,digestive,other,Gercor
1492,Denmark,Advanced melanoma,"DABRAFENIB, ENCORAFENIB, BINIMETINIB, TRAMETINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,other,Region Hovedstaden
1493,France,microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis,"Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Fondation Franc.Cancerologie Digestive
1495,Italy,Relapsed/refractory malignant central nervous system tumors,"CYCLOPHOSPHAMIDE, FLUDARABINE",1,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I,other,other,Ospedale Pediatrico Bambino Gesu
1496,Netherlands,Urothelial carcinoma of the bladder and bladder cancer,"NIVOLUMAB, IPILIMUMAB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,genitourinary,checkpoint inhibitor,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
1497,Austria,Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin,"OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,checkpoint inhibitor,Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH
1498,Spain,Hepatocellular Carcinoma,"CellCept 500 mg powder for concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Remicade 100 mg powder for concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.",12,"Pharmaceutical company, Pharmaceutical company",other,Pharmaceutical company,Industry,Phase I & II,digestive,other,"Biocompatibles UK Limited, Biocompatibles UK Limited"
1499,France,"The patients enrolled in IMMUNORARE will be adult patients with  5 rare cancers: 
-Cohort 1: Peritoneal mesotheliomas (PM)
-Cohort 2: Gestational trophoblastic tumors (GTT)
-Cohort 3: B3 thymomas and thymic carcinomas (TET)
-Cohort 4: Anaplastic thyroid carcinomas (ATC)
-Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET)

Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.","OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., FOLINATE DE CALCIUM KALCEKS 10 mg/mL, solution injectable/pour perfusion, DOMVANALIMAB, Zimberelimab, FLUOROURACILE PFIZER 50 mg/mL, solution à diluer pour perfusion",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,other,Hospices Civils De Lyon
1500,France,"Patients with locally advanced, metastatic or unresectable hepatocellular carcinoma","Tecentriq 1,200 mg concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, UCPVax 1mg/2ml",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility",other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,"CHUR Of Besançon, Centre Hospitalier Regional Universitaire"
1501,Germany,resectable and borderline resectable stage IIIA/B NSCLC,"Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, DURVALUMAB, Vinorelbin NC 10 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, DURVALUMAB",12,Educational Institution,checkpoint inhibitor,Educational Institution,Academic,Phase I & II,other,checkpoint inhibitor,Rheinische Friedrich-Wilhelms-Universitaet Bonn
1502,Germany,"Relapsed or refractory CD19 positive B cell malignancies (pediatric acute lymphatic leukemia [ALL], aggressive NHL), Relapsed or refractory CD19 positive B cell malignancies (adult ALL, adult NHL/chronic lymphatic leukemia [CLL]), Refractory/relapsed B-NHL",MB-CART19.1,12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,hematologic,other,Miltenyi Biomedicine GmbH
1503,Belgium,advanced non-squamous non-small cell lung cancer (NSCLC),"JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel 20 mg/ml concentrate for solution for infusion, IOA-244",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,lung/thoracic,other,iOnctura SA
1504,France,"For patients with advanced/metastatic gastric adenocarcinomas in
progression",,12,Hospital/Clinic/Other health care facility,unknown,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,unknown,Hospices Civils De Lyon
1506,Italy,Malignant Pleural Mesothelioma,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CISPLATIN, CARBOPLATIN",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,lung/thoracic,chemotherapy,Istituto Oncologico Veneto
1507,France,Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma,OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,hematologic,other,Institut Gustave Roussy
1508,France,Localised and operable soft tissue sarcomas,Tecentriq 1 200 mg concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,sarcoma,other,Centre Leon Berard
1509,Netherlands,early stage NSCLC,IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Stichting Amsterdam UMC
1510,Belgium,"High-grade glioma (HGG), Diffuse intrinsic pontine glioma (DIPG)",WT1 LAMP mRNA DC,12,Hospital/Clinic/Other health care facility,cancer vaccine,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,brain/CNS,cancer vaccine,Antwerp University Hospital
1511,Netherlands,"Locally advanced, irresectable dMMR colorectal cancers",KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,other,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
1512,Spain,Treatment of immunotherapy-naive patients with previously untreated or recurrent locally advanced or metastatic cSCC not amenable to curative surgery and/or radiotherapy,INCB099280,12,"Pharmaceutical company, Pharmaceutical company",other,Pharmaceutical company,Industry,Phase I & II,multiple,other,"Incyte Corp., Incyte Corp."
1513,Spain,Advanced Solid Tumors,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, ASP1570, ASP1570",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,multiple,other,Astellas Pharma Global Development Inc.
1514,France,Advanced / Metastatic cancers,"Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, IMJUDO 20 mg/ml concentrate for solution for infusion., Tasigna 200 mg hard capsules",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,multiple,other,Centre Leon Berard
1515,Netherlands,Metastatic Melanoma,"Zirconium Zr 89 crefmirlimab berdoxam, TIL cells, PEGINTERFERON ALFA-2A",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,skin,cytokine / immunomodulator,Leids Universitair Medisch Centrum (LUMC)
1516,Sweden,Patients with histologically (or via cytology) confirmed cancer that develop arthritis secondary to treatment with immune checkpoint inhibitors.,"Prednisolon Pfizer 5 mg tabletter, RoActemra 162 mg solution for injection in pre-filled pen., Prednisolon Pfizer 2,5 mg tabletter",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Karolinska University Hospital
1517,Netherlands,"MDS with excess blasts, MDS/AML or AML patients",Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie,12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Stichting Radboud universitair medisch centrum
1518,Norway,Acute Lymphoblastic Leukaemia,"MERCAPTOPURINE, IMATINIB, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion, BESPONSA 1 mg powder for concentrate for solution for infusion, MERCAPTOPURINE, METHOTREXATE, PREDNISOLONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE, MERCAPTOPURINE, METHOTREXATE, METHYLPREDNISOLONE SODIUM SUCCINATE, MERCAPTOPURINE, VINCRISTINE SULFATE, TIOGUANINE, CYTARABINE, METHOTREXATE, VINCRISTINE SULFATE, DEXAMETHASONE, DEXAMETHASONE, DOXORUBICIN, HYDROCORTISONE SODIUM PHOSPHATE",12,Hospital/Clinic/Other health care facility,other,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,other,other,Karolinska University Hospital
1519,France,liver transplanted patients with advanced hepatocellular carcinoma,"ATEZOLIZUMAB, BEVACIZUMAB",12,Hospital/Clinic/Other health care facility,checkpoint inhibitor,Hospital/Clinic/Other health care facility,Hospital/Clinic,Phase I & II,digestive,checkpoint inhibitor,Assistance Publique Hopitaux De Paris
1520,Finland,"Melanoma, SCCHN",,1,Pharmaceutical company,unknown,Pharmaceutical company,Industry,Phase I,skin,unknown,TILT Biotherapeutics Oy
1521,Poland,Acute lymphoblastic leukemia,"BLINATUMOMAB, BORTEZOMIB, PREDNISONE, IFOSFAMIDE, CRISANTASPASE, ETOPOSIDE, PREDNISOLONE, DEXAMETHASONE, CYCLOPHOSPHAMIDE, PREDNISOLONE SODIUM SUCCINATE, IFOSFAMIDE, PREDNISOLONE SODIUM SUCCINATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISONE, PREDNISONE, METHOTREXATE, ETOPOSIDE, DOXORUBICIN HYDROCHLORIDE, METHOTREXATE DISODIUM, DEXAMETHASONE, DEXAMETHASONE PHOSPHATE, METHOTREXATE, ETOPOSIDE, DOXORUBICIN HYDROCHLORIDE, CYTARABINE, PEGASPARGASE, CYTARABINE, PREDNISONE, VINDESINE SULFATE, MERCAPTOPURINE, CYTARABINE, METHOTREXATE, DAUNORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, TIOGUANINE, PREDNISOLONE SODIUM SUCCINATE, ETOPOSIDE, CYTARABINE, PREDNISOLONE SODIUM SUCCINATE, DOXORUBICIN HYDROCHLORIDE, FLUDARABINE PHOSPHATE",12,Educational Institution,other,Educational Institution,Academic,Phase I & II,hematologic,other,Medical University Of Silesia Katowice Poland
1522,Norway,Recurrent or metastatic squamous cell carcinoma of the head and neck,"PACLITAXEL, DOCETAXEL, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, CETUXIMAB, CAPECITABINE",12,Pharmaceutical company,other,Pharmaceutical company,Industry,Phase I & II,head/neck,chemotherapy,Merck Sharp & Dohme LLC
1523,Spain,Advanced Melanoma,,1,Pharmaceutical company,unknown,Pharmaceutical company,Industry,Phase I,skin,unknown,Microbiotica Limited
1524,Poland,"Light chain amyloidosis (AL amyloidosis) is an incurable plasma cell neoplasm and the most common among a heterogeneous group of over 30 rare and ultra-rare diseases known as amyloidoses. In AL amyloidosis the deposition of amyloid fibrils resulting from misfolded immunoglobulin light chains leads to end-stage failure of the affected organs, most often of the heart or kidneys. Current therapy of AL amyloidosis is based on the destruction of clonal plasma cells with chemotherapy or immunotherapy, which leads to the inhibition of the production of immunoglobulin light chains, which are the precursors of amyloid. Effective inhibition of amyloid production enables slow resorption of already formed deposits, which results in organ responses in some patients. In vitro and in vivo studies showed amyloid deposits removal via phagocytosis by macrophages and neutrophils.So far, no therapies have been approved that would directly affect the amyloid deposits, however, clinical trials with opsonizing antibodies are ongoing,he mechanism of which is binding and neutralization of amyloid deposits in the process of phagocytosis. 
In 2021, based on the results of the ANDROMEDA phase III clinical trial, the most effective therapy for AL amyloidosis was registered so far: the D-VCD regimen combining anti-CD38 monoclonal antibody, daratumumab, with standard chemotherapy bortezomib, cyclophosphamide and dexamethasone. The recombinant granulocyte macrophage colony stimulating factor (GM-CSF) sargramostim will be used in this study with the D-VCD regimen. Currently, the indication for its use in the USA includes mobilization of progenitor cells and support for the reconstruction of white blood cells after autologous bone marrow transplantation, induction treatment of acute myeloid leukemia and myelosuppressive radiation.In patients with rheumatoid arthritis, a relationship between high levels of GM-CSF in the synovial fluid and a lower risk of developing Alzheimer's disease, which is associated with the accumulation of amyloid beta deposits in the brain, has been observed. In studies in a transgenic mouse model, it was shown that injections of GM-CSF led to a rapid reduction in the amount of beta amyloid in the brain and to neurological improvement. In a recent clinical trial in patients with Alzheimer's disease, a 3-week treatment with sargramostim resulted in improved cognitive function, decrease plasma markers of neurodegeneration and increase of amyloid beta (decreased in AD) compared to placebo. We assume that activation of tissue phagocytes thanks to the use of sargramostim will result in more effective phagocytosis of amyloid deposits, which, together with the active destruction of clonal plasma cells by D-VCd immunochemotherapy, may lead to an increase in the frequency of organ responses.","Dexamethasone Krka, 20 mg, tabletki, DARZALEX 1800 mg solution for injection, Endoxan® „Baxter“ 50 mg - Dragees, VELCADE 3.5 mg powder for solution for injection, VELCADE 1 mg powder for solution for injection, Endoxan 200 mg pulbere pentru solutie perfuzabila/injectabila, Dexamethasone Krka, 4 mg/ml, roztwór do wstrzykiwań/do infuzji",12,Educational Institution,other,Educational Institution,Academic,Phase I & II,genitourinary,other,Medical University Of Warsaw
